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Cancer is the second leading cause of death among both men and women and accounts 
for 13% of total deaths worldwide. Enormous efforts have therefore been made to cope 
with this problem, but unfortunately limited success has been achieved with most of the 
current therapeutic strategies. The T-box family of developmentally important 
transcription factors plays a role in the genesis of cancer and shows much promise as a 
focus for targeted therapeutic approaches to treat cancer. For example, the T-box factor 
TBX3 is overexpressed in a number of cancers including breast cancer but the 
mechanism(s) responsible for this upregulation as well as the precise role of TBX3 in the 
progression of this disease still need to be elucidated. This study provides novel data that 
show that TBX3 is specifically involved in breast cancer cell proliferation and migration 
and that its upregulation by the TGF-β1 signalling pathway mediates the 
TGF-β1-regulated anti-proliferative and pro-migratory effects. Furthermore, this study 
demonstrates that TBX3 mediates the anti-proliferative function of TGF-β1 through 
repressing transcription of its homologue, TBX2, which allows for the de-repression of 
p21 and a G1 cell cycle arrest. The findings of the current study are of great significance 
as it identifies TBX3 as a potential target for the development of novel breast cancer 
therapeutics. 
 
In order to ascertain the function of upregulated expression of TBX3, cell culture models 
were established in which TBX3 was either (1) stably silenced in an invasive breast ductal 
carcinoma cell line (MCF-7) which was previously shown to overexpress TBX3 or (2) 
overexpressed in a normal human breast epithelial cell line (MCF-12A). The resultant 
cells were then compared to control cells and tested for key characteristics of cancer. The 
data generated provide evidence that increased TBX3 levels inhibit breast epithelial cell 
proliferation in growth curve, BrdU incorporation and MTT assays. However, in vitro 
motility assays show that TBX3 may contribute to breast cancer progression by 




To identify the molecular mechanism(s) that upregulate TBX3 in breast epithelial cells, 
this study focused on the TGF-β1 signalling pathway because like TBX3, it plays an 
important role in mammary morphogenesis and is notoriously activated during breast 
cancer development. Indeed, TGF-β1 is shown to transcriptionally upregulate TBX3 
protein and mRNA levels. Using luciferase reporter assays and both in vitro and in vivo 
DNA-binding assays this transcriptional activation is shown to be mediated by a 
co-operation between Smad3/4 and JunB through a Smad binding element in the TBX3 
proximal promoter. Furthermore, cell proliferation and migration assays demonstrate 
that TBX3 is key in mediating the anti-proliferative and pro-migratory roles of TGF-β1 in 
epithelial cells.  
 
Finally, the question regarding which TBX3 target genes are responsible for its 
anti-proliferative effect downstream of TGF-β1 is explored. Previous data from our 
laboratory as well as that of others have showed that TBX2, the homologue of TBX3, 
functions as a pro-proliferative factor and it was hypothesized that in response to TGF-β1, 
TBX3 represses TBX2 in order to inhibit cell proliferation. Using luciferase reporter and 
DNA-binding assays, this study demonstrates that when the TGF-β1 pathway is 
stimulated in breast epithelial and melanoma cells, TBX2 expression is repressed through 
the direct binding of TBX3 to a half T-element in the TBX2 promoter. Furthermore, using 
a combination of knockdown and overexpression studies and growth curve analyses the 
downregulation of TBX2 is shown to be required for the anti-proliferative effect of 
TGF-β1, primarily through allowing upregulation of p21.  
 
Taken together, results from this study suggest that TBX3 plays an important role in the 
proliferation and migration of breast epithelial cells. Furthermore, this study provides 
compelling data that demonstrate that TBX3 is a key mediator of the anti-proliferative 
and pro-migratory roles of the TGF-β1 pathway. These findings are of great significance 
as they identify TBX3 as a potential target for the development of novel therapeutic 





LITERATURE REVIEW  
  
1.1 Introduction   
Cancer, or malignant neoplasm, is the leading cause of death worldwide and the number 
of cancer-related deaths is projected to double over the next 20-40 years with 26 million 
new cancer cases predicted to occur by 2030 (Thun et al., 2010). Despite major advances 
in the field of cancer research, cancer continues to present a serious health problem 
because many cancers are not detected early and there are still no effective treatments 
for most cancers. To address this requires an understanding of the molecular 
mechanisms underpinning the disease because it will lead to the identification of early 
markers as well as novel targets in the development of anti-cancer therapies. At a 
molecular level the initiation and progression of cancer can be characterised, in part, by 
the deregulated expression of genes which often belong to networks of closely related 
signalling pathways that regulate normal cell processes. It is therefore not surprising that 
several components of signalling pathways including transcription factors have been 
identified as targets in the design of novel therapies.  
 
Members of the T-box family of developmental transcription factors have emerged as 
potentially important players in the genesis of cancer. In particular, TBX2 and TBX3, play 
critical roles in embryonic development (Naiche et al., 2005; Hoogaars et al., 2007; 
Douglas and Papaioannou, 2013) and there is a rapidly growing body of evidence to 
suggest that they play key roles in the cancer process when they are overexpressed 
(Prince et al., 2004a; Rowley et al., 2004; Abrahams et al., 2008; Davis et al., 2008; Peres 
et al., 2010; Mowla et al., 2011; Ballim et al., 2012). This review will provide a general 
overview of the roles and regulation of TBX2 and TBX3 in cancer genesis and will 




1.2 The T-box gene family   
The founder gene of the T-box family is Brachyury (or T) and investigations into its 
structure and function were seminal to the discovery of other T box genes. Brachyury 
was first identified in mouse in 1927 by Dobrovolskaia-Zavadskaia who observed that 
heterozygous mutations in the Brachyury gene resulted in mice with short and often 
kinked tails, hence the name T denoted for the gene family (Dobrovolskaia-Zavadskaia, 
1927). In 1935, Chesley reported that mice with homozygous mutations of Brachyury die 
shortly after gastrulation (by embryonic day 10.5) with successfully initiated mesoderm 
formation of the anterior primitive streak but a complete loss of posterior mesoderm 
(Chesley, 1935). The main cause of this mesodermal abnormality was later found to be 
related to the role of Brachyury in cell adhesion and migration. Stem cells of homozygous 
mutant embryos showed compromised ability to migrate from the primitive streak and 
the accumulation of these cells eventually triggered cell death. This impaired normal 
mesoderm development and lead to allantois malformation which failed to connect to 
the chorion, thereby affecting the connection to the placenta and eventually resulting in 
the death of the embryo (Gluecksohn-Schoenheimer, 1938, 1944; Rashbass et al., 1991; 
Wilson et al., 1993, 1995). The T gene displays dosage sensitivity as illustrated by 
observations that its increased expression is required for the formation of the 
anteroposterior axis in the mouse embryo (MacMurray and Shin, 1988; Yanagisawa, 
1990). This was confirmed by inter-crossing mice carrying an extra copy of wild-type T 
gene with mice carrying various T mutations (Stott et al., 1993). The degree by which the 
tail length could be rescued directly correlated with the levels of T gene expression. The 
Brachyury gene was first cloned in 1990 and has been shown to act as a transcription 
factor with an N-terminal domain that confers DNA binding to a palindromic sequence 
T(G/C)ACACCTAGGTGTGAAATT with core sequence AGGTG (Herrmann et al., 1990; 
Kispert et al., 1995a). Two sets of alternatively arranged transactivation and repression 
domains have been identified in the C-terminal domain suggesting that Brachyury can 
function as either a transcriptional activator or repressor (Kispert et al., 1995a). In 1992, 
the Drosophila melanogaster omb gene was found to encode a protein containing a 200 
amino acid DNA binding sequence which was homologous to the DNA binding domain of 
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Brachyury (Pflugfelder et al., 1992). Subsequently, Brachyury paralogues were identified 
in several species, including frog Xenopus laevis (Smith et al., 1991), the zebrafish 
Brachydanio rerio (Schulte-Merker et al., 1992), the chick (Kispert et al., 1995b) and the 
ascidian Halocynthia roretzi (Yasuo and Satoh, 1993, 1994; Bollag et al., 1994; 
Papaioannou and Silver, 1998). The collective name, the T-box gene family was then used 
to name this group of genes that encode proteins which share the highly conserved 200 
amino acid core sequence. This sequence corresponds to their DNA binding domain 
called the T-box which is capable of recognising and binding a half-palindromic core 
sequence TCACACCT called the T element (Kispert and Herrmann, 1993; Kispert et al., 
1995a; Wilson and Conlon, 2002). 
 
It is now well established that the T-box gene family encodes transcription factors that 
are highly conserved in evolution ranging from invertebrates to vertebrates (Wilson and 
Conlon, 2002). There are more than 50 protein members that have been assigned to the 
T-box gene family and 18 of them are found in humans. Genomic sequencing of a range 
of vertebrate and invertebrate species has suggested that the T-box gene family can be 
divided into five subfamilies referred to as Brachyury, T-brain1, TBX1, TBX2 and TBX6 
according to their evolutionary backgrounds and expression patterns (Papaioannou, 
2001; Wilson and Conlon, 2002). The TBX2 subfamily, which includes the TBX2, TBX3, 
TBX4 and TBX5 genes, is of particular interest to this review. These genes arose from 
duplication and recombination of a two-gene cluster that was formed by unequal 
crossing over of an ancestral gene (Wilson and Conlon, 2002; Rowley et al., 2004). While 
the DNA-binding domain of T-box proteins is located in their N-termini, their 
transcriptional regulatory domains are generally located in their C-termini (Tada and 
Smith, 2001; Wilson and Conlon, 2002; Rowley et al., 2004). There is evidence to suggest 
that T-box proteins interact with co-factors which is anticipated to play an important role 
in regulating their distinct transcriptional activities on their downstream targets (Tada 
and Smith, 2001; Minguillon and Logan, 2003). For example, in vitro assays from 
different studies showed that Tbx2, Tbx5 and Tbx20 can directly interact with the cardiac 
homeobox protein Nkx2-5 which results in synergistic transcriptional effects (Bruneau et 
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al., 2001; Hiroi et al., 2001; Habets et al., 2002; Stennard et al., 2005). Interestingly, 
recent findings have shown that while Tbx24 generally activates the zebrafish mesp-b 
gene in ripply1-deficient embryos, interaction of ripply1 with the T-domain of Tbx24 
converts it into a repressor by recruiting the transcriptional co-repressor Groucho/TLE 
(Kawamura et al., 2008).  
 
Members of the T-box gene family are widely expressed during all stages of embryonic 
development ranging from gastrulation to organogenesis (Wilson and Conlon, 2002; 
Showell et al., 2006). Consistent with this, T-box factors play critical roles in several 
developmental processes which are highlighted by the congenital birth defects observed 
when they are mutated (Naiche et al., 2005). For example, the lack of TBX1 in humans 
leads to Di-George syndrome which is characterised by facial deformities, behavioural 
and learning difficulties and aplasia of the heart and thymus (Jerome and Papaioannou, 
2001; Baldini, 2005). Mutations in human TBX19 and TBX22 give rise to adrenal 
insufficiency and X-linked cleft palate with ankyloglossia respectively (Braybrook et al., 
2001; Liu et al., 2001b). Moreover, haploinsufficiency of TBX3 and TBX5 causes 
Ulnar-mammary syndrome (UMS) and Holt-Oram Syndrome respectively. UMS is 
characterised by forelimb abnormalities and malformations of the conduction system, 
apocrine glands, mammary glands, heart, dental and genital structures (Tada and Smith, 
2001; Wilson and Conlon, 2002; Davenport et al., 2003; Meneghini et al., 2006; Hoogaars 
et al., 2007; Kawakami et al., 2007; Mesbah et al., 2008). Patients with Holt-Oram 
syndrome exhibit upper limb malformations and congenital cardiac abnormalities 
including atrial or muscular ventricular septal defects (Basson et al., 1999). Due to the 
focus of the current project, the following sections of this literature review will describe 
the structure of TBX2 and TBX3 as well as their function in embryonic development and 





1.3  TBX2 and TBX3   
1.3.1 Genes and proteins   
As mentioned earlier, TBX2 and TBX3 both belong to the TBX2 subfamily which includes 
the TBX4 and TBX5 genes that all originated from the same ancestral gene (Agulnik et al., 
1996). Based on branch length and locations on their phylogenetic tree, analysis reveals 
that TBX2 and TBX3 represent a cognate gene pair whereas TBX4 and TBX5 represent 
another (Agulnik et al., 1996). It is proposed that at certain points along the vertebrate 
lineage, two gene clusters (Tbx2/3 and Tbx4/5) were formed by duplicative unequal 
crossing over events. Each cluster then duplicated again to give rise to four separate 
genes, with TBX2 and TBX4 being located on chromosome 17q23 and TBX3 and TBX5 
being located on chromosome 12q24 in humans (Campbell et al., 1995; Agulnik et al., 
1996; Bamshad et al., 1997). Human TBX2 and TBX3 share a high degree of homology 
with their murine counterparts. For instance, the T-box regions of the human and mouse 
TBX2 gene share 90% similarity and 87% of nucleotides in the human and mouse TBX3 
cDNA sequence are identical (Law et al., 1995; Bamshad et al., 1997). In addition, TBX2 
and TBX3 share ~95% identity in their T-box domain and ~70% identity in their N-termini. 
This suggests that besides having very similar DNA binding domains, they may also share 
functional similarities (Bamshad et al., 1999).  
 
The 3.378 kb TBX2 transcript contains 7 exons which encodes a protein of 712 amino 
acids (Fig. 1.1). The T-box DNA binding domain is located between amino acids 106-289 
in the N-terminus of the TBX2 protein. An arginine at position 122 has been shown to be 
conserved in all T-box proteins and is essential for DNA binding (Sinha et al., 2000). Tbx2 
was shown to bind the palindromic and half-site T-element as a monomer, with the four 
base pair GTGT motif thought to be important for binding (Carreira et al., 1998; Sinha et 
al., 2000). The structure of the TBX3 gene is however more complex and interesting. The 
743 amino acid TBX3 protein is encoded by 7 exons and an alternative splicing event in 
the intronic region between exons 2 and 3 of the TBX3 gene, called exon 2a, produces a 
second transcript (TBX3+2a). Exon 2a contains an additional 60 bp, resulting in the 
addition of 20 amino acids to the TBX3+2a protein (Fig. 1.2) (Bamshad et al., 1999). The 
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TBX3+2a transcript is otherwise identical to TBX3, spanning ~5.2 kb except that it gives 
rise to a protein with an extra 20 amino acids (LAFPSDHATWQGNYSFGTQT at 220-240) 
inserted into the middle of the T-box DNA binding domain (amino acids 105 – 285) 
(Bamshad et al., 1999; Fan et al., 2004). Whether this insertion disrupts the DNA-binding 
ability of the TBX3+2a protein or whether, compared to TBX3, it results in differential 
target gene regulation are unclear. Indeed, Fan et al. (2004) reported that the TBX3 and 
TBX3+2a isoforms have distinct cellular functions. They showed that while 
overexpressing TBX3 led to the immortalization of mouse embryonic fibroblast cells 
(MEFs), overexpression of TBX3+2a accelerated senescence in these cells. Furthermore, 
they demonstrated using in vitro DNA binding assays that TBX3, but not TBX3+2a, is able 
to bind the T-site (Fan et al., 2004). While the results from the study by Fan et al. (2004) 
provided evidence that TBX3 and TBX3+2a are functionally distinct, this was challenged 
by Hoogaars et al. (2008) who showed equivalent binding affinity of these two isoforms 
to the consensus T-element, as well as to repress the T-site previously identified in the 
Nppa and p21 promoter. Using transgenic mouse models they also showed that both 
isoforms were able to inhibit chamber differentiation during cardiac development and 
repress the expression of connexin 40 (Cx40) (Hoogaars et al., 2008). Results from a 
recent study also suggest that during the maintenance of pluripotency, the two Tbx3 
isoforms may both regulate Nanog but through different mechanisms (Zhao et al., 2014). 
Taken together, these results suggest that the functions of TBX3 and TBX3+2a may vary 




Figure 1.1 Schematic representations of human TBX2 mRNA and protein. (A) TBX2 
mRNA depicting seven exons and their sizes. (B) TBX2 protein showing the two 
repression domains (yellow boxes) and the T-box DNA binding domain (grey box). The 





Figure 1.2 Schematic representation of human TBX3 mRNA and protein. (A) TBX3 mRNA 
depicting seven exons. In the TBX3+2a isoform, exon 2a is inserted in exon 2 and exon 3. 
(B) TBX3 protein. Repression domains (yellow boxes), T-box (grey boxes), activation 
domain (green box), additional 20 amino acids in TBX3+2a protein splice form (red box). 
The number of amino acid residues is shown under each box. The amino and carboxy 
termini of the protein are labelled N and C respectively. 
 
Both TBX2 and TBX3 can bind the consensus T-element as monomers in vitro and they 
each contain two repression domains, one in their N-termini and one in their C-termini 
(Carreira et al., 1998; Carlson et al., 2001a; van den Boogaard et al., 2012). Consistent 
with their high degree of homology, TBX2 and TBX3 regulate a few common targets such 
as the cyclin dependent kinase inhibitors p14ARF/p19ARF (Jacobs et al., 2000; 
Brummelkamp et al., 2002a; Lingbeek et al., 2002) and p21WAF1/KIP/CIP1/SDI1/Cap20 (hereafter 
referred to as p21) (Prince et al., 2004a; Hoogaars et al., 2008), Nppa during heart 
development (Christoffels et al., 2004; Hoogaars et al., 2008) as well as the cell adhesion 
molecule E-cadherin (Rodriguez et al., 2008; Wang et al., 2012). There have also been 
reports that TBX3 represses the tumour suppressor PTEN (Burgucu et al., 2012) and the 
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sodium channel genes Scn5a/Scn10a (van den Boogaard et al., 2012) and that TBX2 
transcriptionally represses the melanocyte specific enzyme, tyrosinase related protein 1 
(TYRP-1) (Carreira et al., 1998) and the breast tumour suppressor NDRG1 (Redmond et 
al., 2010). These studies did not however check the effect of both TBX2 and TBX3 on 
these targets and therefore whether they are TBX2/3 specific is unknown. Interestingly, 
while TBX2 and TBX3 have been reported to function predominantly as transcriptional 
repressors, there is evidence to suggest that they may also function as activators. In vitro 
studies performed by Paxton et al. (2002) revealed that TBX2 has a weak activation 
domain located within its T-box region (Carlson et al., 2001a; Paxton et al., 2002) and a 
recent study confirmed that this may be physiologically relevant. Using a luciferase 
reporter assay Tbx2 was shown to directly activate Tgfb2 expression through T-element 
binding during mouse outflow tract cushion development (Sakabe et al., 2012). Carlson 
et al. (2001) performed experiments using a GAL4 fusion protein and mapped a putative 
activation domain at amino acids 423-500 of the TBX3 protein. It was only recent that 
this finding was shown to be physiologically relevant when TBX3 was shown to activate 
Connexin43 (Boogerd et al., 2011) and Gata6 (Lu et al., 2011) which are both important 
during heart development. Moreover, unpublished data from our laboratory show that 
TBX3 is able to directly bind and activate COL1A2 and ID1. These findings suggest that 
TBX2 and TBX3 are able to function as activator or repressor but the mechanism(s) that 
enables them to switch between the two are unknown and deserves further 
investigations.  
 
1.3.2 TBX2 and TBX3 in embryonic development  
As mentioned above, there is a lot of information on the widespread expression and the 
important developmental roles of T-box factors during embryonic development 
(Reviewed by Naiche et al, 2005; Abrahams et al, 2008; Douglas & Papaioannou, 2013). 
The expression of both TBX2 and TBX3 has been observed in many human organs 
including the foetal lung and kidney, and adult kidney, heart, ovary, placenta, prostate, 
lung, spleen, testis and small intestine (Law et al., 1995; Bamshad et al., 1999). In 
addition, TBX3 expression has been observed in the human foetal spleen, liver and heart 
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as well as in adult thyroid, breast, bladder, liver, salivary gland, adrenal gland, thyroid, 
uterus and bladder (Bamshad et al., 1999). The expression patterns of TBX2 and TBX3 in 
these organs may suggest that they play a role in their development and studies using 
mouse models have made important contributions to confirming this.  
 
Mutations in a single copy of the human TBX3 gene that accelerate protein decay or 
affects its ability to transcriptionally regulate its target genes results in Ulnar-mammary 
syndrome (UMS) (He et al., 1999; Carlson et al., 2001a; Coll et al., 2002). UMS is an 
autosomal dominant disorder which is characterised by a range of congenital defects as 
described earlier (Tada and Smith, 2001; Wilson and Conlon, 2002; Davenport et al., 
2003; Meneghini et al., 2006; Hoogaars et al., 2007; Kawakami et al., 2007; Mesbah et al., 
2008). It is worth noting that a number of tissues and organs where TBX3 is expressed 
are unaffected in individuals with UMS. This suggests that differential expression of TBX3 
is required for different tissues which is consistent with observations that the severity of 
the UMS phenotype varies within and among families and depends on the degree of 
TBX3 deficiency (Bamshad et al., 1999; Sasaki et al., 2002; Wollnik et al., 2002; 
Meneghini et al., 2006; Frank et al., 2013). It is however also possible that other T-box 
factors, for example TBX2, may compensate for TBX3 in such tissues and organs 
(Bamshad et al., 1999). Interestingly, Frank et al. (2013) generated different truncated 
Tbx3 proteins and showed that in mouse models the deletion of the T-box encoding 
region does not necessarily lead to functionally null alleles but rather produces aberrant 
transcripts and proteins. The authors further suggested that as TBX3 may function as 
both repressor and activator, the mutant proteins that only possess one of these 
functional domains in the absence of the DNA binding domain may have significantly 
different and/or unexpected activities. UMS results in various degrees of mammary 
gland abnormalities from hypoplasia to complete aplasia of the mammary gland and 
areola (Bamshad et al., 1997). Whereas no homozygous mutant patient has been 
identified, probably due to lethality, mouse models of UMS showed that homozygous 
Tbx3 embryos have severe defects in mammary gland induction and limb development 
and die in utero by embryonic day (E) 11.5 (Davenport et al., 2003). Unlike their human 
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counterparts, the heterozygous mice exhibited a relatively normal phenotype although a 
minor genital anomaly and ductal aplasia in mammary glands 1, 2 and 3 (MG1, MG2 and 
MG3) is observed in female mice (Davenport et al., 2003; Jerome-Majewska et al., 2005).  
 
Frequent microdeletions of the long arm of chromosome 17 that results in 
haploinsufficiency of TBX2 and TBX4 have been shown to lead to a range of 
developmental abnormalities. This includes severe congenital microcephaly, heart 
defects (patent ductus arteriosis, atrial septal defects and pulmonary hypertension), mild 
facial dysmorphia, musculoskeletal abnormalities and anomalies of the hand and foot, 
particularly long, thin fingers and toes (Ballif et al., 2010; Nimmakayalu et al., 2011). Due 
to the loss of several other genes resulting from the above microdeletions, it is difficult 
to determine the exact impact of TBX2 deficiency on this phenotype. However, mouse 
Tbx2 null mutants also show a phenotype with heart defects (including abnormal 
formation of the atrioventricular canal and outflow tract), facial dysmorphia and digit IV 
duplication in the hindlimb (Harrelson et al., 2004). Functional redundancy between 
Tbx2 and Tbx3 has been reported in Xenopus eye development (Takabatake et al., 2002), 
in the atrioventricular canal and in mammalian secondary palate formation (Singh et al., 
2012). Moreover, individual loss of function of either of these proteins resulted in a delay 
of gastrulation movements in the Xenopus embryo (Weidgang et al., 2013). It is however 
important to note that there are also studies that have illustrated that TBX2 and TBX3 
may play distinct roles during embryogenesis. For example, mouse Tbx2 homozygous 
mutant embryos display digit IV duplication in the hindlimb, whereas Tbx3 homozygous 
embryos show abnormalities in digits IV and V of the forelimbs and severely reduced 
hindlimb development (Gibson-Brown et al., 1996; Davenport et al., 2003; Harrelson et 
al., 2004). 
 
Together, clinical reports and mouse studies from mutations in Tbx2/TBX2 and 
Tbx3/TBX3 have revealed the critical roles of TBX2 and TBX3 in, at the very least, the 
development of the heart, mammary glands and limbs. As the results of the current 
project have implications for the role and regulation of TBX3 in breast development and 
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cancer, the following section will focus on mammary gland development and what is 
known of the role of TBX2 and TBX3 in this process.  
 
1.3.2.1 TBX2 and TBX3 in embryonic mammary gland development 
Mammary gland development is a continuous biological remodelling process which 
begins during embryogenesis, continues after birth and through lactation and involution 
(Platonova et al., 2007; Cowin et al., 2010). Tbx2 and Tbx3 are the only members of the 
T-box family that have been detected in developing mammary glands (Douglas and 
Papaioannou, 2013). During mouse embryonic development, the first sign of 
mammogenesis becomes evident at E10.5 along the anteroposterior axis between fore 
and hind limb buds of each flank (Fig. 1.3A) (Veltmaat et al., 2004). It is evidenced by the 
formation of a milk line which is an elevated bilateral ectodermal ridge and is defined by 
the expression of several markers in the canonical Wnt signalling pathway, especially 
Wnt10b (Chu et al., 2004; Veltmaat et al., 2004, 2006). The Wnt and fibroblast growth 
factor (FGF) signalling pathways, particularly FGF10, FGF8, FGFR1 and FGFR2B, play 
pivotal roles to induce and maintain the expression of TBX3 as early as E10.25 in a thin 
line overlapping the milk line (Eblaghie et al., 2004a). During E10.5-E11.5, the underlying 
mesenchyme induces the thickened ectodermal cells along the milk line to resolve into a 
columnar and multilayered structure called the mammary placode (MP) (Fig. 1.3B) 
(Jerome-Majewska et al., 2005). The expression of both Tbx2 and Tbx3 are detected at 
E10.5 in overlapping stripes along the ventro-lateral border between the developing 
limbs (Jerome-Majewska et al., 2005). Tbx3 is one of the first markers which accumulates 
in the epithelium of MP1 and MP3 at E10.5 and in all 5 pairs of placodes at E11.5 and its 
ventral extension at this stage is antagonized by bone morphogenic protein 4 (Bmp4). 
Tbx2, however, remains only in the mesenchyme underlying the mammary line at E10.5 
and E11.5 (Chapman et al., 1996; Jerome-Majewska et al., 2005; Cho et al., 2006; 
Douglas and Papaioannou, 2013). The confined TBX3 expression, in a positive feed-back 
loop, induces FGF signalling, Wnt10b and its target gene Lef1, which later define the 
dorsal-ventral positioning of the milk line (Eblaghie et al., 2004a; Cho et al., 2006). At 
E12.5 and E13.5, all mammary buds express Tbx3 which seems to be critical for their 
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maintenance (Chapman et al., 1996; Davenport et al., 2003; Eblaghie et al., 2004b; 
Jerome-Majewska et al., 2005). In loss of function studies, Tbx3+/- mice show normal 
induction of all five placodes but fail to maintain the development of the three thoracic 
pairs of the future mammary glands. These compromised mammary glands exhibited 
reduced numbers of ductal trees in branching morphogenesis, especially in adult virgin 
females. The Tbx3-/- mice, however, fail to induce MPs and die during gestation due to 
both cardiac and yolk sac defects (Davenport et al., 2003; Jerome-Majewska et al., 2005; 
Frank et al., 2012). At E18.5, both Tbx2 and Tbx3 are found in overlapping domains in the 
mammary mesenchyme underlying the nipple, with Tbx3 also expressed in the 
epithelium of the branching mammary ducts (Jerome-Majewska et al., 2005). In 
postnatal female mammary glands, the Tbx3 transcript is detected at various stages of 
development including virgin, pregnancy, lactation and involution (Platonova et al., 2007). 
The precise role(s) of TBX2 and TBX3 in late stage mammary gland development still 






Figure 1.3 Embryonic development of the mammary glands. (A) Schematic diagram 
depicting the invagination of the mammary epithelium (orange) into the underlying 
mesenchyme (blue) and fat pad (light green) to form the embryonic rudimentary 
mammary glands through E10.5—E18.5. (B) Schematic depicting the position of the five 
mammary placodes along the lateral body wall at E11.5, with mammary gland 1 (MG1) 
found next to the forelimb and mammary gland 5 (MG5) next to the hindlimb on the 
ventral body wall of the embryo (Modified from Robinson, 2007). 
 
While Tbx2 is expressed during mammary gland development, studies using 
heterozygous and homozygous mutant embryos showed no statistical differences in their 
mammary gland development, suggesting that Tbx2 may not be required for MP 
induction (Jerome-Majewska et al., 2005). In comparison, Tbx3 homozygous mutant 
embryos failed to develop mammary buds, revealing the essential role of Tbx3 in this 
process (Davenport et al., 2003). It is however worth noting that Tbx2, Tbx3 double 
heterozygotes exhibited a higher degree of ductal tree aplasia compared to the Tbx3 
heterozygotes which suggests some contribution of Tbx2 to the formation of the ductal 
tree (Jerome-Majewska et al., 2005).  
 
1.3.2.2 TBX2 and TBX3 in embryonic stem cell biology  
Pluripotent embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are 
specialised progenitor cells which are characterised by the potential to continuously 
self-renew. They have the ability to maintain an undifferentiated state of pluripotency 
and have the potential to differentiate into all three germ layers (Hirai et al., 2011). ESCs 
originate from the inner cell mass of the blastocyst, where Tbx3 is among the first T-box 
factors to be detected (Chapman et al., 1996). Tbx3 has been found sufficient to 
maintain pluripotency of mouse ESCs (mESCs) by mediating LIF/STAT signalling (Niwa et 
al., 2009). It also helps their reprogramming by direct binding and activation of the OCT4 
promoter and the loss of function of Tbx3 in mESCs abolishes self-renewal and induces 
differentiation (Han et al., 2010). Moreover, levels of Tbx3 expression is highest in the 
undifferentiated mESCs and it blocks differentiation into mesoderm, ectoderm, 
trophectoderm and neural crest cells (Ivanova et al., 2006; Lu et al., 2011). In addition to 
Tbx3 playing a role as a repressor of specific cell fates, it also encourages differentiation 
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into extraembryonic endoderm (ExEn) by directly activating GATA6 expression (Lu et al., 
2011) and mediates Wnt signalling to induce a metastable primitive endoderm state that 
gives rise to visceral endoderm (Price et al., 2013). The dual function of Tbx3 in 
sustaining pluripotency of undifferentiated mESC and promoting differentiation of ExEn 
suggests that the function of Tbx3 is intricate and may be intertwined with a number of 
signalling networks. In addition, Tbx3 has recently been found highly expressed in 
definitive endoderm progenitor cells and is involved in endoderm formation with the 
histone demethylase JMJD3 and EOMES (Cheng et al., 2012; Kartikasari et al., 2013). A 
recent study showed that Tbx3 directs ESC differentiation toward mesendoderm by 
transcriptionally regulating specific mesoderm and endoderm transcription factors 
(Weidgang et al., 2013). 
 
The mESCs isolated from blastocysts of the preimplanted embryo have been denoted as 
having a naïve state as they exhibit less ‘mature’ features than the ‘primed’ state of 
mouse epiblast stem cells (mEpiSC). These two sets of stem cells are distinct with respect 
to X chromosome inactivation and developmental potential and also differ with regard to 
colony morphology, growth dependent signalling and gene expression (Hanna et al., 
2010; Pera and Tam, 2010). Interestingly, while human ESCs (hESCs) and mESCs are both 
derived from the explanted blastocysts before implantation, hESCs show more biological 
similarities with the primed state mEpiSC. Moreover, the hESCs that have been treated 
with reprogramming factors to revert back to a more naïve state show higher expression 
of Tbx3 transcripts than the mEpiSC (Tesar et al., 2007). In addition to the maintenance 
of the naïve state of ESCs during development, Tbx3 also improves the quality of iPSCs 
generated from mouse embryonic fibroblasts. With reprogramming factors Sox2, Oct4, 
and Klf4, it accelerates stem cell colony formation, expression of pluripotency markers 
and enhances germline contribution and transmission (Han et al., 2010). Tbx3 can also 
improve the generation of porcine-induced pluripotent stem cells (piPSCs) when 
co-expressed with Oct4 (Pou5f1), Sox2, Klf4 and c-myc (Wang et al. 2013). ESCs and iPSCs 
sporadically enter a two-cell-like state (2C-state) that resembles the totipotent two-cell 
stage and expresses 2-cell genes including Zscan4, which is crucial for repair and 
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maintenance of telomeres and genomic stability (Macfarlan et al., 2012; Surani and 
Tischler, 2012). Dan et al. (2013) showed that Tbx3 can activate Zscan4 promoter activity 
by negatively regulating DNA methylation, suggesting a role for Tbx3 in telomere 
maintenance and the self-renewal of ESCs. 
 
While there is limited information of Tbx2 in stem cell biology, microarray studies on 
somatic stem cell populations have revealed that Tbx2 gene expression is upregulated in 
hematopoietic stem cells (Park et al., 2002) and the epithelial basal stem-cell like 
population (Rock et al., 2009). However, further investigations are needed to confirm the 
role of Tbx2 in somatic stem cell populations.  
 
1.3.3 TBX2 and TBX3 in cancer   
In recent years, T-box factors have also been implicated in the progression of cancer. For 
example, Fernando et al. (2010) reported that in human pancreatic tumour cells, 
elevated levels of Brachyury induces epithelial-mesenchymal transition (EMT), a process 
allowing primary tumour cells to acquire a motile phenotype which promotes metastasis. 
In contrast, Brachyury can also function as a tumour suppressor as evidenced by the fact 
that its expression is reduced in non-small cell lung tumours compared to normal tissues 
due to epigenetic silencing (Park et al., 2008). Similarly, T-bet (also known as TBX21) has 
been implicated as both a tumour promoting and tumour suppressor factor. T-bet was 
found overexpressed in a subset of estrogen receptor alpha positive (ERα+) breast 
cancers which was associated with a negative impact on sensitivity to hormonal therapy 
and prognosis (McCune et al., 2010). In addition, a study by Stoicov et al. (2009) showed 
that T-bet knockout (KO) mice were protected from Helicobacter felis-induced gastric 
cancer. On the other hand, a clinicopathological study from Zhang et al. (2012) suggested 
a tumour suppressor role for T-bet in gastric cancers. The authors observed that the 
T-bet T-1993C polymorphism, which results in the repression of T-bet expression (Li et al., 
2011), correlated with increased risk of gastric cancer, especially with distant metastasis. 
Three other studies also revealed a tumour-suppressing role for T-bet and/or 
Eomes (also known as T-box brain protein 2) through a T cell-mediated adaptive 
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antitumour immunity (Atreya et al., 2007; Zhu et al., 2010; Chen et al., 2013). Moreover, 
a tumour suppressing role has also been reported for Tbx1, TBX4 and TBX5. In many 
mouse skin tumours the expression of Tbx1 was found to be reduced and the 
re-expression of it significantly suppressed tumour growth in vivo and inhibited cell 
proliferation and anchorage-independent growth in cultured cells (Trempus et al., 2011). 
Proteomic analysis in pancreatic ductal cell adenocarcinoma showed that low TBX4 
expression correlates with increased metastasis and reduced patient survival rate (Qi et 
al., 2008; Zong et al., 2011). Similar to Brachyury, TBX5 has been found to be 
downregulated in colon cancer cell lines due to promoter methylation, and re-expression 
of TBX5 in these cells inhibited cell proliferation, migration and colony formation and 
induced apoptosis (Yu et al., 2010). Importantly, the T-box factors most frequently 
implicated in carcinogenesis are TBX2 and TBX3, and so the rest of this review will 
examine the role of these two transcription factors in cancer. 
 
In the last decade, the abnormal expression of TBX2 and TBX3 has been associated with 
a growing list of cancers including breast (Jacobs et al., 2000; Sinclair et al., 2002; Fan et 
al., 2004; Yarosh et al., 2008; Fillmore et al., 2010), pancreatic (Mahlamäki et al., 2002; 
Hansel et al., 2004; Duo et al., 2009), liver (Renard et al., 2007), ovarian (Lomnytska et al., 
2006), gastric (Yamashita et al., 2006), endometrial adenocarcinoma (Liu et al., 2010), 
glioblastomas (Etcheverry et al., 2010), colorectal (Han et al., 2013), uterine cervical 
(Lyng et al., 2006), bladder (Ito et al., 2005; Kandimalla et al., 2012) and melanoma 
(Hoek et al., 2004; Vance et al., 2005; Rodriguez et al., 2008). Relevant to this thesis, 
TBX2 is located on chromosome 17q22–q24, a region that is frequently amplified in 
many cancers including BRCA1/2-associated breast tumours (Bärlund et al., 2000; Jacobs 
et al., 2000; Sinclair et al., 2002; Adem et al., 2004) and of the many cancer types in 
which TBX3 is overexpressed, it has been most extensively assessed in cultured breast 
cancer subtypes and patient samples (Fan et al., 2004; Lomnytska et al., 2006; Yarosh et 





1.3.3.1 TBX2 and TBX3 in senescence, proliferation and apoptosis 
Three early studies suggested that both TBX2 and TBX3 may directly contribute to cancer 
progression by showing that they are able to immortalize mouse embryonic fibroblasts 
(MEFs) and ST.HdhQ111 striatal cells by bypassing senescence, one of the critical 
self-protection mechanisms against cancer (Jacobs et al., 2000; Carlson et al., 2001a; 
Brummelkamp et al., 2002a; Hanahan and Weinberg, 2011). These groups and others 
further showed that the anti-senescence effect is due to TBX2 and TBX3 directly 
repressing mouse p19ARF and human p14ARF through a variant T-site in their initiators 
(Jacobs et al., 2000; Carlson et al., 2001a; Brummelkamp et al., 2002a; Lingbeek et al., 
2002). The anti-senescence function of TBX2 was further investigated by Prince et al. 
(2004) and they found that the overexpression of TBX2 bypassed cell senescence in 
ST.HdhQ111 striatal cells by binding and repressing the cyclin-dependent kinase inhibitor 
p21 promoter via a T-element in its initiator region (Prince et al., 2004a). In addition, the 
role of TBX2 in transformed cells was first investigated by Vance et al. (2005) who 
demonstrated that TBX2 is overexpressed in many melanoma cell lines. The authors 
further showed that high TBX2 levels maintain a high proliferation rate and allow these 
cells to escape senescence by repressing p21 in association with histone deacetylase 1 
(HDAC1). Their data was further validated by inducibly expressing a dominant-negative 
Tbx2 in B16 mouse melanoma cells that led to senescence and elevated levels of p21 
(Vance et al., 2005). The anti-senescence effect of TBX2 has also been observed in 
human vertical growth phase melanoma when TBX2 expression was silenced by a shRNA 
approach (Peres et al., 2010). In contrast, however, no anti-senescence function of TBX3 
has yet been shown in transformed cells. Furthermore, whether TBX2 and TBX3 have 
distinct cell type-specific roles in regulating proliferation in transformed epithelial cells is 
not known. 
 
In line with the pro-proliferative role of TBX2 in mouse and human melanoma cells, Peres 
et al. (2010) showed that the knockdown of TBX2 significantly reduced cell proliferation 
in the 501mel metastatic melanoma cell line (Vance et al., 2005; Peres et al., 2010). 
MCF-7 breast cancer cells also require TBX2 to drive proliferation (Peres et al., 2010; 
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Redmond et al, 2010) which was shown to result from TBX2 interacting with early 
growth response 1 (EGR1) to target and repress N-myc downregulated gene 1 (NDRG1), a 
breast tumour suppressor. Some studies also suggest that Pax3 and Mitf, two potent 
pro-proliferative factors in melanomas upstream of TBX2, may activate TBX2 to promote 
cell proliferation (Carreira et al., 2000, 2006; Liu et al., 2013). There is also evidence that 
TBX3 may function to promote cell proliferation. For example, Ito et al. (2005) showed 
that reducing Tbx3 expression by an anti-sense approach in rat bladder carcinoma cells 
slowed down proliferation of these cells. Moreover, TBX3 was identified in an 
array-based search to be downstream of Wnt/β-catenin, a growth promoter, in the 
human hepatoma cell line HepG2 (Renard et al., 2007). In the same study the authors 
employed a dnTBX3 approach and showed that TBX3 promotes cell proliferation of these 
cells. In contrast, silencing TBX3 was reported to increase cell proliferation in vertical 
growth phase (VGP) melanoma, metastatic melanoma and breast cancer cells suggesting 
an anti-proliferative role of TBX3 in transformed epithelial cells (Peres et al., 2010). In 
summary, while there is consistent data supporting a role for TBX2 as a pro-proliferative 
factor, the data for TBX3 suggests that its role in proliferation may be cell-type and/or 
cell-context dependent. 
 
In addition to the role of TBX2 in promoting cell proliferation, Davis et al. (2008) reported 
that ectopic expression of TBX2 in transformed fibroblasts and murine melanoma cells 
with low endogenous TBX2 levels induced several key features of genomic instability 
such as chromosome missegregation, chromosomal rearrangements and polyploidy. 
During cancer progression, tumour cells gradually acquire functional capabilities to 
enable them to survive, proliferate, invade and disseminate. The development of 
genomic instability is therefore critically important because it allows tumour cells to 
generate random mutations enabling them to adapt to unfavourable conditions 
(Hanahan and Weinberg, 2011). Davis et al. (2008) also demonstrated that the TBX2 
overexpressing cells become more resistant to cisplatin treatment, a widely used 
chemotherapeutic agent. The cisplatin resistance conferred by endogenous 
overexpression of TBX2 in TBX2-driven cancers was soon confirmed by Wansleben et al. 
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(2013). The authors revealed a mechanism by which this occurs by showing that 
knocking down TBX2 sensitises the cells to cisplatin by disrupting the ATM-CHK2-p53 
signalling pathway. Another study by Ismail & Bateman (2009) also reported that ectopic 
TBX2 expression in the p53-negative SW13 adrenocortical carcinoma cell line increased 
resistance to apoptotic stimuli, including doxorubicin, by upregulating apoptosis inhibitor 
cIAP2/BIRC3 and dampening UV–irradiation induced activation of caspase 3, 8 and 9 
which are key mediators of apoptosis.  
 
There is evidence that TBX3 may also contribute to the oncogenic process and to render 
cells resistant to anti-cancer drugs by enabling them to evade apoptosis. For example, it 
was reported that elevated Tbx3 levels protected primary MEFs against oncogene 
Myc-induced apoptosis (Carlson et al., 2002) and that knocking down Tbx3 in rat bladder 
carcinoma cells triggered apoptosis (Ito et al., 2005). Furthermore, two other studies 
showed that modulating TBX3 levels impacted on p53-dependent apoptosis induced by 
doxorubicin, a DNA damaging agent. One group found that TBX3 is a critical downstream 
mediator of β-catenin survival functions in human colon carcinoma and osteosarcoma 
cell lines and that overexpression of TBX3 in these cells conferred resistance to 
doxorubicin-induced apoptosis (Renard et al., 2007). Another group showed that the 
suppression of TBX3 by the aqueous extract of Fructus Ligustri Lucidi sensitized the 
human colorectal carcinoma, DLD-1 cells, to doxorubicin-induced apoptosis (Zhang et al., 
2011). Moreover, in head and neck squamous carcinoma cell lines, TBX3 was also shown 
to protect against anoikis, a specific type of programmed cell death which is triggered by 
the loss of substrate in anchorage dependent cells (Humtsoe et al., 2012). Together, 
these studies all point to the important role of TBX2 and TBX3 in anti-cancer drug 
resistance and the regulation of apoptosis, however, the detailed mechanisms behind 
this still remains to be further elucidated.   
 
1.3.3.2 TBX2 and TBX3 in tumour formation, invasion and metastasis 
The ability of cells to proliferate in the absence of a substrate is widely accepted as an 
important hallmark of cancer cells and is referred to as either substrate- or anchorage- 
21 
 
independent growth (Carney et al., 1980). Anchorage-independent growth not only 
allows cancer cells to grow on top of one another to form tumours but also enables 
them to break away from a monolayer, favouring migration and metastasis. To date, both 
TBX2 and TBX3 have been implicated in promoting anchorage-independent growth. 
Using a soft agar assay, Ismail and Bateman (2009) demonstrated that the 
overexpression of TBX2 confers anchorage-independence on SW13 adrenocortical 
carcinoma cells. Renard et al. (2007) reported that siRNA-mediated Tbx3 depletion 
dramatically reduced the anchorage-independent growth of hepatoma and colon 
carcinoma cells and that injection of cells expressing mutant Tbx3 in nude mice 
significantly inhibited tumour formation. Using a shRNA approach, the same oncogenic 
roles were observed for TBX2 and TBX3 in melanoma cells (Peres et al., 2010). As 
mentioned above, reduced Tbx3 expression also renders cells more susceptible to 
suspension-induced cell death (Humtsoe et al., 2012).  
 
Invasion and metastasis are essential mechanisms by which cancer cells escape the 
primary tumour mass and re-locate to form distant colonies. This dissemination of 
tumour cells is the ultimate cause of death in 90% of cancer patients (Hanahan et al., 
2000). A strong correlation has been observed between TBX3 mRNA expression and 
breast cancer metastasis (Chen et al., 2009) and TBX3 expression was shown to correlate 
with ERα+ tumours and metastatic recurrence (Fillmore et al., 2010). In line with these 
findings, Rodriguez et al. (2008) reported that TBX3 promotes melanoma invasiveness in 
vitro as siRNA-induced TBX3 depletion significantly reduced cell migration. Moreover, 
two studies from our laboratory showed similar results. We demonstrated that silencing 
TBX3 using shRNA reduced migration in both melanoma and breast cancer cells (Peres et 
al., 2010) and that TBX3 could mediate PMA-induced breast cancer cell migration 
(Mowla et al., 2011). Furthermore, a recent study from Wang et al. (2012) demonstrated 
that silencing TBX2 led to reduced tumour cell migration and metastatic potential and a 
meta-analysis of TBX2 expression in 1107 primary human breast tumours revealed that 
TBX2 is highly expressed in metaplastic breast cancers with poor prognosis and is 
associated with shortened recurrence-free survival.  
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TBX3 and TBX2 have also recently been associated with epithelial-mesenchymal 
transition (EMT), an emerging interesting topic. It has been widely observed that EMT 
plays an essential role during development and is characterised by loss of epithelial cell 
junctions, apical-basal polarity and the development of a fibroblast-like motile 
phenotype (Thiery et al., 2009; Heldin et al., 2012; Humtsoe et al., 2012). At a molecular 
level EMT is associated with downregulated expression of epithelial markers such as 
cytokeratin and E-cadherin and increased expression of mesenchymal markers such as 
N-cadherin, fibronectin and vimentin (Kalluri and Weinberg, 2009). EMT occurs in 
response to certain signalling stimuli and during cancer progression dysregulated 
signalling pathways can render a more motile phenotype to cancer cells and facilitate 
metastasis (Klymkowsky and Savagner, 2009; Thiery et al., 2009). In vivo and in vitro 
studies in many cancer cell types have revealed the invasion suppressive role of 
E-cadherin (Jawhari et al., 1997; Richmond et al., 1997; Karatzas et al., 1999; 
Karayiannakis et al., 2001; Joo et al., 2002). In many types of epithelial-derived cancers 
such as breast, ovarian and non-small cell lung carcinoma, loss of E-cadherin disrupts 
intercellular contacts and facilitates metastasis (Sulzer et al., 1998; Onder et al., 2008; 
Rodriguez et al., 2008; Sawada et al., 2008). The repression of the adhesion molecule 
E-cadherin has therefore been suggested as one of the critical contributors in the 
EMT-driven cell invasion (Thiery, 2002; Thiery et al., 2009; Kallergi et al., 2011).  
 
Two studies reported that high TBX3 expression observed in many melanoma cell lines 
and squamous carcinoma correlates with a low E-cadherin expression (Rodriguez et al., 
2008; Humtsoe et al., 2012). A recent study showed that Tbx3 knockdown partially 
reduces cell invasion in squamous carcinoma cells and TBX3 was found to be one of the 
strongly upregulated genes in EMT-like cells and Snail-mediated EMT, suggesting that 
TBX3 promotes invasion in these cells as part of the EMT process (Humtsoe et al., 2012). 
This is consistent with the report from Rodriguez et al. (2008) who showed that Tbx3 can 
directly bind and repress the E-cadherin promoter through a T-element in its initiator. 
Furthermore, they showed that silencing Tbx3 leads to increased E-cadherin mRNA and 
protein levels and conversely, ectopic Tbx3 expression results in reduced levels of 
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E-cadherin. Our group also showed that the silencing of TBX3 by shRNA, significantly 
increased E-cadherin mRNA levels in VGP and metastatic melanoma cells (Peres et al., 
2010). Moreover, Wang et al. (2012) demonstrated that TBX2 alone is able to induce EMT, 
with reduced expression of epithelial markers including E-cadherin, and promotes 
migration and invasiveness in mammary epithelial cells. They further showed that TBX2 
directly binds and represses the activity of the proximal E-cadherin promoter which may 
contribute to the pro-metastatic activities of TBX2-driven EMT in breast cancer cells 
(Wang et al., 2012). Together, while the detailed molecular mechanisms of how TBX3 and 
TBX2 promote invasion and metastasis remain largely to be elucidated, these findings 
suggest that TBX3 and TBX2 may have crucial roles in malignant tumour progression 
through inducing EMT and promoting cell invasiveness and that they may both serve as 
novel prognostic markers. 
 
1.3.3.3 The regulation of TBX2 and TBX3 in cancer 
Since the deregulation of TBX2 and TBX3 levels has devastating consequences on normal 
cell function which contributes to cancer, it is very important to understand how these 
proteins are regulated. However, only a few signalling pathways have been identified 
that regulate TBX2 and TBX3 gene expression in cancers. 
 
PKC signalling pathway 
The protein kinase C (PKC) family consists of serine/threonine-specific protein kinases 
which promote tumourigenesis by modulating cell proliferation, migration, apoptosis 
and survival (Griner and Kazanietz, 2007; Marengo et al., 2011). Many studies which 
have investigated the role of the PKC pathway have employed the phorbol ester 
12-O-tetradecanoylphorbol-13-acetate (TPA, also called PMA) which activates PKC 
isoforms by translocating them to specific cellular compartments (Parker et al., 1987; 
Basu et al., 1990; Marengo et al., 2011). Though acting through different mechanisms, 
both TBX2 and TBX3 have been reported to be induced by TPA in a PKC-dependent 
manner (Teng et al., 2009; Mowla et al., 2011). Teng et al. (2009) demonstrated that 
TBX2 is transcriptionally activated by TPA-activated PKC signalling in normal and 
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transformed embryonic fibroblasts. The authors show that this occurs through activation 
of the mitogen- and stress-activated kinase 1 (MSK1), a protein that phosphorylates 
histone H3, resulting in chromatin remodelling of the TBX2 promoter which enhances 
binding and transcriptional activation by Sp1. A study by Mowla et al. (2011) showed 
that activation of the TPA induced PKC signalling pathway led to the upregulation of TBX3 
mRNA and protein levels via the activator protein-1 (AP-1) transcription factors c-Jun and 
JunB. They further show that these factors transcriptionally activate TBX3 through 
binding a non-consensus TPA response element. Using in vitro motility assays, this PKC 
regulated activation of TBX3 was shown to promote cell migration of MCF-7 human 
breast cancer cells, suggesting a mechanism by which TBX3 may contribute to metastasis. 
Taken together these studies revealed that, while TBX2 and TBX3 share a high degree of 
homology, they may be regulated by different mechanisms in the same signalling 
pathway.  
 
PI3K signalling pathway  
The phosphatidylinositol-3-kinase (PI3K) signalling pathway has also been shown to 
regulate both TBX2 and TBX3. This pathway has been implicated in tumourigenesis for its 
potent contribution to cancer cell growth, cell cycle regulation, adhesion, survival and 
metastasis and thus has been suggested as a drug target in the treatment of certain 
human cancers (Roymans and Slegers, 2001; Courtney et al., 2010). Upon activation by 
growth factor signals, PI3K phosphorylate inositol lipids in the plasma membrane, 
leading to the recruitment of serine/threonine kinase Akt (also known as protein kinase 
B) which in turn conducts a series of downstream regulatory activities (Fry, 2001; Osaki 
et al., 2004; Hemmings and Restuccia, 2012). TBX2 levels were shown to be upregulated 
in p53-negative SW13 adrenal carcinoma cells by growth factor FGF4 in a 
PI3K-dependent manner and this upregulation was abrogated when the phosphorylation 
of Akt was inhibited (Ismail and Bateman, 2009). Moreover, Niwa et al. (2009) 
investigated the pluripotency of mESCs and showed that TBX3 expression is positively 
regulated by the cytokine leukaemia inhibitory factor (LIF), an ESC self-renewal factor, via 
the PI3K-Akt pathway. Unpublished data from our laboratory have also demonstrated 
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that TBX3 is phosphorylated by AKT in advanced melanoma and that this leads to 
increased TBX3 protein stability, nuclear localisation, transcriptional activity and that it 
mediates Akt-induced melanoma cell migration.  
 
Wnt/β-catenin signalling pathway 
The Wnt/β-catenin signalling pathway serves as a critical mediator for both 
embryogenesis and adult tissue maintenance by regulating cell fate, proliferation and 
differentiation (Logan and Nusse, 2004). It is therefore not surprising that deregulated 
Wnt/β-catenin signalling gives rise to many human degenerative diseases and cancers, 
especially the promotion of liver tumourigenesis (Kondo et al., 1999; Inagawa et al., 
2002; Thorgeirsson and Grisham, 2002; Goodall et al., 2004; Logan and Nusse, 2004). 
The Wnt/β-catenin signalling pathway has been implicated in the activation of both TBX2 
and TBX3. For example, Verhoeven et al. (2011) showed that in response to 
Wnt/β-catenin signalling Tbx2 is activated by the bone morphogenetic proteins 2 and 4 
during heart patterning. In addition, the inhibition of β-catenin degradation by treating 
pancreatic cancer cells with lithium chloride induced TBX2 mRNA and protein expression 
(Chen et al., 2008a). Moreover, an array-based search revealed that high TBX3 levels 
were associated with a mutant active form of β-catenin in both human and mouse 
hepatocellular carcinomas and human hepatoblastomas (Renard et al., 2007). In the 
same study it was demonstrated that TBX3 can be upregulated by co-operative binding 
of β-catenin with its co-activator T-cell factor (Tcf) to a Tcf-binding element on the TBX3 
promoter. The authors further showed that TBX3 mediates β-catenin functions in 
hepatocellular carcinoma proliferation and survival.  
 
FGF signalling pathway 
The estrogen/FGF signalling pathway has been demonstrated to regulate Tbx3 
expression in the expansion of breast cancer stem cells (breast CSC) (Fillmore et al., 
2010). This drug-resistant subpopulation of breast cancer cells, which can be isolated 
from primary tumours or cell culture, drives the long process of cancer progression and 
is usually associated with high tumour recurrence (Fillmore and Kuperwasser, 2008). 
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Fillmore et al. (2010) observed that oestrogen treatment of ERα+ MCF-7 cells led to Tbx3 
expression being induced by paracrine FGF9/FGFR3 signalling. Their group also showed 
that the FGF/Tbx3 signalling is conserved in ERα− SUM149, SUM159 and BT-20 breast 
cancer cell lines and that the knockdown of Tbx3 mRNA in these cells significantly 
reduced the number of CSCs and mammosphere forming ability. These data suggest that 
FGF/Tbx3 signalling plays a critical role in enhancing breast cancer tumourigenesis 
through expanding the breast CSC population and is consistent with their findings that 
chemotherapy-resistant breast tumour cell lines generally have high Tbx3 levels (Fillmore 
et al., 2010). 
 
Retinoic acid signalling pathway 
All-trans retinoic acid and its derivatives are used as anti-cancer agents and 
compromised retinoic acid (RA) signalling is often found early in tumourigenesis, 
including breast cancer (Tang and Gudas, 2011; Garattini et al., 2012). Besides the 
regulation of TBX1 and TBX5 by RA during development, a few studies have suggested 
that RA may also be able to regulate TBX2 and TBX3 (Liberatore et al., 2000; Boskovic 
and Niles, 2004; Roberts et al., 2005; Ballim et al., 2012; Sakabe et al., 2012). For 
example, Boskovic & Niles (2004) showed that RA upregulated Tbx2 transcriptionally in 
B16 mouse melanoma cells by directly binding a degenerate retinoic acid response 
element (RARE) between -186 bp and -163 bp in the Tbx2 promoter region. In contrast, a 
recent study revealed that during murine outflow tract development, ectopic RA 
expression represses Tbx2 transcription via direct binding to a highly conserved RARE 
located 210 bp downstream of the Tbx2 transcriptional start site (Sakabe et al., 2012). A 
study from our laboratory also revealed that in human melanoma cell lines RA is a direct 
transcriptional activator of TBX3 through its direct binding to a degenerate RARE half site 
at −87 bp (Ballim et al., 2012). This study also showed that the RA-induced TBX3 
expression correlates with decreased cell proliferation and a knockdown of TBX3 
expression by a shRNA approach significantly reduced the growth-inhibitory effect of RA. 
Taken together these results suggest that TBX3 partly mediates the RA-regulated 





DNA damage stress signalling pathway 
The DNA damage repair pathway is frequently altered in cancer cells and a study 
performed in our laboratory showed that Tbx2 mRNA and protein levels are upregulated 
by UVC-induced DNA damage in MCF-7 cells (Abrahams et al., 2008; Bouwman and 
Jonkers, 2012). In response to UV treatment the p38 MAP kinase was activated and 
phosphorylated Tbx2 on serine residues 336, 623 and 675. This phosphorylation not only 
increased Tbx2 protein stability and nuclear localisation, but it also enhanced the ability 
of Tbx2 to repress its target gene p21. This may provide an explanation for how TBX2 
may disrupt cell cycle control to favour tumourigenesis.  
 
1.6 Overview of the transforming growth factor β (TGF-β) superfamily   
The transforming growth factor β (TGF-β) superfamily comprises a multitude of dimeric 
polypeptide growth factors which have been identified in a wide variety of species 
including at least 30 in mammals. According to their sequence similarities and unique 
manner of signal transduction, these ligands are divided into two functional groups: (1) 
the TGF-β-like group which includes TGF-βs, Activins and Nodals and some Growth and 
Differentiation Factors (GDFs) and (2) the Bone Morphogenetic Proteins (BMP)-like group 
consisting of BMPs, most GDFs and Anti-Müllerian Hormone (AMH) (Weiss and Attisano, 
2012). In humans, three isoforms of TGF-β have been described, namely TGF-β1, TGF-β2 
and TGF-β3. Each isoform is encoded by a distinct but highly conserved gene in 
mammals, giving them unique and overlapping features in terms of spatial expression 
and biological functions. Besides the essential roles of the TGF-β superfamily in 
regulating fundamental cellular processes such as proliferation, apoptosis, adhesion and 
migration, they also have critical functions throughout the entire development of 
multicellular organisms. For example, during early development, Nodal signalling and 
BMP morphogen gradients have essential roles in germ layer formation, determination 
of the left/right axis and body patterning. In addition, several mouse studies suggest that 
the haploinsufficiency of TGF-β superfamily members or the malfunctioning of their 
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receptors in late developmental stages leads to defects in cardiac, kidney, bone, liver, 
gastrointestinal tract and gonad development (Affolter and Basler, 2007; Gordon and 
Blobe, 2008; Mizutani and Bier, 2008; Schier, 2009; Wu and Hill, 2009; Zakin and De 
Robertis, 2010). Disruption of TGF-β signalling is therefore detrimental to human health 
and mutations in mediators of this pathway have been associated with the pathogenesis 
of cancer and a range of autoimmune, muscle, cardiovascular and skeletal diseases 
(Gordon and Blobe, 2008; Moses and Barcellos-Hoff, 2011).  
 
1.4.1 TGF-β1/Smad signalling pathway  
The most well defined TGF-β1 signalling cascade is the canonical Smad signalling 
pathway (Feng and Derynck, 2005) (Fig. 1.4). On the cell surface, TGF-β1 signals through 
“type I” and “type II” receptors, also referred to as TGFβRI and TGFβRII respectively, 
which are structurally similar but differ slightly in their amino acid sequences. The 
complex formed by the binding of TGF-β1 to TGFβRII recruits and phosphorylates the 
TGFβRI, which in turn phosphorylates Smad2 and Smad3 (receptor-activated Smads, also 
known as R-Smads) to release them from the TGFβRI. The phosphorylated Smad2/3 can 
form a complex with Smad4 (common-Smad, also known as Co-Smad), and translocate 
to the nucleus where they bind target genes at a consensus Smad-binding-element (SBE) 
with the sequence 5’-GTCTAGAC-3’ (Massagué et al., 2005). While the TGF-β1 signalling 
pathway has mostly been associated with transcriptional activation there is also 
evidence that it transcriptionally represses target genes. Both R-Smads and Co-Smads 
can bind to DNA, however Smad2 has a small insert which interferes with its DNA 
binding β-hairpin (Shi et al., 1998). Several GC-rich regions have also been identified as 
alternate binding sites for Smad proteins, suggesting that ‘GNCN’ may be a degenerate 
SBE. Interestingly, the affinity of Smads for a single SBE is low and most natural 
promoters regulated by Smads therefore possess multiple SBEs or the Smads physically 
interact with sequence-specific transcription factors as partners to ensure high-affinity 
binding (Fig. 1.4) (Feng and Derynck, 2005; Massagué et al., 2005). Previous reports and 
recent chromatin immunoprecipitation (ChIP) sequencing results revealed that the 
diverse range of SBEs and the transcriptional outcome of Smad signalling are highly 
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dependent on associated spatially and temporally available co-factors (Chen et al., 2008b; 
Morikawa et al., 2011; Mullen et al., 2011). Furthermore, the amplitude of their 
transcriptional activity also depends on the involvement of co-activators or co-repressors 
which will be discussed below.  
 
 
Figure 1.4 Schematic representation of the canonical TGF-β1/Smad signalling pathway. 
 
1.4.2 Transcription factor-related TGF-β1/Smad regulation of gene expression   
TGF-β1 induced transcriptional activation is generally based on the co-operation of Smad 
proteins with sequence-specific DNA binding transcription factors at the promoter of 
target genes. However, Smad proteins alone can also activate some early response genes. 
For example, the AP-1 family member JunB can be directly activated by Smad proteins in 
an immediate response to TGF-β1 signalling via multiple SBEs in the JunB promoter (Jonk, 
1998). Similarly, the Id1 gene is also activated by Smad3/4 from as early as 0.5 hours 
after TGF-β1 treatment (Liang et al., 2009). In most cases the co-operation between 
activated Smad proteins and other sequence-specific DNA binding transcription factors 
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have a synergistic activating effect. For example, activated Smad2/3 and Smad4 form a 
complex with FoXO proteins and bind to adjacent multiple SBEs and the FoXO binding 
element on the distal p21 promoter (Seoane et al., 2004). A similar mechanism has been 
reported for the binding and activation of the Smad2/3/4/Sp1 complex on the p15Ink4b 
(hereafter referred to as p15) promoter (Feng et al., 2000). Interestingly, the proximal 
region of the p21 promoter can also be bound by the Smad3/4/Sp1 complex, suggesting 
that a single promoter can have multiple Smad complexes bound at different locations. 
However, in this case, the binding of Smads to the proximal region is not essential for the 
activation of the p21 promoter, but it enhances the activation by Sp1 (Pardali et al., 
2000). A similar mechanism operates when GATA-3 recruits Smad3 to the GATA-specific 
DNA binding site on the IL-5 promoter upon TGF-β1 stimulation. The complex which is 
formed activates IL-5 independent of Smad3 binding to DNA (Blokzijl et al., 2002). In line 
with the fact that Smad3 can form complexes with AP-1 factors, several reports 
demonstrate a co-operative activation between Smad proteins and AP-1 factors on 
artificial as well as c-Jun and COL7A1 promoters (Zhang et al., 1998; Liberati et al., 1999; 
Wong et al., 1999; Verrecchia et al., 2001). In addition to the SBE and transcription factor 
binding sites on the promoter, a recent study using ChIP-on-chip technology revealed a 
novel SBE located within the first intronic region of the p21 gene, forming a unique 
cis-regulating region together with Ets1 and AP-1/AP-2 transcription factors (Koinuma et 
al., 2009). 
 
In addition to sequence-specific transcription factors, Smads can also recruit 
co-activators to the protein/DNA complex to further enhance Smad-mediated activation. 
Such co-activators include CBP/p300, ARC and the Mediator complex which increase 
transcription by bringing the Smad-interacting transcription factors closer to the RNA 
polymerase II complex, thereby bridging upstream transcription factors with the general 
transcription machinery (Arias, 1996; Kato et al., 2002; Soutourina et al., 2011). The 
histone acetyltransferase activity of CBP/p300 also allows chromatin restructuring which 
improves accessibility of genes such as Id1 for transcription (Liang et al., 2009). Other 
co-activators, such as ZEB1, augment transcription by promoting Smad-CBP/p300 
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interaction (Postigo, 2003).   
 
While much less is known about TGF-β1 driven gene repression, several studies have 
reported on its repressive ability and the underlying roles in cellular activities. Some 
mechanisms of repression involve the prevention of transcriptional activation of target 
genes. For example, in response to TGF-β1, the activated Smad3 binds to MyoD thereby 
interfering with its heterodimerisation with E12 and E47 and hence with DNA binding. 
This results in decreased binding of the complex to E-box response elements on MyoD 
target genes responsible for myogenic differentiation (Liu et al., 2001a). In addition, 
upon TGF-β1 signalling, the cytoplasmic Smad3 can form a repressive complex with both 
E2F-4 or E2F-5 and p107, a RB pocket protein known to recruit HDAC. Smad4 then leads 
the complex into the nucleus to bind to a unique TGF-β1 inhibitory element (TIE) on the 
c-myc promoter which overlaps with a consensus E2F site, and exerts repressive activity. 
(Chen et al., 2001, 2002; Yagi et al., 2002; Frederick et al., 2004). Similarly, the repression 
of the osteocalcin promoter also depends on the recruitment of HDAC to the promoter 
by Smad3 (Kang et al., 2005). TGF-β1 has also been shown to promote target gene 
repression through upregulation of a repressor. For example, in TGF-β1 induced 
repression of Id1, ATF3, a dominant negative regulator of basic helix-loop-helix (bHLH) 
transcription factors that are implicated in cell proliferation and tumourigenesis, is first 
promptly upregulated by TGF-β1. The activated ATF3 in turn interacts with Smad3 to 
repress Id1 expression through binding to the Id1 promoter (Kang et al., 2003).  
 
1.4.3 TGF-β1/Smad signalling pathway in cancer  
TGF-β1 signalling has been widely reported to have a dual role in the progression of 
cancer. As shown in Figure 1.5 while it acts as a tumour suppressor and inhibits cell 
proliferation during the early stages of carcinogenesis, it promotes migration and 




Figure 1.5 Role of TGF-β1 signalling in cancer progression (Figure from Heldin et al., 
2012). 
 
1.4.3.1 Tumour suppressor activity of TGF-β1 in early stages of carcinogenesis 
TGF-β1 generally functions as a tumour suppressor by inhibiting cell proliferation, 
differentiation, apoptosis and preventing tumourigenic inflammation (Fig. 1.5) (Heldin et 
al., 2012). Due to the interest of the current project, the following sections of this 
literature review will focus on the mechanism by which TGF-β1 inhibits cell proliferation 
and promotes apoptosis. 
 
In the cellular context of rapidly growing cells such as epithelial cells, there is a delicate 
balance of homeostasis between the gain and loss of cells. This is a self-protective 
mechanism against tumour formation and TGF-β1 plays an important proliferation 
inhibitory role in this process which was first described in breast epithelial cells (Pierce et 
al., 1993). To date, there has been a significant body of research studying 
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TGF-β1-induced proliferation inhibition which in general, it exerts by inducing cell cycle 
arrest.  
 
During normal cell cycle progression the cyclin dependent kinases, together with their 
cyclin binding partners, drive the transition through G1/S and G2/M. In epithelial cells, 
the anti-proliferative effect of TGF-β1 has been attributed to a G0/G1 cell cycle arrest 
which is primarily caused by upregulating the expression of the cyclin dependent kinase 
(Cdk) inhibitory proteins p15 and p21, which are potent inhibitors of cyclin D–Cdk4/6 
and cyclin E/A–Cdk2 complexes respectively (Reynisdóttir et al., 1995) (Fig. 1.6). One 
mechanism by which p15 and p21 is activated involves a Smad-mediated mechanism in 
co-operation with FoXO proteins, Sp1 and AP-1 transcription factors as described above. 
Another mechanism involves inhibiting the ability of c-myc to repress the p15 and p21 
promoters by interfering with the interaction of c-myc and Myc-interacting zinc-finger 
protein 1 (Miz1) (Claassen and Hann, 2000; Seoane et al., 2001; Staller et al., 2001; Feng 
et al., 2002; Wu et al., 2003). Once induced, p15 inhibits cdk4 resulting in the release of 
p27Kip1 (hereafter referred to as p27) which together with Smad-activated p21 inhibit 
cdk2 kinase activity (Reynisdóttir et al., 1995; Jahn et al., 2012). The reduced kinase 
activity of cdk2 and cdk4 slows down cell cycle progression and therefore inhibits 





Figure 1.6 Fundamental mechanisms of TGF-β1-induced proliferation inhibition. 
(Adapted from Jahn et al., 2012) 
 
Apoptosis is a process of programmed cell death that has critical roles in development, 
cellular homeostasis, immune reactions and many diseases including cancer, AIDS and 
several neurodegenerative disorders (Elmore, 2007). The two main apoptotic pathways 
are the death receptor pathway and the mitochondrial pathway, which lead to the 
activation of caspase 8 or 9 and the apoptosis executioner caspase-3 (Elmore, 2007). 
TGF-β1 has been implicated in a few pro-apoptotic events. For example, early studies 
revealed that TGF-β1 can elicit apoptosis by inducing oxidative stress in fetal hepatocytes 
(Alvarez, 1996) or by activating p38, a stress-responsive mitogen-activated protein kinase, 
in mouse primary hepatocytes (Yoo et al., 2003). A pioneer study that linked TGFβ to the 
apoptotic machinery showed that the death-associated protein Daxx, which associates 
with the Fas receptor in the death receptor pathway, physically interacts with the 
cytoplasmic domain of the TGFβRII (Perlman et al., 2001; Kim et al., 2004). Besides the 
death receptor pathway, mitochondria play an essential role in triggering cell death as 
the release of cytochrome c from mitochondria into the cytoplasm accounts for the 
activation of the apoptotic programme (Wang and Youle, 2009). Larisch et al. (2000) 
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described that in rat prostate carcinoma cells, ARTS (apoptotic-related protein in the 
TGF-β1 signalling pathway), a septin-like protein, translocates from the mitochondria to 
the nucleus in response to TGF-β1 pro-apoptotic stimuli. The authors proposed that 
ARTS is a mitochondrial factor that regulates the activation of cytochrome c.  
 
In addition to the above mechanisms, Smad proteins also play an important role in 
TGF-β1-induced apoptosis. For instance, Jang et al. (2002) connected Smads to 
mitochondrial-based pro-apoptotic events by showing that in response to TGF-β1, 
Smad2, 3 and 4 activate death-associated protein kinase (DAP-kinase) which mediates 
the release of cytochrome c from mitochondria and the dissipation of the mitochondrial 
membrane potential. It was also shown that the AP-1 family members JunD and FosB are 
induced by TGF-β1 and co-operate with Smad proteins to participate in TGF-β1 mediated 
apoptosis (Yamamura et al., 2000). Furthermore, the Smad-dependent upregulation of 
inositol phosphatase SHIP (Src homology 2 (SH2) domain-containing 5' inositol 
phosphatase), an important regulator of phospholipid metabolism, leads to inhibition of 
PKB (protein kinase B)/Akt phosphorylation and cell survival (Valderrama-Carvajal et al., 
2002). It was later found that the sensitivity of TGF-β1-induced apoptosis is determined 
by PKB/Akt modulated phosphorylation of Smad3 (Conery et al., 2004; Remy et al., 
2004). 
 
Other findings linking TGF-β1 to apoptosis include observations that its stimulation lead 
to changes in expression levels or cellular localizations of core components of the cell 
death machinery such as both the pro- and anti-apoptotic members of the Bcl-2 family 
(Saltzman et al., 1998; Yamamoto et al., 1998; Wildey et al., 2003) and the activation of 
caspase proteases (Chen and Chang, 1997; Schiffer et al., 2001; Tótth et al., 2001). These 
core components, together with all the other signalling that the cell receives, further 
determine the cell fate although the exact mechanism of TGF-β1 triggered apoptotic 





1.4.3.2 TGF-β1 promotes late stage tumour progression  
1.4.3.2.1 Evading the TGF-β1 anti-proliferative effect 
In several cancers, including many breast cancers, the anti-proliferative effect of TGF-β1 
is lost to facilitate the progression of malignancies (Bierie and Moses, 2006). Although it 
varies between different cancer types, the mechanisms behind this process generally 
involve somatic mutations in components of the TGF-β1 signalling cascade as well as 
altered expression of key cell cycle regulators. For example, early stage cancer cells lose 
the TGF-β1 governed anti-proliferative effect through alterations in the activity of TGFβRI 
and TGFβRII which may occur at both genetic and epigenetic levels.  
 
In the early 90s, the TGFβRII was reported as a colorectal cancer tumour suppressor as 
its coding sequence was found to be mutated in the majority of sporadic and hereditary 
colorectal cancers with microsatellite instability (MSI). The mutations are caused by a 
deletion or insertion of adenines in a polyadenine repeat, resulting in a truncated 
inactive form of TGFβRII (Markowitz et al., 1995; Parsons et al., 1995; Grady et al., 1999). 
Inactivated TGFβRII has also been observed frequently in gastric cancers and gliomas 
with MSI (Chung et al., 1996; Izumoto et al., 1997) and in some endometrial cancers with 
a frameshift mutation (Parekh et al., 2002). Furthermore, the downregulation of TGFβRII 
expression has also been reported in breast, lung and prostate cancers (Jakowlew, 2006). 
While mutations in TGFβRI are less common, some cases have been reported in breast, 
ovarian, head and neck cancers and T-cell lymphomas (Jakowlew, 2006). 
  
Other mechanisms that were reported to impair normal TGFβRII functioning in cancers 
include epigenetic modification of the gene which reduces the accessibility of the DNA 
for transcription. For example, histone methylation and acetylation/deacetylation were 
shown to result in chromatin remodelling of the TGFβRII leading to its expression being 
downregulated in breast, lung, ovarian and pancreatic cancers (Osada et al., 2005; 
Hinshelwood et al., 2007; Yamashita et al., 2008). In addition, CpG methylation of the 
TGFβRII promoter was also implicated as the cause of gene silencing in human B-cell 
lymphoma cell lines (Chen et al., 2007). Interestingly, later studies using several different 
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lung cancer cell lines suggested that epigenetic silencing of TGFβRII may be due to the 
combined effect of both histone deacetylase and methyltransferase to maintain the 
nucleosome in a compact form (Osada et al., 2005; Chowdhury et al., 2009).  
 
The ablation of TGF-β1 induced proliferation inhibition can also be caused by aberrant 
Smad activity which impairs TGF-β1 signal transduction. In pancreatic and colon cancers, 
Smad2 and Smad4 have frequently been found to be mutated or deleted on 
chromosome 18q21 (Eppert et al., 1996; Hahn et al., 1996; Thiagalingam et al., 1996). 
Although mutations in Smad3 have not been reported, its expression is reduced in 
human gastric cancers which do not respond to TGF-β1 anti-proliferative signals (Han et 
al., 2004). The loss of Smad3 expression has also been marked as a specific feature of 
paediatric T-cell acute lymphoblastic leukaemia (Wolfraim et al., 2004). In addition to the 
negative impact of deregulated c-myc on Smad proteins, several other mechanisms have 
been identified that inactivate the transcriptional activities of Smad3 and Smad4 and 
consequently preventing their ability to inhibit proliferation. For example, the widely 
expressed pro-proliferative transcription factor, serum response factor (SRF), interferes 
with the binding of Smad3 to DNA and its overexpression reduced TGF-β1-induced 
expression of p15 and p21 (Lee et al., 2007). Similarly BCL6, a transcriptional 
co-repressor, can also physically interact with Smad3 and Smad4, disrupting the 
Smad/p300 complex and repressing Smad4 activity in B-cell lymphoma (Wang et al., 
2008a).  
 
Smad7, an inhibitory Smad (I-Smad), also plays an important role in inhibiting TGFβ1 
anti-proliferative signals in many cancer types. Its overexpression has been reported in 
50% of human pancreatic cancers and stable transfection of a Smad7 expression vector 
in COLO-357 pancreatic cancer cells completely abrogated TGF-β1-mediated suppression 
of proliferation (Kleeff et al., 1999). Smad7 was originally reported to exert its repressive 
activity by associating with TGFβRI, and inhibiting its phosphorylation of Smad2 and 
Smad3 which disrupts complex formation with Smad4 and subsequent nuclear 
translocation (Hayashi et al., 1997). Another study using the COLO-357 pancreatic cancer 
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cell line also revealed Smad2/3 independent mechanisms by which Smad7 represses 
TGF-β1-mediated inhibition of proliferation. These mechanisms include interfering with 
TGF-β-mediated repression of cyclin A and B1, inhibition of cdk1 and cdk2 and 
upregulation of p27 (Boyer Arnold and Korc, 2005). Smad7 also functionally inactivates 
retinoblastoma protein (RB) and reverses the repression of E2F activity by TGF-β1 (Boyer 
Arnold and Korc, 2005).  
 
c-Ski is a co-repressor of Smad proteins which renders cells resistant to inhibition of 
proliferation by interfering with the binding of the Smad/p300 complex to DNA and 
recruiting HDAC to inhibit transactivation of a number of anti-proliferative TGF-β1 target 
genes (Akiyoshi et al., 1999; Sun et al., 1999). The amplification of Ski is a negative 
prognostic marker of colorectal cancer and elevated expression of Ski correlates clinically 
with the progression of oesophageal squamous cell carcinoma (Buess et al.; Fukuchi et 
al., 2004). Together with Ski, a highly homologous and structurally similar protein SnoN, 
has also been implicated in the progression of primary cutaneous melanoma (Boone et 
al., 2009). Its repressive action is achieved through binding to Smad2 and Smad4 and 
inactivating their transcriptional activity by recruiting N-CoR, another co-repressor 
(Stroschein, 1999). 
 
The appropriate regulation of key cell cycle proteins is important in the execution of the 
anti-proliferative effects of TGF-β1. As mentioned above, TGF-β1 suppresses proliferation 
by upregulating Cdki proteins p15, p21 and p27 and downregulating cyclins A, B1, D1 
and E (Barlat et al., 1993; Ralph et al., 1993; Reddy et al., 1994; Satterwhite et al., 1994; 
Feng et al., 1995; Ko et al., 1995; Robson et al., 1999; Xie et al., 2003; Hu et al., 2007). 
Anything that interferes with complex formation between cdk/cyclin/cdki would have a 
negative impact on the ability of TGF-β to suppress the proliferation of certain cell types. 
For example, ectopic expression of c-myc abrogates TGF-β1 activated expression of p15 
and p21 and consequently inhibits the TGF-β1-induced anti-proliferative effect (Claassen 
and Hann, 2000; Feng et al., 2002). Several early studies also reported on the 
overexpression of cyclin D and cyclin E in a few mammary epithelial cell lines, primary 
39 
 
keratinocytes and several hepatocellular carcinoma cell lines which are resistant to 
TGF-β1-induced inhibition of proliferation and the reduction of cyclin D in one of these 
studies partially rescued the resistance (Sgambato et al., 1997; Martinez et al., 2000; 
Jong et al., 2002). Furthermore, the constitutive expression of cdk4 in mink lung 
epithelial cells renders them refractory to TGF-β1 and mammary tumours and mink lung 
epithelial cells that are engineered to stably express a cyclin D1-Cdk2 fusion protein are 
also resistant to TGF-β1 induced inhibition of proliferation (Ewen et al., 1993; Chytil et al., 
2004; Corsino et al., 2007) 
 
1.4.3.2.2 TGF-β1 induced EMT in cancer migration and metastasis  
A hallmark of malignant tumours is their ability to metastasize to distant organs through 
a complex series of steps which include: EMT, cell migration, invasion, and intravasation 
and extravasation from the circulatory system (Hanahan et al., 2000; Hanahan and 
Weinberg, 2011). There is considerable evidence to suggest that the overexpression of 
TGF-β1 is linked to tumour progression and the involvement of TGF-β1 in cancer 
metastasis has been extensively studied. High levels of circulating TGF-β1 have been 
reported in the plasma of patients with breast, lung, colon and liver cancer and correlate 
with high death rates (Anscher et al., 1993; Levy and Hill, 2006). Immuno-staining has 
also shown that elevated TGF-β1 levels are associated with a higher rate of metastasis 
and shortened time to relapse in many epithelial cancers. In fact, cancer patients with 
positive staining of TGF-β1, TGFβRI and TGFβRII have the poorest five year survival 
statistics (Takanami et al., 1997).  
 
Figure 1.7 Schematic representation of cells undergoing EMT.  
(Figure from Talbot et al., 2012) 
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As mentioned earlier, EMT plays an important role in metastasis and the mechanism by 
which TGF-β1 promotes cancer cell migration is through its ability to induce EMT. As 
shown in figure 1.7 during EMT, the extracellular matrix is restructured and cell 
adhesion molecules are modified, resulting in a loss of cobblestone-like epithelial 
characteristics and an acquisition of a fibroblastic-like mesenchymal phenotype (Guarino, 
2007; Heldin et al., 2012). This process facilitates the transformation of epithelial 
tumour cells into a malignant metastatic phenotype and enables the invasion of the 
tumour cells into lymph or blood vessels (Thiery et al., 2009). An early in vivo study using 
TGF-β1 transgenic mice showed that TGF-β1 promoted the development of invasive 
spindle skin carcinoma with significantly increased malignant conversion rate (Cui et al., 
1996). Another study demonstrated that the expression of TGF-β1 in papillomas causes 
a loss of the invasion suppressor E-cadherin in the cell membrane and rapid metastasis 
(Weeks et al., 2001). In contrast with the invasion suppressive role of E-cadherin, 
N-cadherin generally functions as a potent invasion promoter (Hazan et al., 2000; 
Cavallaro, 2004; De Wever et al., 2004; Derycke and Bracke, 2004; Nakajima et al., 2004; 
Deramaudt et al., 2006) and TGF-β1-induced EMT has been linked with a transition from 
E-cadherin to N-cadherin. For example, Nakajima et al. (2004) observed a significant 
correlation between TGF-β1, N-cadherin and vimentin in metastatic liver tumours and 
TGF-β1 treatment of pancreatic cancer cells upregulated N-cadherin and vimentin but 
inhibited the expression of E-cadherin. Diamond et al. (2008) further demonstrated that 
TGF-β1 increased the migration of oral keratinocytes by upregulating the expression of 
N-cadherin. These findings were supported by Araki et al. (2011) who reported a strong 
association between a high E-cadherin/N-cadherin ratio and 5-year survival rate, and 
vice versa, of patients with extrahepatic cholangiocarcinoma.  
 
TGF-β1 can induce EMT through transcriptional or post-transcriptional regulation of a 
group of transcription factors which repress E-cadherin (Miyazono, 2009; Heldin et al., 
2012). For example, Smad-mediated expression of high mobility group A2 (HMGA2) has 
been found responsible for the induction of Snail, Slug and Twist which are known to be 
important repressors of E-cadherin (Thuault et al., 2006, 2008; Tan et al., 2012). 
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Interestingly, TGF-β1-induced Smad proteins can also co-operate with factors in other 
pathways to mediate EMT. It has been reported that TGF-β1 co-operates with oncogenic 
H-Ras in both the MAPK and PI3K pathways to activate the Snail promoter (Peinado et al., 
2003), and this co-operation is enhanced by the activation of the transcription factor 
NF-κB (Huber et al., 2004). Moreover, a ChIP-sequencing study of proteins 
immunoprecipitated with ATF3, a known activator of Snail, Slug and Twist, revealed its 
co-operation with Smad2/3 (Yin et al., 2010). TGF-β1-induced EMT can also occur 
through Smad-independent mechanisms which include epigenetic regulation, miRNA 
regulation, differential splicing and regulation of mRNA translation (Heldin et al., 2012). 
Due to the focus of this thesis these mechanisms will not to be discussed in any detail. 
 
1.5  Aims of this study  
The T-box transcription factors, TBX2 and TBX3, play critical roles in embryonic 
development and their deregulated expression has been implicated in a growing list of 
cancers including breast cancer and melanoma. This study aims to elucidate the role of 
the over-expression of TBX3 in breast cancer and to investigate the regulation of TBX2 
and TBX3 by the TGF-β1 signalling pathway. Based on the literature, as well as 
unpublished data from our laboratory, the specific aims of this study were: 
1. To silence TBX3 in breast cancer cells that express high levels of this protein using a 
shRNA approach and to determine whether, at the very least, some features of the 
transformed phenotype could be reversed. 
2. To overexpress TBX3 in “normal” breast epithelial cells and to establish if a 
transformed phenotype could be induced. 
3. To investigate the effect of the TGF-β1 signalling pathway on TBX3 expression in 
breast epithelial cells and its possible function downstream of this pathway. 






MATERIALS AND METHODS  
  
2.1 Plasmids and DNA constructs 
All constructs used in this study were prepared according to standard techniques 
(Sambrook et al, 1989). The pSuper.neo/GFP vectors, containing either a shTBX3- or a 
scrambled shControl- sequence were previously cloned by Dr Emily Davis and are 
available in the Prince laboratory. The human TBX3 promoter luciferase reporter 
constructs have been described previously (Abrahams et al., 2008). The pCMV-JunB 
expression vector was generously provided by Dr. Michael Birrer (National Cancer 
Institute, National Institutes of Health, Bethesda, MD, USA) and the pCMV-Smad3 and 
pCMV-Smad4 expression vectors were from Dr RikDerynck (University of California at 
San Francisco, CA, USA). The human TBX2 promoter luciferase reporter constructs have 
been described previously (Teng et al., 2008). The pcDNA 3.1(+) containing the 
full-length human TBX2 cDNA was supplied by Prof. van Lohuize (Antoni van 
Leeuwenhoek hospital, Amsterdam, The Netherlands). The TBX2 cDNA was then excised 
and the vector re-ligated to generate the pcDNA3.1 (+) empty vector, into which the 
human TBX3 cDNA was cloned using the NheI and BamHI sites. The pRc/CMV containing 
the full-length human p21 cDNA was purchased from Addgene (plasmid # 20814) and 
was provided by Dr William Kaelin (Adams et al., 1996). The p21 cDNA was then excised 
by using HindIII and XbaI and the vector re-ligated to generate the pRc/CMV empty 
vector.  
 
The TBX3 N-terminal construct was constructed by Mrs Aretha Cooper. Briefly, the 
C-terminal portion of the pCMV-TBX3 construct was excised: 1X Reaction buffer, 2 μg 
DNA template, 10 U BglII and 10 U SpeI in a total volume of 50 μl and incubated for 90 
minute (min) at 37 oC. Blunt ends were created using 1 X buffer B, 5 U of T4 DNA 
polymerase (Promega, USA) per μg of DNA and dNTP mix and incubated for 5 min at 
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37 oC followed by heat inactivation at 75oC for 10 min. Product was isolated by running 
through 0.8% agarose gel and purified using QIAquick PCR purification kit according to 
manufacturer’s instruction (Qiagen, USA). The blunt ends were re-ligated using DNA 
ligase, 1 X ligation buffer (Promega, WI, USA) and 100 ng DNA in a total volume of 20 μl. 
The product construct was tested by diagnosis digestion.  
 
2.1.1 Site-directed mutagenesis (SDM) 
The TBX3 DNA binding domain mutant (R133G) construct was produced by Dr Jade Peres. 
Briefly, point mutations were introduced into the pCMV-TBX3 cDNA by site-directed 
mutagenesis using appropriate primer pairs containing the desired mutations (see table 
2.1). Standard polymerase chain reaction (PCR) mix contained: 1X Reaction buffer, 50 ng 
DNA template, 400 nM forward primer, 400 nM reverse primer, 200 nM dNTP mix 
(Promega, Madison, WI USA), 4 μl Dimethyl Sulphoxide (DMSO) (Sigma, St. Louis, MO, 
USA), 3 Units Pfu DNA polymerase (Promega, Madison, WI, USA) in a total volume of 50 
μl. The parameters for PCR amplification were 1 min at 95oC for 1 cycle; 45 second (sec) 
at 95oC, 1 min at 55oC and 14 min at 73oC for 17 cycles. PCR was performed on an 
Applied Biosystems 2720 Thermal cycler. The PCR products were assessed by agarose gel 
electrophoresis to confirm successful amplification. The synthesised DNA containing the 
mutation was selected for by digesting the methylated, non-mutated parental DNA 
template with 1 μl DpnI (10U/μl) endonuclease for 1 hour (hr) at 37oC. XL1-Blue 
supercompetent cells were transformed with 5 μl of the DpnI digested DNA as follows: 
incubation on ice for 30 min, heat shock at 42oC for 1 min and incubation on ice for 2  
min. To each transformation reaction 0.3 ml of Luria broth (LB) (see Appendix, section 
6.1) was added and then incubated for 2 hrs at 37oC with shaking at 225-250 rpm. 
Following incubation, the entire volume of each transformation reaction was plated onto 
LB Ampicillin (100 μg/ml) agar plates. Plates were incubated at 37oC for at least 16 hrs 
and a selection of colonies was expanded by mini-prep culture. DNA constructs extracted 
from these mini-preps were screened for the presence of desired mutation by 




Point mutations were introduced into the pGL3basic-TBX3 promoter luciferase 
constructs containing 141 bp of the 5’ regulatory region of the human TBX3 gene by 
site-directed mutagenesis using appropriate primer pairs containing the desired 
mutations (see Table 2.1). Point mutations were introduced into the pGL3basic-TBX2 
promoter luciferase constructs containing 218 bp of the 5’ regulatory region of the 
human TBX2 gene by site-directed mutagenesis using appropriate primer pairs 
containing the desired mutations (see Table 2.1). 
 
The PCR were performed using 5 μl KAPA HiFi Hot Start Ready Mix 2X (KAPA Biosystems, 
South Africa), 300 nM forward primer, 300 nM reverse primer, 10 ng DNA template in a 
total volume of 10 μl. The parameters for PCR amplification were 2 min at 95oC for 1 
cycle; 20 sec at 98oC, 15 sec at 63oC and 3 min at 72oC for 17 cycles; 5 min at 72oC. PCR 
was performed on an Applied Biosystems 2720 Thermal cycler (Life Technologies 
Corporation, USA). The PCR products were purified using a PCR purification kit (Qiagen, 
USA) and assessed by agarose gel electrophoresis to confirm successful amplification. 
The synthesised DNA containing the mutation was selected for by digesting the 
methylated, non-mutated parental DNA template with 1 μl Dpn I (10U/μl) (Promega, USA) 
endonuclease for 1 hour (h) at 37°C. Dpn I was heat inactivated at 80°C for 20 min and 
Escherichia coli (E.coli) DH5α competent cells were transformed with 10 μl of the Dpn I 
digested DNA by firstly incubating on ice for 30 min, heat pulsing at 42°C for 45 sec and 
incubation for 2 min on ice. To each transformation reaction 0.3 ml of LB was added and 
then incubated for 1 hr at 37°C with shaking at 225-250 rpm. Following incubation, the 
entire volume of each transformation reaction was plated onto LB Ampicillin (100 μg/ml) 
agar plates. Plates were inverted and incubated at 37°C for at least 16 hrs. To confirm 
successful transformation of the mutated plasmid DNA, the presence of the mutation 





Table 2.1 Sequence of primers used to generate mutant TBX2 or TBX3 promoter 
constructs by site-directed mutagenesis. 
Mutant Template Forward primer 










TBX2 (218 bp) WT 
promoter 
5′-GCTGAGGCTTCCaAaAaCTTCTCCCAGGCC-3′ 
pCMV TBX3 DNA  
Binding Domain  
Mutant 
WT TBX3 cDNA full  
length 
5’ CATTACCAAGTCGGGAgGGgGAATGTTTCCTCCATTTAAAG 3’ 
*Primer sequences corresponding to the wild type template are represented in 
uppercase. Mutations are depicted in bold lower case. Putative AP-1 binding sites are 
highlighted in yellow; putative SBEs are highlighted in green and T-element binding sites 
are highlighted in blue. 
 
2.2 Cell culture 
The normal human breast epithelial MCF-12A cells were maintained in complete media 
consisting of DMEM/Ham’s F12 supplemented with 10% FBS, 100 U/ml penicillin, 
0.1 μg/ml cholera toxin (Gibco/BRL), 0.5 μg/ml hydrocortisone (Sigma), 10 μg/ml insulin 
(Sigma), 20 ng/ml EGF (Sigma) and 5% horse serum (Gibco/BRL). HT-1080 human 
fibrosarcoma, WI38 human embryonic lung fibroblasts, HEK293T cells and human 
keratinocyte HaCaT cells were maintained in DMEM (Dulbecco’s modified Eagle’s 
medium) supplemented with 10% (v/v) FBS (fetal bovine serum), 200 U/ml penicillin and 
100 μg/ml streptomycin. B16 mouse melanoma and MCF-7 breast adenocarcinoma cells 
were maintained in RPMI 1640 medium supplemented with 10% (v/v) FBS (fetal bovine 
serum), 200 U/ml penicillin and 100 μg/ml streptomycin. All cell lines were maintained in 
a 5% CO2 humidified incubator at 37
oC. Media was replaced every 2-3 days and cells 
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routinely subjected to mycoplasma tests. Only mycoplasma free cells were used in 
experiments.  
 
2.2.1 Mycoplasma test 
Cells grown on sterile coverslips with antibiotic-free medium for 24 hrs were fixed in 
fixing solution (25% glacial acetic acid; 75% methanol) for 5 sec, washed with water and 
repeated and air-dried at room temperature (RT) for 5 min. DNA was then stained with 
Hoechst 33258 (0.5 μg/ml) for 30 sec, washed with water and mounted on a slide with 
mounting fluid (see Appendix, section 6.2). The cells were viewed immediately by 
fluorescence microscopy using the DAPI filter. Mycoplasma negative cells stained positive 
with Hoechst 33258 only in the nucleus, while cells infected with mycoplasma showed 
staining in both the nucleus and the cytoplasm. 
 
2.2.2 Transfections 
Prior to performing transfections, the concentration and quality of all DNA constructs 
were assessed using a NanoDrop ND-1000 spectrophotometer (Agilent Technologies, 
Boeblingen, Germany) and confirmed by agarose gel electrophoresis. Four different 
transfection reagents were used: 
1. FuGENE HD (Roche, Germany): Cells were transfected using a 3:1 ratio according to 
the manufacturer’s instructions. Cells were plated at 1.5 X 105 cells per 35 mm dish 
(1 X 104 cells per well of 12 well plate) 1 day before transfection. Three microlitres (2 
μl for 12 well plate) of the transfection reagent was added to 97 μl (48 μl for 12 well 
plate) serum-free media (without antibiotic) and incubated at room temperature for 
5 min. The diluted transfection reagent was then added to the DNA, mixed and 
incubated at room temperature for a further 15 min. The transfection reagent: DNA 
complex was added dropwise to the cells and incubated for thirty hours at 37°C.  
MCF-7 shctrl and shTBX3 cell lines: MCF-7 cells at 70% confluency in 35mm dishes 
were transfected with 1 μg of pSuper.neo/GFP-shctrl or pSuper.neo/GFP-shTBX3 
vectors.  
TGF-β1 activates TBX3: MCF-12A cells were co-transfected with 400 ng of a 
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TBX3-luciferase reporter plasmid plus 40 ng of the JunB or 30 ng each of the Smad3 
and Smad4 expression plasmids or corresponding amounts of an empty-vector 
plasmid. 
p21 overexpression: MCF-12A-TBX2 cells 24-well plate were transfected with 150 ng 
of pRc/CMV-p21 or pRc/CMV. 
2. X-tremeGENE HP (Roche, Germany): Operations were the same as for FuGENE HD 
except cells were transfected using a 2:1 ratio.  
MCF-12A EC and TBX2 overexpressing cell lines: MCF-12A cells at 70% confluency in 
35mm dishes were transfected with 1 μl of pcDNA3.1 (+) or pcDNA3.1 (+)-TBX2 
vectors. 
TBX3 represses TBX2: MCF-12A cells were co-transfected with 400 ng of a 
TBX2-luciferase reporter plasmids plus 100 ng of the pCMV-TBX3 expression 
plasmids or corresponding amounts of an empty-vector plasmid.  
3. Lipofectamine™ LTX with PLUS™ (Invitrogen, USA): HEK 293 cells at a density of 70% 
in 10 cm dish were switched to 0.5% serum medium before transfection. 3.5 μg 
linearized Adeno-X-TBX3 vector was diluted in 720 μl serum-free medium and mixed 
with 20 μl PLUS reagent and incubated at RT for 5 min. 30 μl Lipofectamine LTX was 
then added to the mixture and incubated for 30 min. The whole mixture was then 
added directly to the cells and the dishes were incubated at 37oC for 6 hrs before the 
medium was replaced with normal growth medium. 
4. HiPerFect®: Transient knockdown of JunB, Smad4, TBX3 or p21 expression in 
MCF-12A cells was achieved by siRNA that specifically targets JunB, Smad4, TBX3  or 
p21 mRNA (siJunB, siSmad4, siTBX3 or sip21). Cells at 60% confluency in each well of 
24 well plate (6 well plate) were washed twice with 1X PBS and replaced with 400 µl 
(1.9 ml) serum-starved medium (for TGF-β1 treated experiments) or complete 
medium. 30 nM of siJunB (sc-35726, Santa Cruz Biotechnology, USA) or siSmad4 
(SI00076041, Qiagen, USA) or 50 nM of siTBX3 (SI00083503, Qiagen, USA) or 25 nM 
of sip21 (Dharmacon siRNA, ONTARGETplus SMARTpool, CDKN1A L-003471-00-0005, 
Thermo Fisher Scientific., Lafayette, CO, USA) or a control (non-silencing) siRNA 
(Qiagen, USA) was diluted in 100 µl serum-free, antibiotic-free medium. Three 
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microlitres (6µl) of HiPerFect was added directly to the diluted siRNA solution, 
incubated at RT for 5 min and added to cells. Numbers in bracket indicate amount 
used for 6 well plate for RNA analysis.  
 
2.2.3 Generation of stable cell lines in which TBX3 was knocked down 
The MCF-7 breast cancer cells have been shown to over-express TBX3 and were thus 
selected to generate stable cell lines knocking down TBX3 (Fan et al., 2004). Cells were 
stably transfected with the pSuper.neo/GFP vector, containing either a TBX3- 
(constructed by Dr Jade Peres) or a scrambled control- sequence. Stable transfectants 
were selected for with 400 μg/ml G-418 antibiotic (Promega, USA) (as described below) 
48 hrs post transfection and individual clones selected. Among subcloned cell lines, 
those chosen for subsequent analysis were: MCF-7 shTBX3(2) and MCF-7 shTBX3(8) and 
expressing the shTBX2 construct while MCF-7 shcontrol(5) expressed the shcontrol 
construct.  
 
2.2.4 Generation of adenoviral inducible adeno-TBX3 virus 
The adeno-TBX3 virus was generated using Adeno-X Tet-off expression system 1 
(Clontech, USA) according to manufacturer's instructions. The system was a kind gift 
from Dr Luiz (International Centre for Genetic Engineering and Biotechnology, University 
of Cape Town, SA). Briefly, both of pcDNA3.1 (+)–TBX3 and pTRE-Shuttle 2 vectors were 
restriction digested using Promega reagents: RE 1 x buffer B, 5 μg BSA, 5 U NheI, 5 U XbaI, 
15 μg plasmid DNA in a total volume of 50 μl, incubated at 37oC overnight (O/N). The 
digested vectors were ligated using Promega reagents as follows: 100 ng pTRE-Shuttle 2 
vector, 20 ng pcDNA3.1 (+) –TBX3 vector, Ligase 1X buffer, 0.5 U T4 DNA ligase in a total 
volume of 5 μl, incubated at RT for 3 hrs and transformed into DH5α supercompetent 
cells as described above. Agar plates containing 50 μg/ml kanamycin were incubated at 
37oC O/N. The successful ligation was confirmed by restriction enzyme digestion. To 
subclone the expression cassette into the Adeno-X genome, the recombinant 
pTRE-Shuttle2-TBX3 vector was further digested using the provided I-Ceu and PI-Sce I 
enzymes, purified and ligated using provided reagents as instructed. To destruct 
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non-recombinant Adeno-X DNA construct, the ligation product was restriction digested 
using provided Swa I enzyme as instructed. The successfully ligated Adeno-X-TBX3 vector 
was transformed into DH5α supercompetent cells as described. Agar plates containing 
100 μg/ml ampicillin were incubated at 37oC O/N. The successful ligation was confirmed 
by restriction enzyme digestion and linearized by Pac I restriction enzyme digestion as 
instructed. Pac I digested Adeno-X-TBX3 was transfected into low passage HEK 293 cells 
using Lipofectamine™ LTX and PLUS™ Reagents (Cat. no. 15338-100, Invitrogen, USA) 
according to manufacturer's instructions. The cytopathic effect (CPE) was observed 
within two weeks. Cells and medium were transferred to 15 ml centrifuge tube and 
centrifuged at 1500 g for 5 min at RT. Cell pellet was resuspended in 500 μl PBS. Cells 
were then lysed with 3 consecutive freeze-thaw cycles between 37oC and liquid nitrogen 
bath, centrifuged and cell debris discarded. To obtain high-titre stocks, HEK293 cells were 
transduced with cell lysate and cells exhibiting CPE were lysed and virus purified using 
Adeno-X Maxi Purification kit (Clontech, USA). The viral titre was determined by 
end-point assay according to manufacturer's instructions. Briefly, 1X104 HEK 293 cells 
were plated in 96-well plate 24 prior to transfection with a serial dilution (10-3-10-10) of 
the purified virus and incubated at 37oC. Wells were examined for CPE and the viral titre 
was calculated as: Titre (pfu/ml) = 10(x+0.8), x=the sum of the fraction of CPE-positive wells. 
The MCF-12A cells were infected with multiplicity of infection (M.O.I.) of 50 pfu/cell.  
 
2.2.5 Generation of lentiviral inducible MCF-12A cell line 
The MCF-12A cells were stably transduced using a tetracycline inducible third generation 
lentiviral system expressing short hairpin TBX3 RNA (shTBX3) alongside constitutively 
expressed enhanced green fluorescent protein (eGFP). The system was a kind gift from 
Dr Marc Weinberg (University of Witswatersrand, Johannesburg, SA), who designed and 
cloned the shTBX3 sequence into the pHIV7-TetRIRESeGFP (Aagaard et al., 2007) 
lentiviral vector (pTIG-shTBX3) (see Appendix, section 6.3). The third generation 
lentiviral system consists of key components of the HIV7 virus contained 1 lentiviral 
vector and 3 packaging plasmids that produce proteins which package the lentiviral 
vector into replication-deficient infectious particles that deliver the lentiviral vector into 
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target cells where it integrates into the genome.  
 
2.2.5.1 Infectious particle production 
Lentivirus infectious particles were produced by transfecting HEK293T cells using the 
calcium phosphate method. Early passage HEK293T cells plated in 5 x 10 cm tissue 
culture dishes were grown to 50-60% confluency in medium containing antibiotic. For 
transfection, 65 µg of pTIG-shTBX3 lentiviral vector was combined with 18.75 µg pVSV-G 
(pLP), 15 µg pRSV-Rev (pLP1) and 18.75 µg pRRE (pLP2) packaging vectors (Invitrogen) 
made up to 1.25 ml with sterile water, to which an equal volume (1.25 ml) of 0.5 M CaCl2 
was added and mixed well. An equal volume (2.5 ml) of HBS2X (see Appendix, section 
6.4) was placed in a separate 50 ml sterile conical tube and continuously agitated by 
bubbling with a pipette aid while adding the DNA solution directly to the liquid in 
dropwise fashion. After 20 min incubation at RT, 1 ml of the DNA mix was added per 10 
cm dish of HEK293T cells and incubated at 37°C, 5% CO2 overnight. The next day, 
medium was removed from the cells and replaced with 8 ml complete medium and 
incubated for another 24 hrs. The following day, virus-containing medium was collected 
and fresh medium added to the cells for a second round of virus collection. The collected 
medium was centrifuged at 2000 x g at 4°C for 7 min to pellet cell debris, and then 
filtered through a 0.45 µM disposable filter to remove any particulate matter. Virus was 
concentrated by ultracentrifugation at 25 000 rpm at 4°C for 2 hrs in a (SW 55 Ti, 
Beckman Coulter) swing bucket rotor using a (OptimaTML-80 XP, Beckman Coulter) 
ultracentrifuge and the viral pellets resuspended in total of 80 µl sterile PBS per 20 ml of 
virus-containing medium (250 fold concentration). Virus concentrates were stored as 10 
μl aliquots at -80°C. 
 
2.2.5.2 Infectious particle transduction of target cell lines 
The lenti-MCF-12A cells were produced by transducing the parental MCF-12A cell line 
using virus concentrate. Cells were grown to 50% confluency in a 6 cm dish and medium 
was replaced with 6 ml of fresh medium and 30 µl of virus concentrate, along with 8 
µg/ml polybrene (Hexadimethrine bromide) (Sigma, St Louis, USA) and returned to 37°C 
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O/N. The next day medium was replaced with fresh to remove the polybrene. Successful 
transduction was monitored by cells expressing GFP 48 – 96 hrs after infection, using an 
Axiovert fluorescent microscope (Zeiss, Germany) and a pure population was obtained 
by fluorescence activated cell sorting (FACS) for GFP expression using a FACSVantage SE 
(Becton Dickinson) cell sorter. Tetracycline induction of knockdown transcripts was 
achieved by treating the cells with 1 µg/ml doxycycline hyclate (Sigma, St Louis, USA) and 
effective knockdown assessed by western blot analysis with appropriate antibodies. 
 
2.2.6 Generation of MCF-12A cell lines in which TBX2 was stably overexpressed 
To generate stably transfected cell lines, MCF-12A cells at 70% confluency were 
transfected with either the empty expression vector pcDNA3.1 (+) or with this vector 
containing the full length human TBX2 cDNA (Lingbeek et al., 2002) using X-tremeGENE 
HP (Roche, Germany). Transfected cells were selected by 400 µg/ml G-418 antibiotic for 
10 days and were pooled for further analysis.  
 
2.2.7 G-418 selection 
To determine the effective concentration of antibiotic for each cell line, untransfected 
cells were seeded in a 6-well plate so that cells were approximately 60% confluent on the 
first day of treatment. Cells were treated with concentrations of G-418, ranging from 0 – 
800 μg/ml and monitored daily. The lowest concentration which resulted in complete 
cell death after approximately 10 days was selected. Four hundred µg/ml G-418 was 
chosen for MCF-7 cells. 
 
2.3 Cell treatments 
2.3.1  TGF-β1 treatment 
Equally plated cells were serum starved for at least 16 hrs and were treated with either 
5ng/ml rhTGF-β1 (R&D systems, MN, USA), diluted in 4mM HCl, 1mg/ml BSA, or vehicle.  
 
2.3.2 Actinomycin D treatment and Cycloheximide treatment 
For transcription inhibitor experiments, cells were treated with 5 µg/ml Actinomycin D 
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(Sigma) or vehicle DMSO for control 1 hr prior to TGF-β1 treatment. For inhibition of de 
novo protein synthesis experiments, cells were pre-treated with 30 µg/ml cycloheximide 
(Sigma) or vehicle DMSO for control for 1 hr prior to TGF-β1 treatment. All inhibitors 
were added in the dark. 
 
2.4 Western blot analysis  
Cells were harvested on ice by scraping with a 1 ml plunger in RIPA buffer (see Appendix, 
section 6.5). Whole cell extracts were incubated on ice for a minimum of 30 min, 
centrifuged at 12,000 g for 20 min at 4°C and the supernatants recovered. Protein 
concentrations were determined using the BCA assay (Pierce, Rockford, IL, USA), 
according to the manufacturer’s instructions with bovine serum albumin as the standard. 
Equal amounts of protein were loaded and separated on 8-10% SDS-polyacrylamide gels 
(see Appendix, section 6.5) and transferred to Hybond ECL nitrocellulose membrane 
(Amersham, Biosciences, USA). Membranes were blocked for 1 hr at RT with PBS 
containing 5% non-fat dry milk and probed with appropriate primary antibodies O/N at 
4°C with shaking. Membranes were washed in PBS containing 0.1% Tween 20 (PBS/T) 
and incubated with peroxidase-conjugated anti-mouse or anti-rabbit (BioRad, Hercules, 
CA, USA) or anti-goat antibody (1:5000) (Santa Cruz Biotechnology, CA, USA). 
Membranes were again washed in PBS/T and visualised by enhanced 
chemiluminescence (Pierce, Rockford, IL, USA). The primary antibodies and appropriate 
dilutions were: rabbit polyclonal anti-JunB (sc-73, Santa Cruz Biotechnology, CA, USA), 
goat polyclonal anti-Smad2/3 (sc-6202, Santa Cruz Biotechnology, CA, USA), rabbit 
polyclonal anti-Smad4 (sc-7154, Santa Cruz Biotechnology, CA, USA), goat polyclonal 
anti-TBX2 (1:1000) (sc-17880, Santa Cruz Biotechnology, CA, USA), rabbit polyclonal 
anti-TBX3 (1:250) (42-4800, Invitrogen, USA) and rabbit polyclonal anti-p38 (1:5000) 
(Sigma, Missouri, USA). To analyse the membrane with a primary antibody targeted 
towards a different protein, bound primary antibody was removed as follows: 
membranes were rinsed with PBS/T, stripped in stripping buffer (see Appendix, section 
6.5) for 30 min at 50°C and washed twice with PBS/T. If necessary, the expression of 
proteins was quantified as the densitometry value analysed by UN-SCAN-IT gel 6.1 
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software and normalised to the appropriate loading control. 
 
2.5 Quantitative real-time PCR (qRT-PCR) 
Total RNA was extracted from cells using the High Pure RNA Isolation Kit (Roche). 
Reverse transcription of RNA (1 µg) was performed according to the manufacturer’s 
instructions using the InProm-IITM reverse transcription system (A3800; Promega, USA). 
Using 1 µl of cDNA, PCR was conducted with the SensiMix Lite Kit (Quantace QT 405-05, 
USA) according to the manufacturer’s protocol. Real-time PCR was performed on a 
LightCycler Version 4 (Roche, Basle, Switzerland) using the following parameters: 
denaturation (15 min at 95°C), annealing and amplification at 35 cycles (15 s at 94oC; 20 s 
at 55oC; 20 s at 72°C), melting temperature (15 s at 65°C), and a cooling step (30 s at 
40°C). Each DNA sample was quantified in duplicate, and a negative control without 
cDNA template was run with every assay to assess the overall specificity. Melting curve 
analyses were carried out to ensure product specificity, and data were analysed using 
the 2−ΔΔCt method. Relative mRNA expression levels were normalized to glucuronidase 
beta (GUSB) for each reaction with PCR efficiency correction calculated using the formula 
Ratio = EtargetCPtarget(control – sample)/ErefCPref(control – sample), where E is the real-time 
PCR efficiency and CP is the crossing point. Primers used to amplify the human TBX3 
(QT00022484) and GUSB (QT00046046) were purchased from Qiagen. 
 
Total RNA was extracted from cells using the RNeasy Plus Mini kit (Qiagen, USA). The 
quality and concentration of RNA was determined by spectrophotometry. Only samples 
exhibiting an A260/A280 ratio equal to or above 1.8 were selected and stored at -80°C 
for further applications. Reverse transcription of RNA was performed according to the 
manufacturer’s instructions using the InProm-IITMreverse transcription system (Promega 
A3800). Briefly, 1 μg of RNA was combined with 0.5 μg of Oligo (dT)15 primer in a 5 µl 
volume and denatured at 70°C for 5 min, chilled on ice and combined with reverse 
transcription reaction mix (1X ImProm-IITMReaction buffer, 3 mM MgCl2, 0.5 mM dNTP 
mix, 20 units RNasin® ribonuclease inhibitor and 1 µl of ImProm-IITMreverse 
transcriptase) to a final volume of 20 µl. After a brief annealing at 25°C for 5 min, the 
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reactions were incubated at 42°C for 1 hr, followed by a 15 min incubation at 70°C to 
inactivate the reverse transcriptase prior to PCR. Quantitative real time PCR was 
conducted with the Sensimix lite kit (Quantace QT 405-05, USA). PCR reactions 
containing 1X Sensimix Lite, 1X SYBR Green, 0.75 µl Enzyme mix and 1.5 µl of combined 
forward and reverse primers (Quantitect real-time PCR primers, Qiagen) per 9 µl reaction 
were made up as a master mix and aliquoted into glass capillaries, with 1 μl of cDNA 
added to give a final reaction volume of 10 µl. The capillaries were sealed, centrifuged at 
522500 rpm for 30 sec and placed in the LightCycler Version 3 (Roche, Switzerland). PCR 
cycle parameters were: denaturation (15 min at 95°C), annealing and amplification at 35 
cycles (5 sec at 95°C; 3 sec at 55°C; 5 sec at 72°C), melting temperature (15 sec at 65°C) 
and a cooling step (30 sec at 40°C). Each DNA sample was quantified in duplicate and a 
negative control without cDNA template was run with every assay to assess the overall 
specificity. Melting curve analyses was carried out to ensure product specificity and data 
was analyzed using the 2-ΔΔCtmethod. Relative mRNA expression levels were 
normalized to glucuronidase beta (GUSB) for each reaction with PCR efficiency 
correction calculated using the formula Ratio = (Etarget)CPtarget(control  –
sample)/(Eref)CPref(control – sample) ; E: real-time PCR efficiency, CP: crossing-point. 
Primers used to amplify the human TBX2 (QT00091266), TBX3 (QT00022484) and GUSB 
(QT00046046) cDNAs were purchased from Qiagen, USA. The Microsoft Excel 
programme was used to calculate the standard deviation and statistically significant 
differences between samples using the Student t test. P values of <0.05 were considered 
statistically relevant. 
 
2.6 Cell proliferation assays 
2.6.1 Growth curves 
Cell counts, using a haemocytometer, were determined as described previously (Prince 
et al., 2003). Cells were seeded in triplicate in a 12-well plate at a density of 1 X 104 
cells/well for the MCF-7 shctrl and shTBX3 cell lines. Cells were collected by 




2.6.2 5-bromo-2-deoxyuridine (BrdU) incorporation assay 
Cells were seeded on glass coverslips in 35 mm tissue culture dishes at a density of 4 X 
104 cells/ml and allowed to adhere. The cells were then incubated in medium containing 
10 μM BrdU for 3 hrs followed by fixing with Carnoy’s Fixative (see Appendix, section 6.6) 
at -20°C for 20 min. For immunostaining, the cultures were incubated in 2N hydrochloric 
acid at 37°C for 1 hr, neutralised in 0.1 M borate buffer (see Appendix, section 6.6), 
rinsed with 1 X PBS containing 0.05% Tween-20  (1XPBS/T) and incubated in 1 X PBS/T 
with 5% swine serum for 30 min at 37°C. BrdU was detected with the anti-BrdU mouse 
monoclonal antibody (6 μg/ml, Roche, Germany) for 30 min at 37°C, followed by a 
secondary IgG coupled to Alexa 488 (1:1000, Molecular Probes, USA) for 30 min at 37°C. 
Cells were washed with  1 X PBS/T, incubated with 1 μg/ml DAPI 
(4’,6-diamidino-2-phenylindole) (Sigma, USA) diluted in 1 X PBS for 10 min at RT in the 
dark, washed again, mounted onto slides  and visualised by fluorescence microscopy 
using an Axiovert fluorescent microscope (Zeiss, Germany). 
 
2.6.3 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay 
To determine cell growth using the methylthiazol tetrazolium (MTT) Cell Proliferation Kit, 
cells were seeded in quadruplicate in a 96-well plate (1000 cells/well) and cell viability 
determined according to the manufacturer’s instructions. Briefly, 24 hrs prior to 
harvesting 10 µl of pre-warmed MTT labelling reagent was added to each well and 4 hrs 
later 100 µl of pre-warmed solubilisation solution was added to the cells. The 
spectrophotometrical absorbance of the samples was determined at a wavelength of 
595 nm using a 96-well plate reader, with the absorbance of the medium only control 
being subtracted from the samples. Cell proliferation was determined over 10 days. 
 
2.7 Transformation assays 
2.7.1 Growth factor dependence assay 
For the growth factor-dependence assay, cell proliferation was compared in medium 




2.7.2 Soft agar assay 
For soft agar assays, 35 mm tissue culture dishes were coated with a 1% agar/medium 
layer to prevent cells from attaching to the bottom of the dish. Dishes were incubated at 
4°C O/N to allow the agar to solidify. Cells were resuspended in 0.35% agar/medium 
slurry and plated on top of the 1% agar/medium layer at a concentration of 5000 cells 
per 35mm dish. In order to prevent the agar/medium slurry from desiccation, 1 ml of 
fresh medium was added per dish. The dishes were incubated at 37°C in the presence of 
5% CO2 for 30 days and a few drops of fresh medium was added twice a week. Cell 
viability was determined by O/N incubation with p-iodonitrotetrazolium-chloride (Sigma, 
USA), which forms a purple formazan dye when reduced. Pictures were taken using a 
non-phase contrast lens (Sony cybershot, DSC-T20). Higher magnification images were 
taken using an Axiovert fluorescent microscope (Zeiss, Germany) (10x magnification).    
 
2.7.3 Cell migration assays 
Two methods were utilised to determine cell migratory ability, namely: two-dimensional 
in vitro scratch motility assay and transwell cell motility assay, which will be described 
below. 
 
2.7.3.1 Cell scratch motility assay 
Cells were grown to confluence in 35 mm tissue culture dishes. A linear wound was 
made by scratching through the monolayer using a sterile 200 µl pipette tip. To remove 
cell debris, the growth medium was replaced, and to prevent cell proliferation Mitomycin 
C (Sigma, USA) was added at a final concentration of 10 μg/ml. Several markings were 
made along the edges of the scratch line which were used as reference points and the 
wound widths measured at the time of the scratching (0 hr) and thereafter at 1 – 2 hrs 
intervals. To induce migration in the MCF-7 cells, 12-O-tetradecanoyl-phorbol-13-acetate 
(TPA) was added at a final concentration of 10 nM. TPA induces migration in poorly 
migrating cell lines, including MCF-7 cells, by downregulating protein kinase C, a factor 
which suppresses cell migration (Jackson et al., 2005). Pictures were taken using a phase 
contrast microscope and migration distances were measured using Axio software (Zeiss, 
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Germany). The difference in width represents the distance migrated in μm. 
 
2.7.3.2 Transwell migration assay 
1x105 serum starved cells were plated on the upper section of transwell chamber in 500 
µl medium containing 1% FCS. Transwells were then placed on well of 12-well plate filled 
with 1 ml medium containing 10% FCS which was served as chemo-attractant. Each 
condition is carried out in triplicate and there is a well designated for total cell control. To 
encourage cell migration, TPA was added to all wells at a final conc. 100 nM. Plates were 
covered with foil and incubated at 37 oC for 24 hrs. The upper section of each triplicate 
well was wiped cleaned by a sterile ear bud to get rid of the cells that had not migrated 
through the membrane. The remaining cells and cells from total cell control wells were 
fixed in methanol and stained by crystal violet by dipping the wells into appropriate 
solutions and rinsed twice by sterile water. The wells were then dried O/N in the hood 
before the stains on the wells was washed off using 150 μl 50% acetic acid solution. The 
stain solution was then transferred to 96-well plate and the spectrophotometrical 
absorbance of the samples was determined at a wavelength of 595 nm using a 96-well 
plate reader. 
 
2.8 Luciferase assays 
Cells were transfected as described (see 2.2.2), cultured for 40 hrs and extracts were 
then assayed for firefly luciferase activity using the dual luciferase assay system 
(Promega, Madison, WI, USA) according to the manufacturer’s instructions. Briefly, cells 
cultured in a 35 mm dish were lysed using 1 X lysis buffer (Promega, Madison, WI, USA) 
and subjected to freeze-thaw cycle O/N. On the next day, the cell lysate was briefly 
pulsed by bench top picofuge at RT and the supernatant was immediately assayed for 
firefly luciferase reporter activity using the dual luciferase assay system (Promega, USA). 
Luciferase activities were measured using the Luminoskan Ascent luminometer (Thermo 
Labsystems, Franklin, MA, USA). Firefly luciferase values were expressed relative to (a) 
empty-vector control or (b) untreated samples as compared to TGF-β1 treated. All 
transfections were performed in duplicate and at least three independent experiments 
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were done to confirm reproducibility. The Microsoft Excel programme was used to 
calculate the standard deviation and statistically significant differences between samples 
using the Student t test. P values of <0.05 were considered statistically relevant. 
 
2.9 Immunofluorescence microscopy 
MCF-12A or HaCaT cells grown on glass coverslip slides 3 hrs or 12 hrs after TGF-β1 
treatment were washed with phosphate-buffered saline (PBS) and fixed with 4% 
paraformaldehyde for 10 min at room temperature. After three PBS washes, cells were 
then permeablised in 0.2% Triton X-100 in PBS for 5 min at room temperature, followed 
by a 1 hr incubation in blocking buffer (5% swine serum in PBS) at RT and incubated with 
rabbit TBX3 polyclonal antibody (42-4800, Zymed, Invitrogen, USA) at a dilution of 1:25 
in blocking buffer at 4°C O/N in a humidifying chamber. Cells were washed in PBS and 
incubated with the appropriate secondary antibody coupled to Cy3 (Jackson 
ImmunoResearch, USA) at 1:1000 dilution for 2 hrs at RT in the dark. Cells were again 
washed in PBS and the DNA was stained by incubating the cells with 1 μg/ml DAPI 
(4’,6-diamidino-2-phenylindole) (Sigma, USA) diluted in PBS for 5 min at RT in the dark. 
Cells were washed, the coverslips mounted onto glass slides with mounting medium (80% 
glycerol in water containing anti-fade (n-Propyl gallate) (Sigma, USA)) to prevent the 
signal fading and the cells visualised by fluorescence microscopy using an Axiovert 
fluorescent microscope (Zeiss, Germany). Negative controls were as for above, but the 
primary antibody was excluded.  
 
2.10 siRNA sequences and transfection  
The Cells were transfected with siRNAs using HiPerFect (Qiagen, USA) according to 
manufacturer's instructions. Treatment started 24 hrs post transfection. The anti-Smad4 
siRNA (SI00076041), anti-TBX3 siRNA (SI00083503) and a control (non-silencing) siRNA 
were purchased from Qiagen (USA) and the anti-JunB siRNA (sc-35726) was purchased 





2.11 Chromatin immunoprecipitation (ChIP) assays  
ChIP assays were carried out as previously described (Prince et al., 2004b). Briefly, 15cm 
dishes containing 80% confluent MCF-12A cells treated with TGF-β1 for 3 hrs were fixed 
in 1% formaldehyde at RT for 10 min, to crosslink proteins to DNA. The reaction was 
quenched with 125 mM glycine for 5 min at room RT. Cells were span down at 1600 rpm 
for 5min at 4°C and resuspended in 15 ml chilled 1 X PBS and span and resuspended in 
1.5 ml 1XPBS. Cells were pelleted at 1500 x g at 4°C for 5 min, washed once in PBS, once 
in buffer 1 (see Appendix, section 6.7) and once in buffer 2 (see Appendix, section 6.7) , 
prior to lysis in 500 µl lysis buffer (see Appendix, section 6.7) plus protease inhibitors. 
Samples were sonicated to obtain fragments between 300 bp to 500 bp and span at 
13 000 rpm for 10 min at 4°C and cell debris discarded. For each sample, 330 µl of 
sonicated cell lysate was diluted with immunoprecipitation buffer (see Appendix, section 
6.7) plus protease inhibitors to a final volume of 1.5 ml and pre-cleared three times with 
Protein A/G PLUS-Agarose beads (sc-2003, Santa Cruz Biotechnology, USA) rotating at 
4°C for 1 hr each time. Protein-bound DNA was immunoprecipitated using Protein A/G 
PLUS-Agarose beads and 5 µg of antibody against JunB (sc-73) or Smad4 (sc-7154) or 
TBX3 (sc-17871) or IgG (negative control, sc-2027, Santa Cruz Biotechnology, USA) with 1% 
of the supernatant volume reserved as input. Samples were rotated at 4°C O/N, followed 
by incubation with 50 µl of protein A/G beads rotating at 4°C for 3 hrs. Samples were 
span down and beads were sequentially washed twice for 10 min rotating at 4°C in 500 
µl wash buffers 1-4 (see Appendix, section 6.7). The beads were collected and incubated 
in 100µl Extraction buffer (see Appendix, section 6.7) for 15 min at RT, span at 2000 x g 
for 1 min and supernatant saved. The extraction was repeated with another 100 µl to 
yield 200 µl supernatant in total. The input sample was made up to 200 µl with 
extraction buffer and all samples were incubated at 65°C in the heating block O/N to 
reverse the crosslink between DNA and proteins. The immunoprecipitated DNA was 
purified using the PCR purification kit (Qiagen, USA) and analysed by qRT-PCR using a 
primer pair amplifying the region spanning the AP1 binding site or SBE at position -80 bp 
of TBX3 promoter or a T-element at -187 bp on TBX2 promoter or a non-specific 
promoter region (GAPDH, Qiagen, USA). Crossing values (Ct) of precipitated DNA were 
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normalized against the Ct values of IgG. qRT-PCR was perform same as described in 
section 2.5. Primer pairs specific for the TBX3 promoter: 
(5’-CTAGAGGCGACTCTGTGCGC-3’ and 5’-CGCTTTCGGACCAATTGTGTTGC-3’), or for the 
TBX2 promoter: (5’-TGGCCTGAGCTGTCAAAAC-3’ and 5’-GCGCGACTGGTTAGATCTTG-3’), 
or a non-specific region in the GAPDH gene: (5’-CAGCCAGACGAGGACACA-3’ and 
5’-CCTTTCTGGGATTGCCTTTC -3’). Fold enrichment was determined using the ∆∆Ct 
method: Fold enrichment= 2-(∆Ct1-∆Ct2), where ∆Ct1 is the ChIP of interest and ∆Ct2 is the 
IgG. Statistical differences were determined using a student T-test. Significance was 
accepted at p< 0.05. 
 
2.12 Non-radioactive Electromobility shift assay (EMSA) 
Nuclear extracts from 3hr TGF-β1 treated MCF-12A cells were prepared as previously 
described (Smith et al., 2011). Briefly, cells from sub-confluent 15 cm dishes were 
washed twice with 1X PBS, trypsinised, span down at 1500 rpm for 5 min at 4oC. Cell 
pellet was 1 ml ice cold 1 X PBS, span down and resuspended in 800 μl ice cold 1 X PBS 
and span down at 3000 g for 30 s at 4oC. The pellet was resuspended in 5 cell volumes of 
cold cell buffer 1 (see Appendix, section 6.8), incubated on ice for 15 min and was added 
with 0.3% volume 10% Triton-x100, incubated on ice for 5 min and span down for 4 min 
at 3000 g at 4oC. Cell pellet was resuspended in equal volumes of buffer 2 (see Appendix, 
section 6.8) with protein inhibitors and DTT (5 mM final conc.) Protein concentration was 
assayed by BCA assay (Pierce, USA). The biotin labelling of DNA oligo was performed 
using the DNA 3’ end Biotinylation kit (Pierce) according to manufacturer’s instructions. 
Briefly, the labelling reaction was made with: 1X TdT Reaction Buffer, 100 nM Unlabeled 
Control Oligo (single stranded), 0.5 µM Biotin-11-UTP and 0.2 U/µl diluted TdT in a total 
volume of 50 µl and incubated at 37°C for 30 min. The reaction was stopped with 2.5 μl 
0.2M EDTA. The labelled DNA oligo was purified using 50 μl chloroform:isoamyl alcohol 
and the top aqueous phase was collected. To anneal the labelled oligos, complementary 
strands were mixed and heated at 90°C and slowly cooled down to RT.  
 
For EMSA assay, protein-oligo binding reactions were prepared with 15 μg nuclear 
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extract, 4 μl 5 x incubation buffer (see Appendix, section 6.8), 1 μl poly dI/dC (1 μg/μl), 1 
μl DTT (10 mM) and unlabeled wild type (5’-GCCAATCAAGAGGCCTCCGGCTCCCCGC-3’) or 
mutant competitor (5’-GCCAATCAAGAAGCTTTCGGCTCCCCGC-3’) to a final volume of 20 
μl. The full reaction volume was loaded onto a pre-electrophoresed 8% native 
polyacrylamide gel, electrophoresed at 200 V for 1 hr and transferred on nylon 
membrane at 380 mA for 30 min. DNA was cross linked to the membrane using a UV 
Stratalinker 1800 apparatus (Stratagene) and processed for chemiluminescence 
detection using the LightShift Chemiluminescent EMSA Kit (Pierce) according to 
manufacturer’s instructions. Signals were visualized with a UVP biospectrum imaging 
system (visionworks LS software). 
 
2.13 DNA affinity immunoblot (DAI) assay 
Biotinylated DNA oligos and nuclear extract were prepared as described for EMSA. 
Biotinylated probes were immobilized on 100 µg of Dynabeads Streptavidin (Dynal 
Invitrogen, USA) according to the manufacturer’s instruction. For each DNA-binding 
reaction, 40 µg nuclear extract was incubated with 1 µg bound biotinylated DNA probe in 
200 µl binding buffer (see Appendix, section 6.9) at 4°C for 30 min with gentle rotation. 
The beads were extensively washed with binding buffer and boiled in 25 µl of 2 × protein 
loading buffer (see Appendix, section 6.9) to release proteins bound to the oligo. 
Proteins bound to the biotinylated probes were analyzed by SDS–PAGE, followed by 
immunoblotting using rabbit polyclonal anti-JunB (sc-73) or anti-Smad4 (C-19) antibodies 
or anti-TBX3 (sc-17871) (Santa Cruz Biotechnology, Santa Cruz, CA). 
 
2.14 Flow Cytometry    
Cells were collected by trypsinisation, washed twice with PBS, resuspended in 2 ml of 
cold PBS and counted on a haemocytometer to determine the volume of Propidium 
Iodide solution (see Appendix, section 6.10) that will be added. Cells were fixed in 8 ml 
of 70% cold ethanol for at least 30 min at -20°C. Fixed cells were collected by 
centrifugation at 1500 rpm for 5 min at RT, washed twice with PBS and centrifuged at 
6000 rpm for 1 min at RT. Before flow cytometry analyses, the samples were treated with 
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RNase A (50 μg/ml) for 15 min at 37°C and immediately stained for 30 min at RT with PI 
solution, to yield a final concentration of 1 X 106 cells/ml. A minimum of 50 000 
cells/sample were subjected to analysis using a Beckman Coulter FACSCalibur flow 
cytometer (Beckman Coulter, USA). Cell cycle profiles were analysed using the Modfit 








TBX3 is overexpressed in a slew of cancers including a subset of breast cancer cell lines 
and tumours (Fan et al., 2004; Hansel et al., 2004; Lomnytska et al., 2006; Renard et al., 
2007; Rodriguez et al., 2008; Yarosh et al., 2008; Fillmore et al., 2010). However, at the 
time that this project started, it was unclear whether this aberrant expression was 
causative or consequential to cancer formation. Furthermore, the mechanism(s) 
responsible for upregulating TBX3 and the targets that mediate TBX3’s role in breast 
cancer were poorly understood. The current study therefore aimed to address these 
questions by first establishing both TBX3 knock down and overexpressing cell culture 
models and investigating the effects of altering TBX3 levels on key features of 
tumourigenesis including cell proliferation, migration and anchorage independence. 
Secondly, the regulation of TBX3 by TGF-β1 signalling pathway implicated in breast 
cancer was investigated. Finally, the TBX3 homologue, TBX2, is shown to be downstream 
of TBX3 in inducing the anti-proliferative effect of TGF-β1 and a full characterisation of 
this regulation is described.  
 
3.1 Establishment and characterisation of a human breast cancer cell culture model in 
which TBX3 expression was stably knocked down 
3.1.1 Establishment of MCF-7 cell lines in which TBX3 was stably silenced 
A good way to understand the function of a protein is to knock out or knock down its 
gene expression and to study the consequences on cellular functions. Silencing a specific 
gene can be achieved by using RNA interference (RNAi) approaches which include short 
interfering (si)RNA and short hairpin (sh)RNA. While both of these two approaches 
specifically target homologous mRNAs for degradation (Hannon, 2002; Dykxhoorn et al., 
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2003), the siRNA only transiently knocks down the expression of targeted genes but 
shRNAs work in a more sustained manner because it gets integrated into the host 
genomic DNA. The shRNA approach was therefore employed in order to study the 
long-term effects of knocking down TBX3 in the MCF-7 breast cancer cell line.  
 
The MCF-7 breast cancer cells were stably transfected with the pSuper.neo/GFP 
(Oligoengine) expression vector containing a shRNA sequence that target TBX3 or a 
non-specific control sequence (these constructs are described in Peres et al., 2010). The 
cells were treated with G-418 (400 µg/ml) for a minimum of 10 days to select for 
successfully transfected Neomycin-resistant clones. The knock down of TBX3 expression 
was monitored and verified by qRT-PCR and western blot analysis (Fig. 3.1). As the TBX3 
knock down cell lines shTBX3(2) and shTBX3(8) showed significant reduction of TBX3 
mRNA and protein levels compared to the control cell line shctrl(5), these cell lines were 
used for further analyses. Expression of p38 was used as a measure of equal loading 
throughout this study because although its activity is modulated by phosphorylation, 





Figure 3.1 Establishment of MCF-7 breast cancer cell lines in which TBX3 was stably 
silenced. Cells were stably transfected with the pSuper.neo/GFP (Oligoengine) 
expression vector containing either a TBX3 specific siRNA sequence (MCF-7 shTBX3) or a 
non-specific, scrambled control sequence (MCF-7 shctrl). (A) qRT-PCR was performed on 
reverse transcribed RNA using primers specific to TBX3 and mRNA levels were 
normalised to GUSB and expressed relative to shctrl(5) mRNA. The result of one qRT-PCR 
experiment is shown which is representative of two independent experiments, each 
performed in duplicate. A Microsoft Excel student t-test was performed to calculate 
statistical significance (**p<0.001). Error bars represent standard deviation. (B) Protein 
extracts harvested from the indicated cell lines were subjected to western blotting using 
an anti-TBX3 antibody and p38 was used as a loading control.  
 
3.1.2 Knocking down TBX3 in MCF-7 breast cancer cells results in an increase in 
substrate dependent and substrate independent proliferation and a decrease in 
expression of key cell cycle regulators 
A critical trait of cancer cells involves their ability to bypass senescence and sustain 
uncontrolled proliferation (Hanahan and Weinberg, 2000). While expanding the cell lines, 
it was observed that the MCF-7 shTBX3 cells were growing more rapidly than the shctrl 
cells. To confirm this, MCF-7 shTBX3 and shctrl cells were cultured in standard medium 
containing 10% serum and their growth rate compared by counting cells using a 
haemocytometer over a 9 day period. Indeed, the shTBX3(2) and shTBX3(8) cells started 
to significantly outnumber the shctrl cells from day 7 (Fig. 3.2A).  
 
As growth factor independence is another trait acquired by transformed cells (Hanahan 
et al., 2000), the impact of knocking down TBX3 expression on the proliferative ability of 
the MCF-7 breast cancer cells cultured in medium containing low (2%) serum was 






to the shctrl cells in low serum (Fig. 3.2B), the growth rate of the cells cultured in 2% 
serum was reduced in general compared to the cells cultured in 10% serum (compare 
cell numbers in Fig. 3.2A and B). Taken together, these results suggest that silencing 
TBX3 expression increases cell proliferation in a growth factor independent manner. 
 
To investigate whether the positive effect of knocking down TBX3 on cell proliferation 
was due to an altered expression of key negative regulators of the cell cycle, the levels of 
p53, p21 and p14ARF were checked by western blot analyses. As figure 3.2C shows, the 
expression of these factors was largely reduced in shTBX3 cells compared to the shctrl 
cells. This suggests that the increase in the proliferative ability observed when TBX3 was 
silenced in MCF-7 cells resulted from the repression of these factors. Interestingly, 
however, this is not consistent with previous reports showing that TBX3 transcriptionally 
represses p14ARF and p21 (Brummelkamp et al., 2002b; Hoogaars et al., 2008). As these 
factors can also be repressed by TBX2, which has been implicated as a TBX3 target 
(Prince et al, 2004; Jacobs et al, 2000; Lingbeek et al, 2002; Rodriguez et al, 2008), it was 
speculated that the reduced levels of these key cell cycle regulators resulted from an 
enhanced expression of TBX2. However, western blot results do not support this 
hypothesis suggesting that their decreased expression is caused by factors other than 
TBX2 (Fig. 3.2C).  
 
Cancer cells acquire the ability to proliferate independently of a substrate in order to 
form tumours (Hanahan et al., 2000; Hanahan and Weinberg, 2011). To determine 
whether TBX3 is required for anchorage independent growth, the ability of shctrl and 
shTBX3 cells to form colonies in suspension was next investigated using soft agar assays. 
MCF-7 shctrl(5) and shTBX3(8) cells were suspended in 0.35% soft agar and plated on top 
of a 0.5% agar-medium layer and the colonies formed were monitored after 30 days. 
Figure 3.2D shows that unlike the shctrl(5) cells that formed predominantly small 
colonies, the shTBX3(8) cells formed considerably larger viable colonies. Taken together, 
these results suggest that TBX3 impacts negatively on both substrate-dependent and 




Figure 3.2 Silencing TBX3 increases the proliferation rate of MCF-7 cells and leads to a 
decrease in key cell cycle regulators. (A) Cells were seeded in triplicate at a density of 1 
X 10
4 
cells per well of a 12-well plate and were grown in medium containing 10% fetal 
bovine serum (FBS). Growth curve assays were performed over a 9 day period and cells 
harvested by trypsinisation and counted on a haemocytometer. (B) Cells were seeded as 
in (A) in medium containing 2% FBS. Growth curve assays were performed as described 
for (A). The results shown in A and B are representative of three independent 
experiments. A Microsoft Excel student t-test was performed to calculate statistical 
significance (*p<0.05; **p<0.001); error bars, SD. (C) Protein extracts harvested from the 
indicated cell lines were analysed on 10-15% SDS-PAGE and by western blotting using 
antibodies to indicated proteins. p38 was used as a loading control. (D) 5000 cells were 
resuspended in 0.35% agar-medium slurry and plated on top of a 0.5% agar-medium 
layer and allowed to proliferate for 30 days. Cell growth was assessed by staining with 
p-iodinitrotetrazolium chloride to indicate viable populations. Whole dishes were 
photographed and micrographs were captured at 10x magnification (left) and the 
number of colonies of shctrl and shTBX3 cell lines tested. The result of one soft agar 
assay is shown which is representative of three independent experiments, each 
performed in duplicate. 
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3.1.3 Silencing TBX3 in MCF-7 breast cancer cells inhibits cell migration  
While transformed cells acquire the ability to migrate and invade adjacent tissue this has 
been reported to be mutually exclusive to their ability to proliferate which is referred to 
as the migration-proliferation dichotomy (Fedotov & Iomin, 2007). The effect of knocking 
down TBX3 on the migratory ability of MCF-7 breast cancer cells was therefore 
investigated using a two-dimensional in vitro scratch cell motility assay. As MCF-7 cells 
have poor invasive ability, their migration was induced in the experiment by the addition 
of 12-O-tetradecanoylphorbol-13-acetate (TPA), a chemical that activates the protein 
kinase C pathway (Parker et al., 1987; Basu et al., 1990). Briefly, cells were grown to 
confluence and a linear wound was made by scratching the cell monolayer. To exclude 
the effect of cell proliferation on the results, cells were treated with mitomycin C, a de 
novo proliferation inhibitor, before TPA treatment. As figure 3.3A shows, the shTBX3 cells 
had a significantly reduced migration rate compared to that of the shctrl cells. These 
results were confirmed by a three-dimensional transwell assay. Briefly, serum starved 
cells were plated on a transwell membrane of an upper transwell chamber in medium 
containing 1% FBS and a lower transwell chamber contained medium with 10% FBS 
which served as chemo-attractant. TPA and mitomycin C were added to both transwell 
chambers at a final concentration of 100 nM and 10 μg/ml respectively. The number of 
cells that migrated through the transwell membrane was counted and calculated as a 
percentage of total cells originally plated. As can be seen in figure 3.3B, significantly 
fewer shTBX3(8) cells were able to migrate through the membrane compared to shctrl 
cells. These results are consistent with previous reports demonstrating a pro-migratory 




Figure 3.3 Knocking down TBX3 in MCF-7 cells reduces migration. (A) Cell migration was 
measured using a two-dimensional in vitro scratch motility assay. Cells were grown to 
confluence and a linear wound was made by scratching through the monolayer using a 
sterile 200 µl pipette tip. TPA (10 nM) and mitomycin C (10 μg/ml) were added to induce 
cell migration and prevent cell proliferation respectively. The distance migrated between 
pre-marked points along the scratch was measured using AxioVision 4.8 software (Zeiss, 
Germany) at 2 hr intervals over an 8 hr period. (B) Cell migration was measured using a 
transwell motility assay. 1x105 serum starved shctrl(5) and shTBX3(8) cells were plated in 
a transwell insert (upper compartment) in 1% FBS serum media which was placed over a 
lower chamber containing 10% FBS serum media which serves as chemo-attractant. 
After 24 hr the cells that migrated through the membrane were stained and dried. The 
stain was then dissolved and measured with a spectrophotometer. Microsoft Excel 
student t-test was performed to calculate statistical significance (*p<0.05; **p<0.001); 
error bars, SD. The results shown for (A) and (B) are representative of three independent 
experiments which were performed in triplicate. 
 
3.2 Establishment and characterisation of normal human breast epithelial cells 
transiently overexpressing TBX3  
3.2.1 Overexpressing TBX3 in normal breast epithelial cells inhibits cell growth and 
promotes migration.  
The above results showed that knocking down TBX3 in MCF-7 breast cancer cells 
resulted in increased proliferation and reduced migration. Because these experiments 
were performed in an already transformed cell line, the question arose as to whether the 
overexpression of TBX3 in normal breast epithelial cells is sufficient to inhibit cell 
proliferation while promoting migration. To this end, TBX3 was transiently overexpressed 
in “normal” human MCF-12A breast epithelial cells using an inducible adenovirus tet-off 
system. Briefly, the human TBX3 cDNA was cloned into the vector component of an 
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Adeno-X Tet-off system 1 and the adeno-TBX3 virus was produced in human embryo 
kidney HEK293 cells and purified. To overexpress TBX3, the MCF-12A cells were 
transduced with adeno-TBX3 virus and the control cells were transduced with 
adeno-TBX3 but were treated with Doxycyclin (Dox) to inhibit the viral-promoter-driven 
transcription of TBX3. As can be seen in figure 3.4A, compared to the untransduced 
(adeno-TBX3-/Dox-) and adeno-TBX3+/Dox+ control cells, the adeno-TBX3 virus 
transduction of MCF-12A cells significantly increased the expression of TBX3.  
 
The 5-bromo-2-deoxyuridine (BrdU) incorporation assay was performed to determine 
the effect of overexpressing TBX3 on the ability of MCF-12A breast epithelial cells to 
proliferate. Briefly, equal numbers of TBX3-overexpressing and control MCF-12A cells 
were plated and pulsed with BrdU, an analogue of thymidine for 3 hrs. BrdU gets 
incorporated into the newly synthesized DNA in place of thymidine and can be detected 
by immunofluorescence with an antibody to BrdU. Figure 3.4B shows the total number 
of BrdU positive nuclei as a percentage of the total number of cells from 10 fields of view 
for each cell line. A significant reduction in BrdU-positive cells was observed in the 
TBX3-overexpressing cells compared to the control cell lines, suggesting that the 
overexpression of TBX3 in MCF-12A cells leads to an inhibition of cell proliferation. 
Consistent with the TBX3 knock down data, TBX3 overexpression was accompanied by an 
increase in p21 levels but interestingly, it correlated with a decrease in TBX2 levels (Fig. 
3.4C). 
 
When the impact of TBX3 overexpression on migratory ability was assessed using a 
scratch motility assay, the results show that the TBX3 overexpressing cells migrated 
significantly faster (Fig. 3.4D). Together, these findings show that TBX3 impacts 
negatively on cell proliferation but promotes cell migration of “normal” MCF-12A breast 





Figure 3.4 TBX3 overexpression inhibits cell proliferation but promotes migration. (A) 
MCF-12A cells were transduced with an Adeno-TBX3 Tet-off virus, which allows TBX3 
expression to be regulated by 10 μg/ml Doxycyclin (Dox). The efficacy of the system was 
tested by subjecting protein from the indicated cells to western blot analysis with an 
antibody specific to human TBX3. p38 was used as a loading control. (B) TBX3 
overexpression inhibits cell proliferation. MCF-12A cells from (A) were incubated with 10 
μM BrdU for 3 hrs and then processed for immunocytochemistry with an anti-BrdU 
antibody. The total number of BrdU-positive nuclei was visualized by fluorescence 
microscopy and expressed as a percentage of the total number of cells from 10 fields of 
view for each condition (images not shown). The result of one BrdU incorporation assay 
is shown which is representative of two independent experiments. (C) MCF-12A cells 
were transduced with adeno-TBX3 virus and doxycycline (Dox) (10 µg/ml) as indicated 
and the protein harvested was subjected to western blot analysis using antibody specific 
to human TBX3, TBX2 or p21 and p38 was used as a loading control. (D) TBX3 
overexpression promotes migration. MCF-12A cells from (A) were incubated for 48 hrs 
and subjected to the two-dimensional in vitro scratch assay. Cells were grown to 
confluence and a linear wound was made by scratching through the monolayer using a 
sterile 20 µl pipette tip. Mitomycin C (10 μg/ml) was added to prevent cell proliferation 
and migration measured. The result shown is representative of two independent 
migration assays and is expressed as an average of 10 fields of view for each condition.  
A Microsoft Excel student t-test was performed to calculate statistical significance 




3.3 TBX3 is a downstream target and mediator of the transforming growth factor β1 
(TGF-β1) signalling pathway 
The results above suggest that increased levels of TBX3 inhibit cell proliferation but 
promote migration of both normal and transformed breast cells. This led to the question 
as to what are the molecular pathway(s) that up-regulate TBX3 gene expression. TGF-β1 
was considered as a candidate because like TBX3, it plays an important role in mammary 
morphogenesis and is notoriously activated during breast cancer development (Moses 
and Barcellos-Hoff, 2011). In addition, it is also well known to inhibit proliferation but 
promote cell migration (Imamura et al., 2012; Jahn et al., 2012). Furthermore, 
microarray studies in which normal human breast epithelial cells and keratinocytes were 
treated with TGF-β1 showed an activation of TBX3 (Kang et al., 2003). This chapter 
explores the possibility that TGF-β1 may directly activate TBX3 expression to mediate its 
biological activity.   
  
3.3.1 TGF-β1 transcriptionally activates TBX3 expression in MCF-12A breast epithelial 
cells and HaCaT keratinocytes 
To begin to explore the possibility that TBX3 expression is regulated by TGF-β1, MCF-12A 
and HaCaT keratinocytes were treated with TGF-β1 or vehicle over a time course 
spanning 8 hrs to 36 hrs and total protein harvested from the cells was subjected to 
western blot analyses. The results show that TBX3 levels increased substantially in 
response to TGF-β1 treatment in both cell lines (Fig. 3.5A, B). To confirm the activation 
of TBX3 levels by TGF-β1, MCF-12A and HaCaT cells were treated with TGF-β1 for 12 hrs 
and processed for immunofluorescence with an antibody specific to human TBX3 and 
the cells visualised by fluorescence microscopy. Figure 3.5C, D shows that TGF-β1 treated 
cells have an increase in nuclear TBX3 levels compared to the control cells. Together, 







Figure 3.5 TGF-β1 activates TBX3 protein expression. TBX3 protein from MCF-12A cells 
(A) or HaCaT cells (B) were treated with TGF-β1 (5 ng/ml) for the indicated times and 
total protein extracted and examined by western blot analysis using an antibody specific 
to TBX3. p38 was used as a loading control. MCF-12A cells (C) or HaCaT cells (D) were 
treated with TGF-β1 (5 ng/ml) for 12 hrs and TBX3 levels and subcellular localization 
were determined by immunocytochemistry using an antibody specific to TBX3. All cells 
were co-stained with 4’,6-diamidino-2-phenylindole (DAPI) to determine the location of 
the nuclei and in the merged image the red and blue represent TBX3 and DAPI 
respectively. 
 
To examine the effect of TGF-β1 on TBX3 mRNA levels, quantitative real-time PCR 
(qRT-PCR) experiments were performed on mRNA extracted from cells treated with 
TGF-β1 for 3 and 12 hrs. The results demonstrate a 2 and 2.5 fold increase in TBX3 mRNA 
levels respectively in MCF-12A cells and 1.4 and 1.8 fold increase respectively in HaCaT 
cells (Fig. 3.6A, B). This corresponded with the results from western blotting and 
suggested that TGF-β1 may regulate TBX3 transcriptionally. To confirm this possibility, 
MCF-12A cells were pre-treated with a transcriptional inhibitor, actinomycin D (AD) 
before treatment with TGF-β1. The results show that when transcription is inhibited, the 
TGF-β1-mediated activation of TBX3 mRNA (Fig. 3.6C) and protein (Fig. 3.6D) levels were 






Figure 3.6 TBX3 is transcriptionally activated by TGF-β1. Total RNA extracted from 
MCF-12A cells (A) or HaCaT cells (B) after 3 or 12 hrs of TGF-β1 treatment was 
reverse-transcribed and subjected to quantitative real-time PCR (qRT-PCR) using primers 
specific to TBX3. mRNA levels were normalized to GUSB. (C, D) MCF-12A cells were 
pre-treated with vehicle (control) or 5 µg/ml actinomycin D (AD) for 1 hr and treated 
with TGF-β1 for 3 hrs. RNA and protein were harvested for use in (C) qRT-PCR and (D) 
western blotting with an antibody specific to human TBX3, respectively. Results from A, B 
and C are representative of two independent experiments, each performed in duplicate. 
A Microsoft Excel student t-test was performed to calculate statistical significance (**p< 
0.001). Error bars represent standard deviation. 
 
3.3.2 TGF-β1-activated TBX3 expression is mediated by JunB and Smad3/4 
The Smad proteins are known to play an important role in the TGF-β1 signalling pathway 
(Feng and Derynck, 2005) and therefore to identify the mechanism(s) by which TGF-β1 
transcriptionally activates TBX3 their possible involvement was considered. To this end, 
MCF-12A cells were co-transfected with -2186 bp of the TBX3 promoter driving a firefly 
luciferase reporter with increasing concentrations of Smad3/4. The results of three 
independent experiments in which each construct was tested in duplicate, are shown in 
figure 3.7A. Interestingly, at all concentrations tested, Smad3/4 had very little effect on 
basal TBX3 promoter activity suggesting that the Smads may require another 
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co-operating protein to transactivate TBX3 in the TGF-β1 signalling pathway. Based on 
previous reports, it was speculated that JunB may be a co-factor involved in this 
regulation (Verrecchia et al., 2001). To test this, MCF-12A cells were treated with 5 ng/ml 
TGF-β1 over a time course of 0.5 to 4 hours and the levels of JunB and Smad proteins 
were examined by western blot analysis. The results showed that TGF-β1 treatment led 
to an increase in JunB and pSmad3 protein levels, which preceded the increase in TBX3 
protein levels (Fig. 3.7B). As expected, the total levels of Smad2/3, Smad4 and the p38 
loading control remained unchanged. These results suggested that JunB and the Smad 
proteins may be involved in the TGF-β1-induced activation of TBX3.  
  
To confirm the possible in vivo role of JunB and Smad proteins in TGF-β1 regulated TBX3 
expression, the MCF-12A cells were transfected with small interfering RNAs (siRNAs) that 
specifically target and knock down JunB or Smad4. The rationale for knocking down 
Smad4 was based on reports that it is the nuclear transporter for Smad2/3 (Feng and 
Derynck, 2005). Briefly, MCF-12A cells were transiently transfected with siJunB or 
siSmad4 or siControl and untransfected cells (UT) were included as an additional control. 
Proteins from all cells were harvested after 24 hrs and subjected to western blot analysis. 
As shown in figures 3.7C and D, compared to the UT or control siRNA cells, knocking 
down either JunB or Smad4 did not completely abrogate, but severely compromised, the 
TGF-β1-induced activation of TBX3 protein and mRNA levels. Together these results 
provided compelling evidence that both JunB and Smad proteins are important in the 





Figure 3.7 JunB and Smad proteins mediate the regulation of TBX3 by TGF-β1. (A) 
MCF-12A cells were co-transfected with the TBX3 -2186 bp promoter luciferase reporter 
(400 ng) and increasing doses of Smad3/4 expression vectors and luciferase activity 
measured. Mean values (± SD) are presented as fold activity over that of an empty firefly 
luciferase reporter construct and are representative of at least three independent 
experiments. (B) MCF-12A cells were serum starved and treated with TGF-β1 at the 
indicated time points and analysed by western blotting with antibodies specific to TBX3, 
JunB, pSmad3, Smad2/3 or Smad4. p38 was used as loading control. (C) MCF-12A cells 
were either untransfected (UT), or transfected with 30 nM siJunB (upper panel) or 50 nM 
siSmad4 (lower panel) or the equivalent concentration of control siRNA for 24 hrs, 
followed by 3 hrs of TGF-β1 treatment and subjected to western blotting using 
antibodies specific to TBX3, JunB or Smad4. p38 was used as loading control. (D) mRNA 
from (C) was subjected to qRT-PCR analysis. mRNA levels were normalized to GUSB. The 
result of one qRT-PCR experiment is shown which is representative of two independent 
experiments, each performed in duplicate. A Microsoft Excel student t-test was 
performed to calculate statistical significance (*p<0.05, **p< 0.001). Error bars represent 
standard deviation. 
 
3.3.3 JunB and Smad proteins co-operate to activate the TBX3 promoter at the SBE-67 
Having shown that the JunB and Smad proteins play an important role in the 
TGF-β1-induced activation of TBX3, the next objective was to identify the potential 
cis-acting regulatory element(s) of JunB and Smad proteins. To this end, the TBX3 
promoter was firstly examined for AP-1 and Smad binding sites. Six putative AP-1 binding 
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sites (Fig. 3.8A left panel) and numerous Smad binding elements (SBEs) (not shown) 
were identified in the -2.1 kb promoter region upstream of the transcription start site. To 
narrow down the region of the TBX3 promoter involved in the TGF-β1 mediated 
activation, MCF-12A cells were co-transfected with a series of 5’ deletion constructs of 
the human TBX3 promoter and JunB and Smad3/4 expression vectors, and luciferase 
reporter assays were performed. As shown in figure 3.8A, whereas Smad3/4 had no 
effect on all four constructs, JunB activated all TBX3 promoter deletion constructs. 
Interestingly, the co-transfection of JunB and Smad3/4 demonstrated that they 
co-operate to activate all four promoters.  
 
To identify the site(s) responsible for this activity, putative sites in the shortest TBX3 
promoter construct (−141/+38 bp) was used for subsequent analysis, because it 
maintained a high level of promoter activity. Given that the ability of Smads to 
co-operate with their co-factors requires their respective binding sites to be in close 
proximity, the two AP-1 sites at -86 bp and the adjacent SBE (-67 bp) were mutated 
individually by site-directed mutagenesis (Fig. 3.8B upper panel). These constructs were 
compared to the WT -141 bp construct in luciferase reporter assays. Interestingly, as 
shown in figure 3.8B lower panel, while the activity of the AP-1 mutant was comparable 
to that of WT, the SBE mutant significantly dampened the JunB-induced activation and 
abolished the co-operative effect of JunB and Smad3/4 in response to TGF-β1. This result 
is consistent with previous reports that in response to signals from TGF-β1 receptors, 
Smad proteins can co-operate with other sequence-specific transcription factors to 
regulate transcription of target genes (Poncelet and Schnaper, 2001; Wang et al., 2008b).  
Together, these data suggest that not only does Smad co-operate with JunB to activate 
the TBX3 promoter, but that this activity is mediated by a Smad binding element. The 
possibility that the TBX3 promoter used in this study does not contain all regulatory 






3.3.4 TGF-β1 treatment enhances binding of JunB and Smad4 to the TBX3 promoter 
To confirm that JunB and the Smad proteins can bind to the proximal region of the TBX3 
promoter in vivo, a chromatin immunoprecipitation (ChIP) assay was performed. Briefly, 
MCF-12A cells were fixed with formaldehyde and the cross-linked chromatin was 
extracted and sheared and the JunB- or Smad4-bound chromatin was 
immunoprecipitated with an anti-JunB or anti-Smad4 antibody respectively. After 
reversing the cross-link a set of primers spanning the SBE at -67 bp in the TBX3 promoter 
was used to amplify the immunoprecipitated DNA using qRT-PCR analysis. Primers 
specific to the GAPDH coding region were used as a negative control. The results 
obtained show that compared to the IgG control, JunB and Smad4 were able to bind to 
the TBX3 promoter in untreated cells and that in the presence of TGF-β1 this binding was 
enhanced by a 2.5 fold (JunB) and 5.5 fold (Smad4) increase in signal respectively (Fig. 
3.8C). These data suggest that JunB and Smad4 directly bind the proximal TBX3 promoter 
during basal regulation and that this mechanism is significantly enhanced by TGF-β1 
treatment. 
 
To verify that JunB and/or Smad4 specifically bind the SBE -67 site in the TBX3 promoter, 
an electromobility-shift assay (EMSA) was performed. Nuclear extract isolated from 
TGF-β1-treated MCF-12A cells was incubated with a biotin-labelled probe spanning the 
wild-type (WT) SBE at -67 in the TBX3 promoter and protein-bound biotinylated DNA run 
on an acrylamide gel, transferred to a nylon membrane and analysed by 
chemiluminescence using streptavidin-HRP conjugate. Figure 3.8D left panel shows there 
were four complexes observed (lane 2, see arrows) and the lowest two were competed 
efficiently by non-biotin-labelled homologous WT competitor oligonucleotides (lanes 3, 4, 
two lower arrows), but not by the oligonucleotide in which the SBE-67 was mutated (MT) 
(lanes 5, 6). The topmost complex was not competed by either WT or MT competitors 
suggesting that it may be a non-specific (NS) band or that it represents a complex that 
binds biotin. Furthermore, the fourth complex was competed by both WT and MT 
competitors and may thus represent a nuclear factor bound to the probe at a site 
adjacent to the SBE. To confirm that it was indeed JunB and Smad4 in the nuclear extract 
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used in figure 3.8D that bound the SBE at -67 in the TBX3 promoter, a DNA affinity 
immunoblot assay (DAI) was performed. To this end, the same nuclear extracts used for 
the EMSAs were incubated with biotinylated DNA probes containing either the WT or MT 
SBE -67 oligos. Protein-bound biotinylated DNA was isolated and analysed by western 
blotting using antibodies specific to JunB, pSmad3 and Smad4. The results show that in 
the absence of TGF-β1 stimuli, both JunB and Smad4 but not pSmad3 bound the probes 
carrying the WT -67. However, when TGF-β1 is present, all three proteins could bind the 
WT -67 and their binding affinity was greatly decreased when this SBE was mutated (Fig. 
3.8D, right panel). Taken together, these results suggest that in response to TGF-β1, JunB 
and Smad4 form protein complexes at SBE -67 to directly activate TBX3 expression.
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Figure 3.8 TGF-β1 activation of the TBX3 promoter is mediated by a degenerate SBE at 
−67 base pairs. (A) Schematic illustrations of luciferase reporter constructs containing 
sequential 5’- deletions of the human TBX3 promoter (400 ng) which were transiently 
co-transfected into the MCF-12A cells with vectors expressing human JunB (40 ng) and 
Smad3/4 (30 ng each). The arrow indicates the transcription start site at +1 and the * 
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indicates the putative AP-1 binding sites. Mean values (± SD) are presented as fold 
activity over that of an empty firefly luciferase reporter and are representative of at least 
three independent experiments. (B) MCF-12A cells were co-transfected with a wild type 
(WT) TBX3 -141 bp promoter luciferase reporter (400 ng) or a reporter in which the 
indicated AP-1 (AP1mt) or Smad-binding-element (SBEmt) was mutated and JunB (40 ng ) 
or Smad3/4 (30 ng each) expression constructs and luciferase activity analysed. The 
result of one luc assay is shown which is representative of two independent experiments, 
each performed in triplicate. (C) Upper panel: Schematic representation of a region of 
the human TBX3 promoter. SBE at position -67 bp is marked with a cross. Forward (ChIP 
Fwd) and reverse (ChIP Rv) primers are shown according to where they bind, producing a 
207 base pair size fragment of the TBX3 promoter. Lower panel: MCF-12A cells were 
treated with 5 ng/ml TGF-β1 for 3 hrs and chromatin immunoprecipitation assays 
performed with antibodies against JunB, Smad4 or IgG (negative control). 
Immunoprecipitated DNA was assayed by qRT-PCR with primers against the TBX3 
promoter or GAPDH (negative control). The results of one ChIP experiment is shown 
which is representative of two independent experiments, each performed in triplicate. 
Error bars represent standard error of the mean. (D) Left panel: For EMSA, 
biotin-labelled double stranded oligo-nucleotide probes containing the homologous WT 
SBE −67/−58 site were incubated with nuclear extracts from MCF-12A cells (lanes 2–6). 
Observed complexes are indicated by arrows on the left. Unspecific complexes are 
indicated by *NS on the right. Competition analyses were carried out in the presence of 
5 x (lanes 3 and 4) or 25 x (lanes 5 and 6) molar excess of unlabelled homologous probes. 
The complex bands observed for the SBE site are indicated by the two lowest arrows. 
Right panel: Biotinylated DNA probes of the TBX3 promoter containing the homologous 
WT or MT SBE were immobilized on streptavidin beads, and incubated with nuclear 
extracts from MCF-12A cells treated with or without 5 ng/ml TGF-β1 for 3 hrs. The 
DNA-bound protein complexes were isolated and analysed by western blotting using 
antibodies to JunB or Smad4. A Microsoft Excel student t-test was performed to calculate 




3.3.5 The anti-proliferative and pro-migratory roles of TGF-β1 are mediated in part by 
TBX3 
TGF-β1 has an anti-proliferative and a pro-migratory role and recent findings from our 
laboratory have reported similar roles for TBX3 (Peres et al., 2010; Mowla et al., 2011). 
Having shown that TGF-β1 transcriptionally activates TBX3, it was therefore next 
speculated that these biological effects of TGF-β1 are mediated in part by TBX3. To test 
this, an inducible MCF-12A cell line (lenti-MCF-12A) was generated using a lentiviral 
system. Briefly, the MCF-12A cells were stably transduced with lentiviral infectious 
particles that contain a GFP-tagged doxycycline (Dox)-inducible shTBX3 that specifically 
targets and knocks down TBX3. Successfully transduced cells were sorted by 
fluorescence activated cell sorting (FACS) for GFP expression. The efficacy of the system 
was confirmed by western blot analysis (Fig. 3.9A) that shows that compared to the 
untreated cells, the addition of 1 μg/ml Dox for as early as 48 hrs led to a significant 
reduction in TBX3 levels in the lenti-TBX3 cells and this knock down of TBX3 was not 
observed when the MCF-12A parental cells were treated with Dox under the same 
conditions.  
 
To examine the role of TBX3 in the TGF-β1-regulated anti-proliferative effect, BrdU 
incorporation assays were performed where an equal number of cells were plated and 
pulsed with BrdU for 3 hrs. Results show the total number of BrdU positive cells 
expressed as a percentage of the total number of cells from 10 fields of view for each 
condition. When control cells were treated with TGF-β1, TBX3 protein levels increased 
(Fig. 3.9B), which corresponded with a decrease in proliferation as measured by BrdU 
incorporation (Fig. 3.9C). However, when TBX3 expression was knocked down (Fig. 3.9B) 
there was no statistical difference in the proliferative ability of control and TGF-β1–
treated cells (Fig. 3.9C), suggesting that TBX3 was required for the inhibitory effect of 
TGF-β1 on cell proliferation. To measure the impact of TBX3 on the TGF-β1-regulated 
pro-migratory effect scratch motility assays were performed. Figure 3.9D shows that in 
the Dox- cells TGF-β1-induced TBX3 upregulation correlated with increased cell migratory 
ability by approximately 3 fold. However, when TBX3 levels were inhibited by Dox, the 
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fold change of TGF-β1-induced migration was significantly reduced to approximately less 
than 1.5 fold. The migration observed when TBX3 was knocked down is probably due to 
incomplete knock down of TBX3. These results show that TBX3 also plays an important 
role in mediating the pro-migratory effect of TGF-β1 on these cells. 
 
The above results were reproducible when TBX3 was knocked down in HaCaT cells using 
a siTBX3 approach (Fig. 3.9E-G). Briefly, HaCaT cells were transfected with either 50 nM 
siControl, which had been validated to have no off-target effects, or 50 nM siTBX3, that 
specifically target and knock down TBX3 expression. Successful TBX3 knock down was 
confirmed by western blotting (Fig. 3.9E) and the effect of TBX3 knock down on cell 
proliferation was measured after 30 hrs using the methylthiazol tetrazolium (MTT) assay. 
While the control cells exhibited reduced proliferation by approximately 1.4 fold in 
response to TGF-β1, there was no significant difference between the untreated and 
TGF-β1-treated siTBX3 cells (Fig. 3.9F). Similarly, unlike siControl cells, siTBX3 cells failed 
to respond to TGF-β1-induced pro-migratory stimuli in scratch motility assays (Fig. 3.9G). 
Together, these results suggest that TBX3 is key in mediating the anti-proliferative and 






Figure 3.9 TBX3 is a key downstream mediator of TGF-β1 regulated cell proliferation 
and migration. (A) MCF-12A cells were stably transduced with lentiviral infectious 
particles containing a GFP-tagged shTBX3 construct and a pure population of shTBX3 
cells (lenti-MCF-12A cells) was obtained by fluorescence activated cell sorting (FACS) for 
GFP expression. Lenti-MCF-12A and parental MCF-12A cells were treated with or without 
1 μg/ml Doxycyclin (Dox) for 48 hrs and protein extracts analysed by western blotting 
using an anti-TBX3 antibody. p38 was used as a loading control. (B, E) Western blot 
85 
 
analyses show the lentiviral shRNA-mediated knock down of TBX3 in MCF-12A cells (B) or 
siTBX3-mediated knock down in HaCaT cells (E) in the presence or absence of 3 hrs 
TGF-β1 treatment. p38 was used as a loading control. (C) MCF-12A cells from (B) were 
incubated with 10 μM BrdU for 3 hrs and harvested for immunocytochemistry using an 
anti-BrdU antibody. BrdU-positive nuclei were visualized by fluorescence microscopy to 
measure cell proliferation. The result shown is representative of two independent 
experiments. (F) Net cell growth of HaCaT cells from (E) was assessed by the 
methylthiazol tetrazolium (MTT) assay over 30 hrs. The result shown is representative of 
two independent experiments, each performed in triplicate. (D, G) Cells treated as in (B) 
and (E) were subjected to a two-dimensional in vitro scratch motility assay as described 
before. Each result shown is representative of two independent experiments and is 
expressed as an average of 10 fields of view for each condition. A Microsoft Excel student 
t-test was performed to calculate statistical significance (*p<0.05, **p< 0.001). Error bars 





3.4 TBX3 represses its homologue TBX2 to execute its anti-proliferative role in the 
TGF-β1 signalling pathway 
The results above show that TGF-β1 upregulates expression of TBX3 which is key for 
mediating TGF-β1-induced anti-proliferation and pro-migration of epithelial cells. This 
raised the question as to which TBX3 target genes are responsible for this. Previous data 
from our laboratory as well as others showed that TBX2, the homologue of TBX3, 
functions as a pro-proliferative factor and preliminary reports suggest that TBX3 may be 
able to repress TBX2 (Jacobs et al., 2000; Vance et al., 2005; Peres et al., 2010; Redmond 
et al., 2010). It was therefore hypothesized that in response to TGF-β1, TBX3 represses 
TBX2 in order to inhibit cell proliferation and the following section explores this 
possibility. 
 
3.4.1 TGF-β1 transcriptionally represses TBX2 expression in MCF-12A breast epithelial 
and B16 melanoma cells. 
To determine if TBX2 is indeed a downstream target of TBX3 in the TGF-β1 
anti-proliferative pathway, the effect of TGF-β1 signalling on TBX2 expression was firstly 
examined. Briefly, MCF-12A breast epithelial and B16 mouse melanoma cells were 
exposed to TGF-β1 or vehicle over a time course spanning 1 – 36 hours and western 
blotting performed on extracts from these cells with an antibody to TBX2. Results show 
that TBX2 levels decrease substantially in response to TGF-β1 treatment in both cell lines 
from 8 hrs in MCF-12A cells and 4 hrs in B16 cells (Fig. 3.10A, B). It is important to note, 
that this robust repression was also previously observed by an ex-PhD student, Dr Teng, 
in WI-38 normal human fibroblasts (data not shown). To examine the effect of TGF-β1 on 
TBX2 mRNA levels, qRT-PCR experiments were performed on mRNA extracted from cells 
treated with TGF-β1 or vehicle over a time course spanning 1 – 36 hours. The results 
demonstrate a corresponding decrease in TBX2 mRNA levels in MCF-12A and B16 cells 




Figure 3.10. TGF-β1 represses TBX2 protein and mRNA expression. TBX2 protein from 
TGF-β1 (5 ng/ml) treated MCF-12A cells (A) or B16 cells (B) were prepared after the 
indicated times and was examined by western blot analysis with an antibody specific to 
human TBX2. p38 was used as a loading control. (C, D) Total RNA extracted from 
MCF-12A cells (C) or B16 cells (D) after indicated times of TGF-β1 (5 ng/ml) treatment 
were reverse-transcribed and subjected to qRT-PCR using primers specific to TBX2. 
mRNA levels were normalized to GUSB. Each result shown is representative of two 
independent qRT-PCR experiments, performed in duplicate. A Microsoft Excel student 
t-test was performed to calculate statistical significance (**p< 0.001). Error bars 
represent standard deviation. 
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To investigate if this regulation is transcriptional, a luciferase assay was performed to test 
whether the TBX2 promoter is responsive to TGF-β1 treatment. Briefly, MCF-12A cells 
transfected with the -1604 bp human TBX2 promoter construct were treated with 5 
ng/ml TGF-β1 for 8 hrs, 24 hrs and 36 hrs and the results show a time-dependent 
decrease in reporter activity in response to TGF-β1 (Fig. 3.11A). To distinguish the need 
for de novo protein synthesis, cells were pre-treated with cycloheximide (CHX), a protein 
synthesis inhibitor, which abolished the repression of TBX2 mRNA and protein levels by 
TGF-β1 (Fig. 3.11B, C). Together these results suggest that TGF-β1-mediated repression 
of TBX2 is transcriptional and that it requires the production of nascent protein. 
 
Figure 3.11 TBX2 is transcriptionally regulated by TGF-β1. (A) Luciferase assay using 
MCF-12A cells which were transfected with a full length human TBX2 promoter (400 ng) 
construct and were treated with 5 ng/ml TGF-β1. Mean values (± SD) are presented as 
fold activity over that of an empty firefly luciferase reporter and are representative of at 
least three independent experiments. (B, C) MCF-12A (B) and B16 (C) cells were 
pre-treated with vehicle (control) or 30 µg/ml cycloheximide (CHX) for 1 hr followed by 
TGF-β1 treatment for 8 hrs for MCF-12A cells and 4 hrs for B16 cells. Upper panels: RNA 
was harvested for use in qRT-PCR using primers specific to TBX2 and mRNA levels were 
normalized to GUSB. Lower panels: Protein was harvested for western blot analysis using 
an antibody specific to human TBX2 and p38 was used as a loading control. The 
expression of TBX2 was quantified using UN-SCAN-IT gel 6.1 software and the 
densitometry values normalised to p38 levels. A Microsoft Excel student t-test was 
performed to calculate statistical significance (*p<0.05, **p< 0.001). Error bars represent 
standard deviation.  
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3.4.2 The downregulation of TBX2 by TGF-β1 is mediated by TBX3 in breast epithelial 
cells.  
To narrow down the region of the TBX2 promoter mediating its repression by TGF-β1, a 
series of 5’ deletion constructs of the human TBX2 promoter driving a firefly luciferase 
reporter were tested in luciferase assays. The results show that the repression of TBX2 by 
TGF-β1 treatment is sustained even in the -218 bp TBX2 promoter construct (Fig. 3.12A). 
Since the primary mediators of canonical TGF-β1 signalling are the Smad proteins it was 
first investigated whether Smad3 and Smad4 (Smad3/4) are involved in this regulation. 
To this end, MCF-12A cells were co-transfected with increasing amounts of Smad3/4 
expression vectors and the -218 bp TBX2 promoter luciferase construct and luciferase 
activity analysed. Figure 3.12B shows that Smad3/4 had very little effect on TBX2 
promoter activity suggesting that the regulation of TBX2 by TGF-β1 either requires a 
Smad co-factor(s) or involves a mechanism that does not directly require the Smads. 
These experiments were therefore repeated in the presence or absence of the 
well-known Smad co-factors, JunB or Sp1, but no repression was observed (data not 
shown). As shown earlier, TGF-β1 activates TBX3 expression to impact negatively on cell 
proliferation and previous work from Rodriguez et al. (2008) as well as unpublished work 
from our laboratory indicated that TBX2 and TBX3 may be reciprocally expressed. It was 
therefore speculated that TBX2 may be downstream of TBX3 in the TGF-β1 pathway. To 
address this, the -218 bp TBX2 promoter was screened for T-elements and a T-element 
which is highly conserved between Tbx2 promoters across several species was identified 
at -186 bp (Fig. 3.12C).  
 
To investigate the possible in vivo role of TBX3 in the repression of TBX2 by TGF-β1, TBX3 
was silenced by siRNA and TBX2 protein and mRNA levels determined in TGF-β1 treated 
cells. Indeed, depleting TBX3 levels in MCF-12A cells diminished the ability of TGF-β1 to 
repress TBX2 protein and mRNA levels (Fig. 3.12D, E). It is worth noting that while the 
fold repression of TBX2 by TGF-β1 in the siTBX3 cells was still significant, it was lower 
than that of the control cells and may be due to incomplete knock down of TBX3. 
Furthermore, knocking down TBX3 in untreated cells resulted in an increase in TBX2 
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mRNA and protein levels suggesting that TBX3 represses basal and TGF-β1 regulated 
TBX2 levels.  
 
 
Figure 3.12 The downregulation of TBX2 by TGF-β1 is mediated by TBX3. (A) Luciferase 
assays of MCF-12A cells transfected with 400 ng of the indicated human TBX2 5’- 
deletion promoter constructs and treated with 5 ng/ml TGF-β1 or vehicle. (B) Luciferase 
assays of MCF-12A cells co-transfected with increasing amounts of Smad3/4 expression 
vectors and 400 ng of -218 bp TBX2 promoter reporter construct. For A-B, mean values 
(± SD) are presented as fold activity over that of an empty firefly luciferase reporter and 
are representative of at least three independent experiments. (C) Alignment of the 
T-element at -186 bp in the human TBX2 promoter is conserved in chimpanzee, mouse 
and zebrafish. The box indicates the location of the T-element. (D, E) Serum starved 
MCF-12A cells were transfected with either 50 nM siControl or siTBX3 for 48 hrs, and the 
transfection was repeated to maintain the knock down of TBX3 for another two days in 
which the cells were cultured in 5 ng/ml TGF-β1. The cells were harvested and subjected 
to (D) western blotting using antibodies specific to TBX3 or TBX2 (p38 was used as 
loading control) or (E) qRT-PCR analysis with mRNA levels normalized to GUSB. The 
experiment was performed in duplicate. A Microsoft Excel student t-test was performed 





3.4.3 TBX3 binds to the TBX2 promoter at -186 bp in response to TGF-β1 treatment.  
To confirm that TBX3 can directly repress TBX2 in vivo, chromatin immunoprecipitation 
(ChIP) assays were performed. Briefly, cross-linked chromatin was prepared from 
TGF-β1-treated and control MCF-12A cells and DNA immunoprecipitated with an 
antibody to TBX3. After reversing the cross-link a set of primers spanning the -186 bp 
putative T-element in the TBX2 promoter was used to amplify the immunoprecipitated 
DNA using qRT-PCR analysis. Primers specific to the GAPDH coding region were used as a 
negative control. The results obtained show that compared to the untreated control, the 
binding of TBX3 to the TBX2 promoter was enhanced by 8.5 fold in the presence of 
TGF-β1 (Fig. 3.13A).  
 
To determine whether TBX3 binds specifically to the -186 bp T-element in the TBX2 
promoter, a DNA affinity immunoblot (DAI) assay was performed. Nuclear extracts 
isolated from TGF-β1-treated MCF-12A cells were incubated with biotinylated DNA 
probes containing either the wild type (WT) or mutated T-element (MT) (Fig. 3.13B 
upper panel). As an additional control a probe containing a full T-element consensus site 
was included in these experiments and protein-bound biotinylated DNA was isolated and 
analysed by western blotting using an anti-TBX3 antibody. The results show that while 
TBX3 bound strongly to both the consensus and wild-type probes, it displayed a 
decreased affinity for the probe with the mutated T-element (Fig. 3.13B lower panel). 
Together, these results suggest that TBX3 binds the TBX2 promoter specifically at the 






Figure 3.13 TBX3 binds the TBX2 promoter in vivo and in vitro at the T-element at −186 
bp. (A) TBX3 binds the TBX2 promoter in the region of the consensus T-element in vivo. 
Upper panel: Schematic representation of human TBX2 promoter. T-element at position 
-186 bp is marked with a cross. Forward (ChIP Fwd) and reverse (ChIP Rv) primers are 
shown according to where they bind on the TBX2 promoter. Lower panel: MCF-12A cells 
were treated with 5 ng/ml TGF-β1 for 24 hrs and the cell lysates were used in a ChIP 
assay performed with antibodies against TBX3 or IgG (negative control). 
Immunoprecipitated DNA was assayed by qRT-PCR with primers against the TBX2 
promoter or GAPDH (negative control). A Microsoft Excel student t-test was performed 
to calculate statistical significance (*p<0.05). The results of one ChIP experiment is 
shown which is representative of two independent experiments, each performed in 
triplicate. Error bars represent standard error of the mean. (B) Biotinylated double 
stranded oligo-nucleotide probes of the TBX2 promoter containing the WT T-element at 
-186 bp or MT where this T-element was mutated from CGACACC to CAAAAAC as well as 
93 
 
a probe containing a full consensus T-element were immobilized on streptavidin beads, 
and incubated with nuclear extracts from MCF-12A cells treated with 5 ng/ml TGF-β1 for 
24 hrs. The DNA-bound protein complexes were isolated and analysed by western 
blotting using antibodies to TBX3. (C) Luciferase assay of MCF-12A cells co-transfected 
with 100 ng of TBX3 expression vector or empty control vector and 400 ng of either TBX2 
WT or T-element mutant (MT) promoter luciferase reporter. (D) Luciferase assay of 
MCF-12A cells co-transfected with 400 ng of TBX2 promoter luciferase reporter and 100 
ng of an empty control vector or WT TBX3 or DNA binding domain mutant (DBM) or 
TBX3 N-terminal truncated expression vector. For (C) and (D), mean values (± SD) are 
presented as fold activity over that of an empty firefly luciferase reporter and are 
representative of at least three independent experiments. Western blots (C, D, right) 
show equal expression of TBX3 protein. Bars, SD. *p < 0.05, ** p<0.001 
 
To test whether TBX3 can repress the TBX2 promoter and whether the T-element at -186 
bp mediates this repression, MCF-12A cells were co-transfected with a TBX3 expression 
vector and either a wild type -218 bp TBX2 promoter luciferase construct or a construct 
in which the T-element was mutated by site-directed mutagenesis. The results show that 
TBX3 repressed the TBX2 promoter by approximately 18 fold and that the ability of TBX3 
to repress TBX2 was significantly reduced when the -186 bp T-element was mutated (Fig. 
3.13C), suggesting that TBX3 represses the TBX2 promoter via the -186 bp T-element.  
 
To identify the functional domains of the TBX3 protein that are responsible for repressing 
TBX2, the wild type -218 bp TBX2 promoter luciferase construct was co-transfected with 
vectors expressing either a WT TBX3 protein or a TBX3 protein in which the DNA binding 
domain was mutated or only a N-terminal TBX3 protein lacking the dominant repression 
domain. The DNA-binding domain (DBD) mutant (DBM) has arginine at position 133 
replaced with glycine and was previously shown to disrupt the highly homologous Tbx3 
mouse DBD (Habets et al., 2002; Lingbeek et al., 2002). The data obtained indicate that 
while WT TBX3 represses the TBX2 promoter by 6 fold, the TBX3 DBM and the N-terminal 
TBX3 proteins had significantly reduced ability to repress the TBX2 promoter (Fig. 3.13D). 
These data indicate that the TBX3 DNA binding domain and C-terminus containing a 
repression domain are important for its ability to repress the TBX2 promoter. Western 
blotting confirmed that all three TBX3 constructs were expressed at similar levels and 
hence loss of the ability of TBX3 DBM and TBX3 N-terminal to repress TBX2 was not due 
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to lower levels of expression of these constructs (Fig. 3.13C, D, right panel).  
 
3.4.4 Ectopic expression of TBX2 is able to rescue TGF-β1 inhibited cell proliferation.  
TGF-β1 has been shown to be a potent inhibitor of epithelial cell proliferation (Jahn et al., 
2012) and data from section 3.2 above showed that TBX3 plays a key role in mediating 
this effect in MCF-12A breast epithelial cells. This together with published data showing 
that TBX2 is a pro-proliferative factor (Jacobs et al., 2000; Vance et al., 2005; Peres et al., 
2010; Redmond et al., 2010) led to the hypothesis that the downregulation of TBX2 by 
TBX3 may contribute to the anti-proliferative effect of TGF-β1. TBX2 was therefore stably 
overexpressed in the MCF-12A cell line (MCF-12A-TBX2) to investigate whether it could 
rescue the inhibition of cell proliferation by TGF-β1. Briefly, a pcDNA3.1(+)-TBX2 
expression vector or the empty control vector was stably transfected into MCF-12A cells 
and G418 (400 µg/ml) -resistant clones were pooled after 10 days for subsequent 
analysis. Western blot analysis confirmed the overexpression of TBX2 (Fig. 3.14A) and 
MCF-12A-TBX2 and control cell lines were cultured in 5 ng/ml TGF-β1 for 4 days and cell 
numbers were counted using a haemocytometer. The overexpression of TBX2 was not 
affected by TGF-β1 (Fig. 3.14A) and growth curves show that while cell proliferation was 
significantly reduced by TGF-β1 in the control cells, overexpressing TBX2 was sufficient to 
rescue this phenotype (Fig. 3.14B). The role of TBX2 in this anti-proliferative effect was 
confirmed by flow cytometry which showed that TGF-β1 treatment induced a significant 
G1 cell cycle arrest in the control cells but had no effect on the cell cycle profile of the 
TBX2-overexpressing cells (Fig. 3.14C).  
 
The above results correlated with changes in the protein and mRNA levels of the cyclin 
dependent kinase inhibitor p21 (Fig. 3.14A, E), a known mediator of the 
anti-proliferative function of TGF-β1 and a target gene repressed by TBX2 (Prince et al., 
2004a; Jahn et al., 2012). To confirm that TBX2 is upstream of p21 in the TGF-β1 
response, TBX2 overexpressing cells were transfected with a p21 expression vector and 
growth curve analysis performed as before. The results show that the overexpression of 
p21 in TBX2 overexpressing cells reduced their proliferative ability and that TGF-β1 
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treatment could not reduce this any further (Fig. 3.14D).  
 
Importantly, while TBX2 overexpression abrogated the increase in p21 protein and mRNA 
levels in TGF-β1 treated cells (Fig. 3.14A, E), it failed to have any significant effect on the 
TGF-β1-induced activation of p15 mRNA levels (Fig. 3.14F), another cell cycle inhibitor 
which has been shown to mediate a G1 arrest in response to TGF-β1 (Reynisdóttir et al, 
1995). Together, these data suggested that the anti-proliferative effect of TGF-β1 on 
MCF-12A cells occurs primarily through upregulation of p21, since the continued 
repression of p21 in TBX2 overexpressing cells allowed the cells to proliferate even in the 
presence of TGF-β1 and despite the upregulation of p15. To confirm this, p21 expression 
was knocked down using a siRNA approach and growth curve analysis performed in the 
presence and absence of TGF-β1. As expected, cells in which p21 levels were effectively 
silenced proliferated faster than the control cells in the absence of TGF-β1 (Fig. 3.14G). 
Importantly, the p21-depleted cells also failed to show a significant decrease in cell 
proliferation in response to TGF-β1. These data suggest that the down-regulation of TBX2 
mediates the anti-proliferative effect of TGF-β1, primarily through allowing upregulation 









Figure 3.14 Ectopic TBX2 expression rescues TGF-β1-induced growth inhibition through 
downregulating p21 in breast epithelial cells. (A) MCF-12A cells were stably transfected 
with 100 ng of either pcDNA3.1(+) (Control) or pcDNA3.1-TBX2 (TBX2) and the clones 
were pooled. The MCF-12A-Control or -TBX2 cell lines were treated with or without 5 
ng/ml TGF-β1 for 3 days and were subjected to western blot analysis using antibodies 
specific to human TBX2 or p21. p38 was used as a loading control. (B) MCF-12A-Control 
or -TBX2 cells were seeded in triplicate at a density of 4 X 103 cells per well of a 24-well 
plate and treated with vehicle or 5 ng/ml TGF-β1 for 3 days. Growth curve assays were 
performed over a 3 day period and cells harvested by trypsinisation and counted on a 
haemocytometer. (C) Flow cytometry assays show relative fold change of TGF-β1 treated 
MCF-12A-Control and -TBX2 cells in G1, S and G2/M phases compared to their 
corresponding vehicle-treated cells. The result shown is representative of two 
independent flow cytometries. (D) MCF-12A-TBX2 cells were seeded and treated as in (B). 
After seeding, cells were transiently transfected with either pRc/CMV (TBX2 Control) or 
pRc/CMV-p21 (TBX2 p21), treated with TGF-β1 and subjected to growth curve analysis 
(Right panel). Replicate wells from the growth curve analysis were pooled and protein 
harvested for western blot analysis (Left panel). (E, F) MCF-12A-Control or -TBX2 cell 
lines were treated with vehicle or TGF-β1 for 24 hrs and RNA was harvested for use in 
qRT-PCR analyses to examine the expression of p21 (E) or p15 (F). mRNA levels were 
normalized to GUSB. Each result shown is representative of two independent 
experiments, performed in duplicate. (G) MCF-12A cells were seeded as in (B) and were 
either transfected with 25 nM sip21 (sip21) or the equivalent concentration of control 
siRNA (siControl) for 12 hrs, followed by 3 days of TGF-β1 treatment and subjected to 
(Left panel) western blotting and (Right panel) growth curve analysis as described in (D). 
For all analyses a student t-test was performed to calculate statistical significance (**p< 






DISCUSSION AND CONCLUDING REMARKS 
 
Breast cancer is the most common malignancy worldwide amongst women and it is 
estimated that one out of eight women will develop breast cancer in their life time 
(Cheng et al., 1998; Baselga et al., 2012; Howard and Bland, 2012). Furthermore, the 
majority of breast cancers are still diagnosed at very late stages in low- and middle- 
income countries due to inadequate infrastructure and resources and therefore result in 
a higher mortality compared to the high-income countries (Tfayli et al., 2010). Despite 
enormous efforts to identify effective breast cancer treatments, there is still limited 
success with most of the current therapeutic strategies. There is therefore an urgent 
need to develop novel and effective therapeutic drugs for this disease. The identification 
of transcription factors which play a key role in breast cancer progression is important 
because they may represent good targets in the development of novel therapeutic 
approaches to treat this cancer. The rationale for this is based on the premise that 
transcription factors are ultimately responsible for controlling gene expression patterns 
resulting in tumour formation, progression and metastasis. In the last decade, several 
transcription factors with key roles in breast cancer progression were identified as 
potential therapeutic targets. Among these was TBX3, a member of the T-box 
transcription factor family which was found to be overexpressed in a subset of breast 
cancers (Yarosh et al, 2008; Fan et al, 2004). However, at the start of this study the 
precise role of this aberrant expression of TBX3 in breast cancer progression was unclear. 
Furthermore, the mechanism(s) by which TBX3 is upregulated in breast cancer cells and 
the downstream targets that mediate its roles in this cancer were not known. Using both 
knockdown and overexpression cell culture models this study reveals that TBX3 is indeed 
involved in breast cancer progression, particularly contributing to tumour cell migration. 
Moreover, the Transforming Growth Factor β1 (TGF-β1) pathway, which is frequently 
deregulated in many cancers including breast cancers, is shown to upregulate TBX3 
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expression in breast cells. TBX2, a T-box family member which shares a high degree of 
homology with TBX3 and which is also widely implicated in cancer, is shown to be a 
direct target of TBX3 in the TGF-β1 pathway. Taken together, these results suggest that 
the deregulation of TBX3 and its downstream target TBX2 may be causative to breast 
cancer progression and that they could serve as novel therapeutic targets to treat this 
disease.  
 
The role of TBX3 in breast cancer progression 
TBX3 has been found overexpressed in a subset of breast cancers and at the start of this 
study it was unclear whether this overexpression contributes to breast cancer 
progression. This study addresses this by establishing cell culture models in which TBX3 
was either (1) stably silenced in an invasive breast ductal carcinoma cell line (MCF-7) 
which was previously shown to overexpress TBX3 or (2) overexpressed in a normal 
human breast epithelial cell line (MCF-12A). In both cell culture models the impact of 
altering TBX3 levels were then examined on key features of the cancer process. The 
results showed that TBX3 promotes breast cancer cell migration because when it was 
silenced cell migration was inhibited and the opposite effect was observed when it was 
overexpressed. These findings are consistent with reports linking TBX3 with cell 
migration. In 2008, Rodriguez and colleagues showed that TBX3 may contribute to 
melanoma migration through its ability to directly repress the cell adhesion molecule, 
E-cadherin. Similarly, TBX3 has a pro-migratory role in human bladder cancer cells and its 
levels correlated inversely with E-cadherin levels in these cells (Du et al., 2014). 
Moreover, its role in cancer cell migration and invasion was further highlighted by work 
performed in head and neck squamous cell carcinoma cell lines in which TBX3 was 
strongly induced during epithelial-mesenchymal transition which is considered to play a 
critical role in enhancing cell motility (Humtsoe et al., 2012).   
 
Interestingly, in both knock down and overexpression cell culture models TBX3 was 
shown to have a negative impact on substrate -dependent and -independent 
proliferation of breast epithelial cells. While the anti-proliferative and pro-migratory 
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roles of TBX3 may appear contradictory, they are consistent with previous reports that 
the proliferation and migration of tumour cells are mutually exclusive and that high 
proliferative capacity does not necessarily confer metastatic potential (Marshall et al., 
2004). Indeed, this phenomenon was observed in numerous in vitro and in vivo studies 
including in a study by Ma et al. (2009) which showed that the Raf kinase inhibitor 
protein inhibits cell proliferation but promotes cell migration in rat hepatic stellate cells. 
(Giese et al., 2003). Furthermore, the TGF-β1 signalling pathway also frequently inhibits 
epithelial cell proliferation while promoting cell migration (Imamura et al, 2012). These 
functions of TGF-β1 were further demonstrated in a study where an inhibitor of TGF-β1 
was shown to promote substrate –dependent and –independent proliferation while 
inhibiting cell migration (Halder et al., 2005). In summary, it would appear that TBX3 may 
function as a reciprocal switch between cell proliferation and tumour invasion in cancers 
where it is overexpressed. 
  
The anti-proliferative function of TBX3 was shown to directly correlate with levels of p53, 
p21 and p14. This is inconsistent with previous reports showing that TBX3 
transcriptionally represses p14 and p21 (Brummelkamp et al., 2002b; Hoogaars et al., 
2008). Importantly, when TBX3 levels were overexpressed in the MCF-12A normal 
human breast epithelial cells, the expression of TBX2, the highly homologous T-box 
factor to TBX3, was largely reduced. This is interesting because TBX2 is a powerful 
pro-proliferative factor in melanoma and breast cancer cell lines (Peres et al., 2010; 
Redmond et al., 2010) and there has been an indication that TBX2 and TBX3 can repress 
each other (Rodriguez et al., (2008); unpublished data from the Goding and Prince 
laboratories). The pro-proliferative function of TBX2 was demonstrated to result from its 
ability to repress both p19/p14ARF and p21 (Jacobs et al., 2000; Lingbeek et al., 2002; 
Prince et al., 2004) suggesting that the increased levels of p21 in the TBX3 
overexpressing cells may be due to an decrease in TBX2 levels. It is however important to 
note that when TBX3 was knocked down in MCF-7 cells there was no change in TBX2 
levels suggesting that in this context the decreased expression of p19/p14ARF and p21 is 




It is important to note that contrary to the findings of the current study, a number of 
studies have shown that TBX3/Tbx3 functions as a pro-proliferative factor (Carlson et al., 
2001b; Brummelkamp et al., 2002b; Lingbeek et al., 2002). There is however a precedent 
for TBX3 functioning as both pro-proliferative and anti-proliferative factor in the context 
of embryonic development. For example, during heart development Tbx3 functions in an 
anti-proliferative manner. Ectopic expression of Tbx3 in the highly proliferative tissue of 
the chamber myocardium resulted in a decrease in cell division, while silencing Tbx3 in 
the non-chamber myocardium promoted cell proliferation in this region (Ribeiro et al. 
2007; Bakker et al. 2008). However, during liver development, Tbx3 acts as a 
pro-proliferative factor. A study by Suzuki et al (2008) showed that hepatoblasts isolated 
from the attenuated livers of Tbx3-null mice showed a decrease in proliferative ability 
and increased p19ARF expression, suggesting that Tbx3 represses p19ARF in these cells 
to promote liver cell proliferation. Moreover, Peres et al. (2010, 2013) also reported an 
anti-proliferative role for TBX3 in human radial growth phase and vertical growth phase 
melanoma cells which correlated with TBX3 activating p19ARF levels. Together with the 
dual roles described for TBX3 in cancer cell proliferation, these findings suggest that 
TBX3 may act as a pro- or anti-proliferative factor depending on the cellular context. 
Together, these findings suggest that the duality of TBX3 in cell proliferation depends on 
the particular cellular context. 
 
In summary, the results from the knock down and overexpression models generated in 
this study provide evidence that increased TBX3 levels may contribute to breast cancer 
progression by enhancing cell migratory ability. 
 
The upregulation of TBX3 by the TGF-β1 signalling pathway in epithelial cells 
Having shown that TBX3 inhibits cell proliferation and promotes cell migration, the 
question arose as to what the mechanisms are that upregulate TBX3 and in particular 
those involved in regulating its oncogenic activity. This study provides novel data to 
show that the stimulation of the TGF-β1 signalling pathway results in the upregulation of 
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TBX3 expression and that TBX3 is a key mediator of its anti-proliferative and 
pro-migratory roles in epithelial cells.  
 
TGF-β1 is an intercellular ligand that has a well-established anti-proliferative and 
pro-migratory role in epithelial cells (Massagué, 2012). Based on data from this study 
that TBX3 similarly promotes migration and invasion while having a negative impact on 
cell proliferation, it was speculated that TBX3 may be downstream of TGF-β1. 
Furthermore, microarray studies in which normal human breast epithelial cells and 
keratinocytes were treated with TGF-β1 showed an activation of TBX3 (Kang et al, 2003). 
The data presented in this study show that TGF-β1 transcriptionally activates TBX3 
leading to an increase in TBX3 mRNA and protein expression in normal human breast 
epithelial cells and keratinocytes. Using in vitro and in vivo assays this transcriptional 
activation is shown to be mediated by a co-operation between Smad3/4 and JunB. This is 
consistent with previous reports that JunB and Smad3 can form a complex in vitro 
(Verrecchia et al., 2001) and that the transcriptional activity of Smads in the canonical 
TGF-β1 signalling pathway frequently relies on partner transcription factors such as JunB, 
Sp1, Egr1, ATF3 and forkhead family members (Chen et al., 1997; Feng et al., 2000; 
Verrecchia et al., 2001; Kang et al., 2003; Seoane et al., 2004; Fortin and Bernard, 2010). 
For example, Sp1 has been shown to physically interact with a complex of Smads to 
mediate TGF-β1 induced p15Ink4B (Feng et al., 2000) and Smad3 cooperatively interacts 
with either c-Jun or JunB to upregulate expression of the COL7A1 promoter (Verrecchia 
et al., 2001).  
 
Identification and characterisation of TBX2 as downstream target of TBX3 in the TGF-β1 
signalling pathway  
TGF-β1 is a potent inhibitor of cell proliferation, which is thought to result from its ability 
to induce a G1 cell cycle arrest through the up-regulation of the cyclin dependent kinase 
inhibitors, p15 and p21 (Reynisdóttir et al, 1995). This study demonstrates that TBX3 is a 
pivotal player in TGF-β1 mediated anti-proliferation and dissects the interrelated roles of 




The current study shows that when the TGF-β1 pathway is stimulated in breast epithelial 
and melanoma cells, TBX2 expression is repressed through the direct binding of TBX3 to 
a half T-element in the TBX2 promoter. Results from this study support evidence for TBX2 
being a powerful pro-proliferative factor (Peres et al., 2010; Redmond et al., 2010), and 
indicate that the downregulation of TBX2 blocks proliferation through the de-repression 
of the TBX2 target gene, p21, a cdki that initiates the TGF-β1-induced G1 arrest (Yoo et 
al., 1999). These results are consistent with a recent report that TGF-β1-mediated 
growth arrest in melanoma cells could be bypassed by ectopic TBX2 expression (Liu et al., 
2013). Together these data provide an explanation for how the TGF-β1 pathway exerts its 
anti-proliferative effect and reveal an upstream mechanism involved in regulating TBX2 
and TBX3 in contexts where they are differentially expressed. Moreover, TBX2 
overexpression was able to override the anti-proliferative effects of TGF-β1 without 
affecting p15 levels and knocking down p21 alone abrogated the ability of the cells to 
respond to the anti-proliferative TGF-β1 signal. Together this suggests that p15 is not 
required for the effect of TGF-β1 on the proliferative ability of these cells, though it may 
be involved in other TGF-β1-mediated functions.  
 
TBX2 and TBX3 are highly homologous T-box transcription factors which have distinct 
roles during embryonic development and in breast cancer and melanoma cell lines 
where they are both overexpressed (Davenport et al., 2003; Jerome-Majewska et al., 
2005; Peres et al., 2010; Douglas and Papaioannou, 2013; Li et al., 2013). Importantly, 
whereas TBX2 is essential for promoting cell proliferation, the current study and other 
reports have shown that TBX3 inhibits cell proliferation but is required for cell migration. 
These results together with data from the current study suggest an interesting interplay 
between TBX2, TBX3 and TGF-β1 signalling in normal epithelial cells (Fig. 4.1). Briefly, in 
this context TGF-β1 signalling activates TBX3 expression in a Smad/JunB dependent 
manner and TBX3 then represses TBX2 transcription which allows for the de-repression 
of p21 and a G1 cell cycle arrest. Interestingly, malignant cells acquire immortalising 
mutations that enable them to evade the anti-proliferative effects of TGF-β1 signalling. 
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For example, one of the mechanisms by which TGF-β1 exerts its anti-proliferative effects 
is through inhibiting expression of MYC that leads to the de-repression of p21. Many 
malignant cells however have mutations that result in the constitutive expression of 
MYC and hence these cells are resistant to the anti-proliferative effects of TGF-β1. It is 
therefore possible that cancers in which TBX2 is overexpressed will similarly disregard 
the TGF-β1 anti-proliferative signals. Intriguingly, the TBX3 promoter has a full consensus 
MYC binding site, raising the possibility that MYC will impact the TBX3-TBX2 axis 
identified here. The expression of MYC is usually down-regulated by TGF-β1 treatment, 
and ectopic expression of MYC in mouse keratinocytes desensitized the cells to TGF-β1 
mediated growth inhibition (Alexandrow et al., 1995; Feng et al., 2002; Wu et al., 2003). 
Furthermore, sustained MYC expression in ovarian cancers coincides with resistance to 
the anti-proliferative effects of TGF-β1 (Baldwin et al., 2003). Although, the precise 
relationship between MYC and TBX2 and TBX3 expression remains to be determined, 
there is no doubt that TBX2 and TBX3 are likely to represent key effectors of TGF-β1 
signalling in multiple cell types. 
 
In addition to being a potent inhibitor of cell proliferation, TGF-β1 can also stimulate 
invasiveness by promoting an ‘epithelial to mesenchyme transition’. Understanding how 
TGF-β1 coordinates its effects on the cell cycle and invasion in different cell types is a key 
issue, both for development and disease. While the TBX3 target genes downstream of 
the TGF-β1 signalling pathway that promotes migration was not explored in this study it 
is tempting to speculate that one of them would be E-cadherin, a key epithelial cell 
adhesion molecule. TBX3 has previously been shown to promote melanoma cell 
migration by directly repressing E-cadherin (Rodriguez et al., 2008; Boyd et al., 2012) and 
a study by Vincent et al. (2009) showed that TGF-β1 signalling induces a SNAIL-Smad3/4 
complex which negatively regulates E-cadherin in breast epithelial cells. Interestingly, 
they demonstrated that while knockdown of Smad3/4 significantly rescued the 
repression of E-cadherin by TGF-β1, knockdown of SNAIL only had a marginal effect 
suggesting that other transcriptional repressors may also be required for this repression. 
This study also shows that knocking down TBX3 does not completely abrogate TGF-β1 
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induced migration. It would therefore be worthwhile to examine the impact of knocking 
down both TBX3 and SNAIL on E-cadherin levels as well as to determine its effect on 
TGF-β1 induced breast epithelial cell migration. It is important to note that TBX3 
expression has been demonstrated to be upregulated in SNAIL-expressing cells  
(Humtsoe et al., 2012) and unpublished data from our laboratory show that the 
expression of SNAIL is reduced in TBX3 knockdown cells. The above observations suggest 
that TBX3 and SNAIL can positively regulate one another and since they are both able to 
repress E-cadherin there may be a complex interplay between these three factors. 
 
 




Based on the results generated in this study and the current literature the following 
model is proposed for the role and regulation of TBX3 in breast epithelial cells (Fig 6.6). 
The complex formed by the binding of TGF-β1 to TGFβRII recruits and phosphorylates 
the TGFβRI, which in turn phosphorylates Smad2 and Smad3 to release them from the 
TGFβRI. The phosphorylated Smad2/3 form a complex with Smad4 and translocate to the 
nucleus where they associate with JunB and bind to the SBE on the TBX3 promoter and 
drive the transcription. The activated TBX3 mediates the TGF-β1-regulated 
anti-proliferative and pro-migratory effect. TBX3 inhibits cell proliferation through 
repressing TBX2 transcription which allows for the de-repression of p21 and a G1 cell 
cycle arrest. The findings of the current study are of great significance as it identifies 
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6.2 Mycoplasma Test 
Mounting fluid  
20 mM Citric acid  
55 mM Na2HPO4.2H2O  
50% Glycerol  
pH to 5.5 and store at 4°C  
6.3 Vector map of pTIG




6.4 Stable TBX3 knockdown using a lentiviral delivery system 
HBS2X 
280 mM NaCl 
100 mM Hepes 
1.5 mM Na2HPO4 (pH between 7.11 - 7.13) 
Filter sterilise and store at -20oC 
 
6.5 Western Blot analysis 
RIPA  
150 mM NaCl  
1% Triton X-100  
0.1% SDS  
20 mM Tris (pH 7.5)  
1% deoxycholate  
Protease inhibitors added prior to harvesting: 1X complete protease inhibitor tablets 
(Roche, Germany), aprotinin (1 μg/ml), pepstatin (1 μg/ml), phenylmethanesulphonyl 
fluoride (PMSF) (0.5 mM) 
 
Sodium Dodecyl Sulphate (SDS)‐polyacrylamide gels  
Resolving gel:  
Acryl-bisacryl-amide mix (30:08) (percentage depending on size of protein of interest)  
0.375 M Tris (pH 8.8)  
0.1% SDS  
0.1% TEMED  
0.1% Ammonium persulphate  
 
Stacking gel:  
5% Acryl-bisacryl-amide mix (30:08)  
0.192 M Tris (pH6.8)  
0.1% SDS  
0.1% TEMED  
0.1% Ammonium persulphate  
 
Acryl-bisacryl-amide mix (30:08):  
29 g acrylamide  
1 g N,N`-methylenebisacrylamide  
Make up to 100 ml, heating at 37°C to dissolve chemicals. Store at 4°C, protected from 
light  
 
Running buffer:  
1 g SDS  
3.03 g Tris  
14.41 g Glycine  
Make up to 1 litre  
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Transfer buffer:  
2.9 g Glycine  
5.8 g Tris  
0.37 g SDS  
200 ml isopropanol  
Make up to 1 litere and store at 4°C. 
 
Phosphate buffered saline (PBS)/Tween 
10X PBS: 
8 g NaCl  
1.45 g Na2HPO4.12H2O 
0.2 g KCl 
0.2 g KH2PO4 
Make up to 1 litre, pH to 7.4 
 
PBS/Tween: 
For membrane washes, add 0.1% Tween to 1X PBS  
 
Stripping buffer  
62.5 mM Tris-HCl (pH6.7)  
2% SDS  
100 mM β-mercaptoethanol 
 
6.6 Assessment of proliferation/senescence 
5‐bromo‐2‐deoxyuridine (BrdU) incorporation assay   
Carnoy’s Fixative  
1 : 3 acetic acid : methanol 
 
Borate buffer (0.1 M) 
3.8 g sodium borate (borax) 
Make up to 100 ml, pH to 8.5  
 
Senescence Associated beta-Galactosidase assay 
Staining solution 
5 mM potassium ferrocyanide 
5 mM potassium ferricyanide 
2 mM Mg2Cl2 
1 mg/ml x-gal  
PBS pH 6 
 
6.7 Chromatin immunoprecipitation (ChIP) assay 
Buffer 1 
10 mM EDTA 
0.5 mM EGTA 
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10 mM Hepes, 
0.25% Triton X-100 
 
Buffer 2  
1 mM EDTA 
0.5 mM EGTA 
10 mM Hepes 
200 mM NaCl 
 
Lysis buffer  
10 mM EDTA 
50 mM Tris-Cl pH 8.1 
0.5% Nonidet P-40 
1% SDS  
 
Immunoprecipitation Buffer  
2 mM EDTA 
150 mM NaCl 
20 mM Tris-Cl pH 8.1 
1% Triton X-100 
 
Wash buffer 1  
2 mM EDTA  
20 mM Tris-Cl pH 8.1  
0.1% SDS  
1% Triton X-100  
150 mM NaCl  
 
Wash buffer 2  
2 mM EDTA  
20 mM Tris-Cl pH 8.1  
0.1% SDS  
1% Triton X-100  
500 mM NaCl  
 
Wash buffer 3  
1 mM EDTA  
10 mM Tris-Cl pH 8.1  
250 mM LiCl  
1% sodium deoxycholate  
1% Nonidet P-40  
 
Wash buffer 4  
1 mM EDTA  
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10 mM Tris-Cl pH 8.1 
 
Extraction buffer  
100 mM NaHCO3 
1% SDS 
 
6.8  Non-radioactive Electromobility Shift Assay 
Buffer 1 





20mM HEPES pH 7.9 
420mM NaCl 
1.5mM MgCl2 
0.2mM EDTA pH8 
25% glycerol 
 
5x Incubation Buffer  
100 mM HEPES pH 7.9 
250 mM KCl 
2.5 mM DTT 
10 mM EDTA 
5 mM MgCl2 
20% Ficoll 400 
 
6.9 DNA affinity immunoblot (DAI) assay 
Binding buffer 
20 mM Tris-HCl pH 7.6 
50 mM NaCl 
1 mM MgCl2 
0.2 mM EDTA 
0.5 mM dithiothreitol 
5% glycerol 
10 ng/µl poly(dI-dC)) 
 
Protein loading buffer 







6.10 Flow Cytometry    
Propidium Iodide solution  
2 mM MgCl2  
10 mM Pipes buffer  
0.1 M NaCl  
0.1% Triton X-100  
0.01 mg/ml Propidium iodide 
 
